

CORRECTED VERSION

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
25 November 1999 (25.11.1999)

PCT

(10) International Publication Number  
WO 1999/059615 A1

(51) International Patent Classification<sup>6</sup>: A61K 38/02,  
38/08, 38/10, 38/16, 38/18, 38/19, 38/22, C07K 7/06,  
7/08, 14/00

(21) International Application Number:  
PCT/US1999/011219

(22) International Filing Date: 20 May 1999 (20.05.1999)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
09/082,279 20 May 1998 (20.05.1998) US

(71) Applicant: TRIMERIS, INC. [US/US]; 4727 University  
Drive, Durham, NC 27707 (US).

(72) Inventors: BARNEY, Shawn; 106 Branchway Road,  
Apex, NC 27502 (US). GUTHRIE, Kelly, L.; 1102 Bibury

Court, Graham, NC 27278 (US). MERUTKA, Gene; 404  
West Hill Avenue South, Hillsborough, NC 27278 (US).  
ANWER, Mohmed, K.; 801 Foster City Boulevard #112,  
Foster City, CA 94404 (US). LAMBERT, Dennis, M.;  
101 Centerville Court, Cary, NC 27513 (US).

(74) Agents: CORUZZI, Laura, A. et al.; Pennie & Edmonds  
LLP, 1155 Avenue of the Americas, New York, NY 10036  
(US).

(81) Designated States (*national*): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE,  
ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP,  
KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD,  
MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD,  
SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN,  
YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM,  
AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT,

[Continued on next page]

(54) Title: HYBRID POLYPEPTIDES WITH ENHANCED PHARMACOKINETIC PROPERTIES

N-terminal Interactive Region										C-terminal Interactive Region									
W	X	X	W	X	X	X	I	Core Polypeptide			W	X	X	X	W	X	W	X	
W	X	X	W	X	X	X						X	X	X	W	X	W	X	
W	X	X	W	X	X								X	X	W	X	W	X	
W	X	X	W	X										X	W	X	W	X	
W	X	X	W												W	X	W	X	
												W	X	X	X	W	X	W	
												X	X	X	W	X	W		
													X	X	W	X	W		
														X	W	X	W		
															W	X	W		

(57) Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.

WO 1999/059615 A1



BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,  
NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA,  
GN, GW, ML, MR, NE, SN, TD, TG).

(15) Information about Corrections:

see PCT Gazette No. 20/2004 of 13 May 2004, Section II

Previous Correction:

see PCT Gazette No. 25/2000 of 22 June 2000, Section II

Published:

— with international search report

(48) Date of publication of this corrected version:

13 May 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

5

HYBRID POLYPEPTIDES WITH ENHANCED  
PHARMACOKINETIC PROPERTIES

10

1. INTRODUCTION

The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked.

15 The invention is based, in part, on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to novel anti-fusogenic and/or anti-viral, peptides, including ones that contain such enhancer peptide

20 sequences, and methods for using such peptides. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically

25 useful peptide that can be used, for example, as a therapeutic or prophylactic reagent. In a non-limiting embodiment, the invention is demonstrated by way of example wherein a hybrid polypeptide comprising, for example, an HIV core polypeptide linked to enhancer peptide sequences, is shown to be a potent, non-cytotoxic inhibitor of HIV-1, HIV-2

30 and SIV infection. Additionally, the enhancer peptide sequences of the invention have been linked to a respiratory

syncytial virus (RSV) core polypeptide and a luteinizing hormone receptor (LH-RH) core polypeptide. In each instance, the hybrid polypeptide was found to possess enhanced pharmacokinetic properties, and the RSV hybrid polypeptide exhibited substantial anti-RSV activity.

5

## 2. BACKGROUND OF THE INVENTION

Polypeptide products have a wide range of uses as therapeutic and/or prophylactic reagents for prevention and treatment of disease. Many polypeptides are able to regulate biochemical or physiological processes to either prevent  
10 disease or provide relief from symptoms associated with disease. For example, polypeptides such as viral or bacterial polypeptides have been utilized successfully as vaccines for prevention of pathological diseases. Additionally, peptides have been successfully utilized as therapeutic agents for treatment of disease symptoms. Such  
15 peptides fall into diverse categories such, for example, as hormones, enzymes, immunomodulators, serum proteins and cytokines.

For polypeptides to manifest their proper biological and therapeutic effect on the target sites, the polypeptides must be present in appropriate concentrations at the sites of  
20 action. In addition, their structural integrity must generally be maintained. Therefore, the formulation of polypeptides as drugs for therapeutic use is directed by the chemical nature and the characteristics of the polypeptides, such as their size and complexity, their conformational requirements, and their often complicated stability, and  
25 solubility profiles. The pharmacokinetics of any particular therapeutic peptide is dependent on the bioavailability, distribution and clearance of said peptide.

Since many bioactive substances, such as peptides and proteins, are rapidly destroyed by the body, it is critical to develop effective systems for maintaining a steady  
30 concentration of peptide in blood circulation, to increase



the efficacy of such peptides, and to minimize the incidence and severity of adverse side effects.

### 3. SUMMARY OF THE INVENTION

The present invention relates, first, to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences i.e., HIV-1, HIV-2 and SIV, that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the surprising result that when the disclosed enhancer peptide sequences are linked to any core polypeptide, the resulting hybrid polypeptide possesses enhanced pharmacokinetic properties including, for example, increased half life and reduced clearance rate relative to the core polypeptide alone. ~~The present invention further relates to~~ such hybrid polypeptides and core polypeptides, and to novel peptides that exhibit anti-fusogenic activity, antiviral activity and/or the ability to modulate intracellular processes that involve coiled-coil peptide structures. Among such peptides are ones that contain enhancer peptide sequences.

Core polypeptides can comprise any peptides which may be introduced into a living system, for example, any peptides capable of functioning as therapeutic, prophylactic or imaging reagents useful for treatment or prevention of disease or for diagnostic or prognostic methods, including methods in vivo imaging. Such peptides include, for example, growth factors, hormones, cytokines, angiogenic growth factors, extracellular matrix polypeptides, receptor ligands, agonists, antagonists or inverse agonists, peptide targeting agents, such as imaging agents or cytotoxic targeting agents, or polypeptides that exhibit antifusogenic and/or antiviral activity, and peptides or polypeptides that function as antigens or immunogens including, for example, viral and bacterial polypeptides.

The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide

through linkage of the core polypeptide to the enhancer peptide sequences to form hybrid polypeptides.

The invention still further relates to methods for using the peptides disclosed herein, including hybrid polypeptides containing enhancer peptide sequences. For example, the methods of the invention include methods for decreasing or inhibiting viral infection, e.g., HIV-1, HIV-2, RSV, measles, influenza, parainfluenza, Epstein-Barr, and hepatitis virus infection, and/or viral-induced cell fusion events. The enhancer peptide sequences of the invention can, additionally, be utilized to increase the in vitro or ex-vivo half-life of a core polypeptide to which enhancer peptide sequences have been attached, for example, enhancer peptide sequences can increase the half life of attached core polypeptides in cell culture or cell or tissue samples.

The invention is demonstrated by way of examples wherein hybrid polypeptides containing an HIV core polypeptide linked to enhancer peptide sequences are shown to exhibit greatly enhanced pharmacokinetic properties and act as a potent, non-cytotoxic inhibitors of HIV-1, HIV-2 and SIV infection. The invention is further demonstrated by examples wherein hybrid polypeptides containing an RSV core polypeptide or a luteinizing hormone polypeptide are shown to exhibit greatly enhanced pharmacokinetic properties. In addition, the RSV hybrid polypeptide exhibited substantial anti-RSV activity.

### 3.1. DEFINITIONS

Peptides, polypeptides and proteins are defined herein as organic compounds comprising two or more amino acids covalently joined, e.g., by peptide amide linkages. Peptides, polypeptide and proteins may also include non-natural amino acids and any of the modifications and additional amino and carboxyl groups as are described herein. The terms "peptide," "polypeptide" and "protein" are, therefore, utilized interchangeably herein.

Peptide sequences defined herein are represented by one-letter symbols for amino acid residues as follows:

- A (alanine)
- R (arginine)
- N (asparagine)
- D (aspartic acid)
- C (cysteine)
- Q (glutamine)
- E (glutamic acid)
- 5 G (glycine)
- H (histidine)
- I (isoleucine)
- L (leucine)
- K (lysine)
- M (methionine)
- F (phenylalanine)
- P (proline)
- S (serine)
- 10 T (threonine)
- W (tryptophan)
- Y (tyrosine)
- V (valine)
- X (any amino acid)

"Enhancer peptide sequences" are defined as peptides having the following consensus amino acid sequences:

15 "WXXWXXXI", "WXXWXXX", "WXXWXX", "WXXWX", "WXXW", "WXXXWXXW", "XXXWXXW", "XXWXXW", "XWXXW", "WXXW", "WXXXWXXW", "WXXXWX", "WXXXW", "IXXXWXXW", "XXXWXXW", "XXWXXW", "XWXXW", "XWXXWXXW", "XWXXWXX", "XWXXWXX", "XWXXW", "XWXXW", "WXXWXXW", or "XWXXW", wherein X can be any amino acid, W represents tryptophan and I represents isoleucine. As discussed below,

20 the enhancer peptide sequences of the invention also include peptide sequences that are otherwise the same as the consensus amino acid sequences but contain amino acid substitutions, insertions or deletions but which do not abolish the ability of the peptide to enhance the

25 pharmacokinetic properties of a core peptide to which it is linked relative to the pharmacokinetic properties of the core polypeptide alone.

"Core polypeptide" as used herein, refers to any polypeptide which may be introduced into a living system and, thus, represents a bioactive molecule, for example any

30 polypeptide that can function as a pharmacologically useful peptide for treatment or prevention of disease.

"Hybrid polypeptide" as used herein, refers to any polypeptide comprising an amino, carboxy, or amino and carboxy terminal enhancer peptide sequence and a core polypeptide. Typically, an enhancer peptide sequence is linked directly to a core polypeptide. It is to be understood that an enhancer peptide can also be attached to an intervening amino acid sequence present between the enhancer peptide sequence and the core peptide.

"Antifusogenic" and "anti-membrane fusion," as used herein, refer to a peptide's ability to inhibit or reduce the level of fusion events between two or more structures e.g., cell membranes or viral envelopes or pili, relative to the level of membrane fusion which occurs between the structures in the absence of the peptide.

"Antiviral," as used herein, refers to the peptide's ability to inhibit viral infection of cells via, e.g., cell fusion or free virus infection. Such infection can involve membrane fusion, as occurs in the case of enveloped viruses, or another fusion event involving a viral structure and a cellular structure, e.g., fusion of a viral pilus and bacterial membrane during bacterial conjugation).

#### 4. BRIEF DESCRIPTION OF DRAWINGS

FIG. 1. Hybrid polypeptides. Enhancer peptide sequences derived from putative N-terminal and C-terminal interactive regions are depicted linked to a generic core polypeptide. Conserved enhancer peptide sequences are shaded. It is to be noted that the enhancer peptide sequences indicated may be used either as - terminal, C-terminal, or - and C-terminal additions. Further, the enhancer peptide sequences can be added to a core polypeptide in forward or reverse orientation, individually or in any of the possible combinations, to enhance pharmacokinetic properties of the peptide.

FIG. 2A. Enhancer peptide sequences derived from various envelope (gp41) protein sequences, representing the

N-terminal interactive region observed in all currently published isolate sequences of HIV-1, HIV-2 and SIV. The final sequence "WXXWXXXI" represents a consensus sequence.

FIG. 2B. Enhancer peptide sequence variants derived  
5 from various envelope (gp41) protein sequences, representing the C-terminal interactive region observed in all currently published isolate sequences of HIV-1, HIV-2 and SIV. The final sequence "WXXXWXXW" represents a consensus sequence.

FIG. 3. Comparison of HIV-1 titres in tissues of HIV-1  
10 9320 infected SCID-HuPBMC mice as measured by P24 Levels in HuPBMC co-culture assays. The figure shows a comparison of in vivo T20 and T1249 viral inhibition.

FIG. 4A-4B. Plasma pharmacokinetic profile of T1249 vs. T1387 core control in CD-rats following IV injection for up  
15 to 2 hrs (FIG. 4A) and 8 hrs (FIG. 4B). The T1387 polypeptide is a core polypeptide and the T1249 polypeptide is the core polypeptide linked to enhancer peptide sequences.

FIG. 5. Plasma pharmacokinetic profile of T1249 vs. T20 control in CD-rats following IV administration. The T1249  
20 polypeptide is a hybrid polypeptide of a core polypeptide (T1387) linked to enhancer peptide sequences. T20: n=4; T1249: n=3.

FIG. 6. Comparison of T20/T1249 Anti-HIV-1/IIIb activity and cytotoxicity.  
25

FIGS. 7A to 7B-1. Direct Binding of T1249 to gp41 construct M41Δ178. <sup>125</sup>I-T1249 was HPLC purified to maximum specific activity. Saturation binding to M41Δ178 (a gp41 ectodomain fusion protein lacking the T20 amino acid sequence) immobilized in microtitre plates at 0.5 mg/ml is  
30 shown.

## FIGS. 8A-8B. Time Course of T1249

Association/Dissociation. The results demonstrate that  $^{125}\text{I}$ -T1249 and  $^{125}\text{I}$ -T20 have similar binding affinities of 1-2 nM. Initial on and off rates for  $^{125}\text{I}$ -T1249 were significantly slower than those of  $^{125}\text{I}$ -T20. Dissociation of bound  
5 radioligand was measured following the addition of unlabeled peptide to a final concentration of  $10\mu\text{M}$  in 1/10 total assay volume.

FIGS. 9A-9B. Competition for T1249 Binding to M41A178. Unlabeled T1249 and T20 were titrated in the presence of a  
10 single concentration of either  $^{125}\text{I}$ -T1249 or  $^{125}\text{I}$ -T20. Ligand was added just after the unlabeled peptide to start the incubation.

FIG. 10A-10B. Plasma pharmacokinetic profile of RSV hybrid polypeptides T1301 (10A) and T1302 (10B) vs. T786 in  
15 CD rats.

FIG. 11A. Plaque Reduction Assay. Hybrid polypeptide T1293 is capable of inhibiting RSV infection with an  $\text{IC}_{50}$  2.6  $\mu\text{g}/\text{ml}$ .

20 FIG. 11B. Plaque Reduction Assay demonstrates the ability of RSV Hybrid Polypeptides T1301, T1302 and T1303 to inhibit RSV infection.

FIG. 12A and 12B. Plasma pharmacokinetic profile of luteinizing hormone hybrid polypeptide T1324 vs T1323 in CD  
25 male rats. The T1323 polypeptide is a luteinizing hormone core polypeptide and the T1324 polypeptide is a hybrid polypeptide comprising a core polypeptide linked to enhancer peptide sequences.

FIGS. 13A-D. Hybrid polypeptide sequences derived from  
30 various core polypeptides. Core polypeptide sequences are

shown shaded. The non-shaded amino and carboxy terminal sequences represent enhancer peptide sequences.

FIG. 14A-B. Circular Dichroism (CD) spectra for T1249 in solution (phosphate buffered saline, pH 7) alone (10  $\mu$ M at 19°C; FIG. 14A) and in combination with a 45-residue peptide from the gp41 HR1 binding domain (T1346); the closed square (■) represents a theoretical CD spectrum predicted for a "non-interaction model" whereas the actual CD spectra are represented by the closed circle (•).

FIG. 15. Polyacrylamide gel electrophoresis showing T1249 protection of the gp41 construct M41Δ178 from proteinase-K digestion; lane 1: primer marker; lane 2: untreated M41Δ178; lane 3: M41Δ178 incubated with proteinase-K; lane 4: untreated T1249; lane 5: T1249 incubated with proteinase-K; lane 6: M41Δ178 incubated with T1249; lane 7: incubation of T1249 and M41Δ178 prior to addition of proteinase-K.

FIG. 16A-C. Pharmacokinetics of T1249 in Sprague-Dawley albino rats; FIG. 16A: pharmacokinetics of T1249 in a single dose administration by continuous subcutaneous infusion; FIG. 16B: Plasma pharmacokinetics of T1249 administered by subcutaneous injection (SC) or intravenous injection (IV); FIG. 16C: Kinetic analysis of T1249 in lymph and plasma after intravenous administration.

FIG. 17A-C Pharmacokinetics of T1249 in cynomolgus monkeys; FIG. 17A: plasma pharmacokinetics of a single 0.8 mg/kg dose of T1249 via subcutaneous (SC) intravenous (IV) or intramuscular (IM) injection; FIG. 17B: Plasma pharmacokinetics of subcutaneously administered T1249 at three different dose levels (0.4 mg/kg, 0.8 mg/kg, and 1.6 mg/kg).

## 5. DETAILED DESCRIPTION OF THE INVENTION

Described herein are peptide sequences, referred to as enhancer peptide sequences, derived from various retroviral envelope (gp41) protein sequences that are capable of enhancing the pharmacokinetic properties of core polypeptides to which they are linked. Such enhancer peptide sequences can be utilized in methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide to form a hybrid polypeptide with enhanced pharmacokinetic properties relative to the core polypeptide alone. The half life of a core peptide to which an enhancer peptide sequence or sequences has been attached can also be increased in vitro. For example, attached enhancer peptide sequences can increase the half life of a core polypeptide when present in cell culture, tissue culture or patient samples, such as cell, tissue, or other samples.

The core polypeptides of the hybrid polypeptides of the invention comprise any peptide which may be introduced into a living system, for example, any peptide that can function as a therapeutic or prophylactic reagent useful for treatment or prevention of disease, or an imaging agent useful for imaging structures in vivo.

Also described herein are peptides, including peptides that contain enhancer peptide sequences, that exhibit anti-fusogenic and/or anti-viral activity. Further described herein are methods for utilizing such peptides, including methods for decreasing or inhibiting viral infection and/or viral induced cell fusion.

25

### 5.1. HYBRID POLYPEPTIDES

The hybrid polypeptides of the invention comprise at least one enhancer peptide sequence and a core polypeptide. Preferably, the hybrid polypeptides of the invention comprise at least two enhancer peptide sequences and a core polypeptide, with at least one enhancer peptide present in the hybrid polypeptide amino to the core polypeptide and at

30



least one enhancer peptide sequence present in the hybrid polypeptide carboxy to the core polypeptide.

The enhancer peptide sequences of the invention comprise peptide sequences originally derived from various retroviral envelope (gp 41) protein sequences, including HIV-1, HIV-2 and SIV sequences, and specific variations or modifications thereof described below. A core polypeptide can comprise any peptide sequence, preferably any peptide sequence that may be introduced into a living system, including, for example, peptides to be utilized for therapeutic, prophylactic or imaging purposes.

Typically, a hybrid polypeptide will range in length from about 10 to about 500 amino acid residues, with about 10 to about 100 amino acid residues in length being preferred, and about 10 to about 40 amino acids in length being most preferred.

While not wishing to be bound by any particular theory, the structure of the envelope protein is such that the putative  $\alpha$ -helix region located in the C-terminal region of the protein is believed to associate with the leucine zipper region located in the N-terminal region of the protein. Alignment of the N-terminal and C-terminal enhancer peptide sequence gp41 regions observed in all currently published isolate sequences of HIV-1, HIV-2 and SIV identified consensus amino acid sequences.

In particular, the following consensus amino acid sequences representing consensus enhancer peptide sequences were identified (the consensus sequences are listed below in forward and reverse orientations because said enhancer peptide sequences can be utilized either in forward or reverse orientation): "WXXWXXXI", "WXXWXXX", "WXXWXX", "WXXWX", "WXXW", "WXXXWXX", "XXXWXX", "XXWXX", "XWXX", "WXWX", "WXXXWX", "WXXXWX", "WXXXW", "IXXXWXXW", "XXXWXXW", "XXWXXW", "XWXXW", "XWXXWXXX", "XWXXWXX", "XWXXW", "WXWXXXW", or "XWXXXW", wherein X can be any amino acid, W represents tryptophan and I represents isoleucine.

Forward orientations of consensus amino acid sequences are shown in FIGS. 1 and 2.

Typically, an enhancer peptide sequence will be about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 amino acid residues in length, with about 4 to about 20 residues in length being preferred, about 4 to about 10 residues in length being more preferred, and about 6 to about 8 residues in length being most preferred.

In a preferred embodiment of the invention, enhancer peptide sequences which may be used to enhance the pharmacokinetic properties of the resultant hybrid polypeptides comprise the specific enhancer peptide sequences depicted in FIGS. 2, 13, and Table 1, below. Among the most preferred enhancer peptide sequences are ones comprising the following amino sequence: "WQEWEQKI" and "WASLWEWF".

By way of example and not by way of limitation, Table 1, below, lists amino acid sequences that represent preferred embodiments of the enhancer peptide sequences of the enhancer peptide sequences of the invention. It is to be understood that while the forward orientation of these sequences is depicted below, the reverse orientation of the sequences is also intended to fall within the scope of the present invention. For example, while the forward orientation of the enhancer peptide sequence "WMEWDREI" is depicted below, its reverse orientation, i.e., "IERDWEMW" is also intended to be included.

TABLE 1

WMEWDREI  
WQEWERKV  
WQEWQKV  
MTWMEWDREI  
NNMTWMEWDREI  
WQEWQKVRYLEANI  
NNMTWQEWQKVRYLEANI  
WNWFI

5                   WQEW DREISNYTSLI  
                  WQEWEREISAYTSLI  
                  WQEW DREI  
                  WQEW EI  
                  WNWF  
                  WQEW  
                  WQAW  
                  WQEW EQKI  
                  WASLWNWF  
                  WASLFNFF  
10                  WDVFTNWL  
                  WASLWEWF  
                  EWASLWEWF  
                  WEWF  
                  ~~EW~~EW  
                  IEWEWF  
                  IEWEW  
15                  EWEW  
                  WASLWEWF  
                  WAGLWEWF  
                  AKWASLWEWF  
                  AEWASLWEWF  
                  WASLWAWF  
20                  AEWASLWAWF  
                  AKWASLWAWF  
                  WAGLWAWF  
                  AEWAGLWAWF  
                  WASLWAW  
                  AEWASLWAW  
25                  WAGLWAW  
                  AEWAGLWAW  
                  DKWEWF  
                  IEWASLWEWF  
                  IKWASLWEWF  
                  DEWEWF  
30                  GGWASLWNWF  
                  GGWNWF

In another preferred embodiment, particular enhancer peptide sequences of the invention comprise the enhancer peptide sequences depicted in FIGS. 2, 13 and Table 1 exhibiting conservative amino acid substitutions at one, two  
5 or three positions, wherein said substitutions do not abolish the ability of the enhancer peptide sequence to enhance the pharmacokinetic properties of a hybrid polypeptide relative to its corresponding core polypeptide.

Most preferably, such substitutions result in enhancer peptide sequences that fall within one of the enhancer  
10 peptide sequence consensus sequences. As such, generally, the substitutions are made at amino acid residues corresponding to the "X" positions depicted in the consensus amino acid sequences depicted above and in FIGS. 1 and 2. "Conservative substitutions" refer to substitutions with amino acid residues of similar charge, size and/or  
15 hydrophobicity/hydrophilicity characteristics as the amino acid residue being substituted. Such amino acid characteristics are well known to those of skill in the art.

The present invention further provides enhancer peptide sequences comprising amino acid sequences of FIGS. 1, 2, 13 and Table 1 that are otherwise the same, but, that said  
20 enhancer peptide sequences comprise one or more amino acid additions (generally no greater than about 15 amino acid residues in length), deletions (for example, amino- or terminal- truncations) or non-conservative substitutions which nevertheless do not abolish the resulting enhancer peptide's ability to increase the pharmacokinetic properties  
25 of core polypeptides to which they are linked relative to core polypeptides without such enhancer peptide sequences.

Additions are generally no greater than about 15 amino acid residues and can include additions of about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 consecutive amino acid residues. Preferably the total number of amino acid  
30 residues added to the original enhancer peptide is no greater than about 15 amino acid residues, more preferably no greater

than about ten amino acid residues and most preferably no greater than about 5 amino acid residues.

Deletions are preferably deletions of no greater than about 3 amino acid residues in total (either consecutive or non-consecutive residues), more deletions preferably of 2  
5 amino acids, most preferably deletions of single amino acids residues. Generally, deletions will be of amino acid residues corresponding to the "X" residues of the enhancer peptide consensus sequences.

Enhancer peptide sequences of the invention also comprise the particular enhancer peptide sequences depicted  
10 in FIGS. 2, 13 and Table 1 exhibiting one, two or three non-conservative amino acid substitutions, with two such substitutions being preferred and one such substitution being most preferred. ~~"Non conservative" substitutions refer to~~ substitutions with amino acid residues of dissimilar charge, size, and/or hydrophobicity/ hydrophilicity characteristics  
15 from the amino acid residue being replaced. Such amino acid characteristics are well known to those of skill in the art.

In addition, the amino acid substitutions need not be, and in certain embodiments preferably are not, restricted to the genetically encoded amino acids. Indeed, the peptides may contain genetically non-encoded amino acids. Thus, in  
20 addition to the naturally occurring genetically encoded amino acids, amino acid residues in the peptides may be substituted with naturally occurring non-encoded amino acids and synthetic amino acids.

Certain commonly encountered amino acids which provide useful substitutions include, but are not limited to,  
25  $\beta$ -alanine ( $\beta$ -Ala) and other omega-amino acids such as 3-aminopropionic acid, 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and so forth;  $\alpha$ -aminoisobutyric acid (Aib);  $\epsilon$ -aminohexanoic acid (Aha);  $\delta$ -aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGly); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine  
30 (t-BuG); N-methylisoleucine (MeIle); phenylglycine (Phg); cyclohexylalanine (Cha); norleucine (Nle); naphthylalanine

(Nal); 4-chlorophenylalanine (Phe(4-Cl));  
2-fluorophenylalanine (Phe(2-F)); 3-fluorophenylalanine  
(Phe(3-F)); 4-fluorophenylalanine (Phe(4-F)); penicillamine  
(Pen); 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid  
(Tic);  $\beta$ -2-thienylalanine (Thi); methionine sulfoxide (MSO);  
5 homoarginine (hArg); N-acetyl lysine (AcLys); 2,4-  
diaminobutyric acid (Dbu); 2,3-diaminobutyric acid (Dab);  
p-aminophenylalanine (Phe(pNH<sub>2</sub>)); N-methyl valine (MeVal);  
homocysteine (hCys), homophenylalanine (hPhe) and homoserine  
(hSer); hydroxyproline (Hyp), homoproline (hPro), N-  
methylated amino acids and peptoids (N-substituted glycines).  
10 While in most instances, the amino acids of the peptide  
will be substituted with L-enantiomeric amino acids, the  
substitutions are not limited to L-enantiomeric amino acids.  
Thus, also included in the definition of "mutated" or  
"altered" forms are those situations where an L-amino acid is  
replaced with an identical D-amino acid (e.g., L-Arg  $\rightarrow$  D-Arg)  
15 or with a D-amino acid of the same category or subcategory  
(e.g., L-Arg  $\rightarrow$  D-Lys), and vice versa.

It is to be understood that the present invention also  
contemplates peptide analogues wherein one or more amide  
linkage is optionally replaced with a linkage other than  
amide, preferably a substituted amide or an isostere of  
20 amide. Thus, while the amino acid residues within peptides  
are generally described in terms of amino acids, and  
preferred embodiments of the invention are exemplified by way  
of peptides, one having skill in the art will recognize that  
in embodiments having non-amide linkages, the term "amino  
acid" or "residue" as used herein refers to other  
25 bifunctional moieties bearing groups similar in structure to  
the side chains of the amino acids. In addition the amino  
acid residues may be blocked or unblocked.

Additionally, one or more amide linkages can be replaced  
with peptidomimetic or amide mimetic moieties which do not

significantly interfere with the structure or activity of the peptides. Suitable amide mimetic moieties are described, for example, in Olson et al., 1993, J. Med. Chem. 36:3049.

Enhancer peptide sequences can be used to enhance the pharmacokinetic properties of the core polypeptide as either  
5 N-terminal, C-terminal, or - and C-terminal additions. While it is preferable for the enhancer peptide sequences to be utilized in a pairwise fashion, that is, preferably hybrid polypeptides comprise an enhancer peptide sequence at both the amino- and carboxy-termini, hybrid polypeptides can also comprise a single enhancer peptide, said peptide present at  
10 either the amino- or carboxy- terminus of the hybrid polypeptide. Further, the enhancer peptides can be used in either forward or reverse orientation, or in any possible combination, linked to a core polypeptide. ~~It is noted that~~ any of the enhancer peptides can be introduced at either the N-terminus or the C-terminus of the core polypeptide. Still  
15 further, multiple enhancer peptide sequences can be introduced to the N-, C-, or - and C-terminal positions of the hybrid polypeptides. Multiple enhancer peptide sequences can be linked directly one to another via the same sorts of linkages as used to link an enhancer peptide sequence to the core polypeptide (see below). In addition, an intervening  
20 amino acid sequence of the same sort as described below can also be present between one or more of the multiple enhancer peptide sequences. Multiple enhancer peptide sequences will typically contain from 2 to about 10 individual enhancer peptide sequences (of the same or different amino acid sequence), with about 2 to about 4 being preferred.

25 It is understood that the core polypeptide is generally linked to the enhancer peptides via a peptide amide linkage, although linkages other than amide linkages can be utilized to join the enhancer peptide sequences to the core polypeptides. Such linkages are well known to those of skill in the art and include, for example, any carbon-carbon, ester  
30 or chemical bond that functions to link the enhancer peptide sequences of the invention to a core peptide.

Typically, an enhancer peptide sequence is linked directly to a core polypeptide. An enhancer peptide sequence can also be attached to an intervening amino acid sequence present between the enhancer peptide sequence and the core polypeptide. The intervening amino acid sequence can  
5 typically range in size from about 1 to about 50 amino acid residues in length, with about 1 to about 10 residues in length being preferred. The same sorts of linkages described for linking the enhancer peptide to the core polypeptide can be used to link the enhancer peptide to the intervening peptide.

10 As discussed for enhancer peptide sequences, above, core and intervening amino acid sequences need not be restricted to the genetically encoded amino acids, but can comprise any of the amino acid and linkage modifications described above.

The amino- and/or carboxy-termini of the resulting hybrid polypeptide can comprise an amino group ( $-NH_2$ ) or a  
15 carboxy ( $-COOH$ ) group, respectively. Alternatively, the hybrid polypeptide amino-terminus may, for example, represent a hydrophobic group, including but not limited to carbobenzyl, dansyl, t-butoxycarbonyl, decanoyl, naphthoyl or other carbohydrate group; an acetyl group; 9-fluorenylmethoxy-carbonyl (Fmoc) group; or a modified, non-  
20 naturally occurring amino acid residue. Alternatively, the hybrid polypeptide carboxy-terminus can, for example, represent an amido group; a t-butoxycarbonyl group; or a modified non-naturally occurring amino acid residue. As a non-limiting example, the amino- and/or carboxy-termini of the resulting hybrid polypeptide can comprise any of the  
25 amino- and/or carboxy-terminal modifications depicted in the peptides shown in FIG. 13 or Table 2, below.

Typically, a hybrid polypeptide comprises an amino acid sequence that is a non-naturally occurring amino acid sequence. That is, typically, the amino acid sequence of a hybrid polypeptide, does not consist solely of the amino acid  
30 sequence of a fragment of an endogenous, naturally occurring polypeptide. In addition, a hybrid polypeptide is not



intended to consist solely of a full-length, naturally occurring polypeptide.

Core polypeptides can comprise any polypeptide which may be introduced into a living system, for example, any polypeptide that can function as a pharmacologically useful polypeptide. Such core polypeptides can, for example, be useful for the treatment or prevention of disease, or for use in diagnostic or prognostic methods, including in vivo imaging methods. The lower size limit of a core polypeptide is typically about 4-6 amino acid residues. There is, theoretically, no core polypeptide upper size limit and, as such a core polypeptide can comprise any naturally occurring polypeptide or fragment thereof, or any modified or synthetic polypeptide. Typically, however, a core polypeptide ranges from about ~~4-6 amino acids to about 494-500 amino acids~~, with about 4 to about 94-100 amino acid residues being preferred and about 4 to about 34-40 amino acid residues being most preferred.

Examples of possible core polypeptides, provided solely as example and not by way of limitation, include, but are not limited to, growth factors, cytokines, therapeutic polypeptides, hormones, e.g., insulin, and peptide fragments of hormones, inhibitors or enhancers of cytokines, peptide growth and differentiation factors, interleukins, chemokines, interferons, colony stimulating factors, angiogenic factors, receptor ligands, agonists, antagonists or inverse agonists, peptide targeting agents such as imaging agents or cytotoxic targeting agents, and extracellular matrix proteins such as collagen, laminin, fibronectin and integrin to name a few. In addition, possible core polypeptides may include viral or bacterial polypeptides that may function either directly or indirectly as immunogens or antigens, and thus may be useful in the treatment or prevention of pathological disease.

Representative examples of hybrid polypeptides which comprise core polypeptides derived from viral protein sequences are shown in FIG. 13, wherein the core polypeptide sequences are shaded. Core polypeptides also include, but

are not limited to, the polypeptides disclosed in U.S. Patent No. 5,464,933, U.S. Patent No. 5,656,480 and WO 96/19495, each of which is incorporated herein by reference in its entirety.

Core polypeptide sequences can further include, but are  
5 not limited to the polypeptide sequences depicted in Table 2,  
below. It is noted that the peptides listed in Table 2  
include hybrid polypeptides in addition to core polypeptides.  
The sequence of the hybrid polypeptides will be apparent,  
however, in light of the terminal enhancer peptide sequences  
present as part of the hybrid polypeptides.

10

15

20

25

30

TABLE 1

T No.	Sequence	Seq. ID No.
1	GIKQLQARILAVERYLKDQ	1
2	NNLLRAIEAQQHLLQLTVW	2
3	NEQEELLELDKWASLWNWF	3
4	YTSLIHSLIEESQNQQEK	4
5	Ac-VWGIKQLQARILAVERYLKDQQLLGIVG-NH2	5
6	QHLLQLTVWGIKQLQARILAVERYLKDQ	6
7	LRAIEAQQHLLQLTVWGIKQLQARILAV	7
8	VQQQNNLLARIEAQQHLLQLTVWGIKQL	8
9	RQLLSGIVQQQNNLLRAIEAQQHLLQLT	9
10	MTLTVQARQLLSGIVQQQNNLLRAIEAQ	10
12	VVSLSNGVSVLTSKVLDLKNYDKQLL	11
13	LLSTNKAVVSLSNGVSVLTSKVLDLKNY	12
15	Ac-VLHLEGEVNNIKSALLSTNKAVVSLSNG-NH2	13
19	Ac-LLSTNKAVVSLSNGVSVLTSKVLDLKNY-NH2	14
20	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASLWNWF-NH2	15
21	Ac-NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	16
22	Ac-IELSNIKENKCNCTDAKVKLKQELDKYKNAVTELQLLMQST-NH2	17
23	Ac-IELSNIKENKCNCTDAKVKLKQELDKY-NH2	18
24	Ac-ENKCNCTDAKVKLKQELDKYKNAVTEL-NH2	19
25	Ac-DAKVKLKQELDKYKNAVTELQLLMQST-NH2	20
26	Ac-CNCTDAKVKLKQELDKYKNAVTELQLL-NH2	21
27	Ac-SNIKENKCNCTDAKVKLKQELDKYKNAVTELQLL-NH2	22
28	Ac-ASGVAVSKVLHLEGEVNNIKSALLSTNKAVVSLSNGV-NH2	23
29	Ac-SGVAVSKVLHLEGEVNNIKSALLSTNKAVVSLSNG-NH2	24
30	Ac-VLHLEGEVNNIKSALLSTHKAHVSLSNGVSVLTSK-NH2	25
31	Ac-ARKLQRMKQLEDKVEELLSKNYHYLENEVARLKKLV-NH2	26
32	Ac-RMKQLEDKVEELLSKNYHYLENEVARLKKLVGER-NH2	27
33	Ac-VQQQNNLLRAIEAQQHLLQLTVWGIKQL-NH2	28
34	Ac-LRAIEAQQHLLQLTVWGIKQLQARILAV-NH2	29
35	Ac-QHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	30
36	Ac-RQLLSGIVQQQNNLLRAIEAQQHLLQLT-NH2	31
37	Ac-MTLTVQARQLLSGIVQQQNNLLRAIEAQ-NH2	32
38	Ac-AKQARSDIEKLKEAIRDITNKAVQSVQSS-NH2	33
39	Ac-AAVALVEAKQARSDIEKLKEAIRDITNKAVQSVQSS-NH2	34
40	Ac-AKQARSDIEKLKEAIRDITNKAVQSVQSSIGNLIVA-NH2	35
41	Ac-GTIALGVATSAQITAAVALVEAKQARSD-NH2	36
42	Ac-ATSAQITAAVALVEAKQARSDIEKLKEA-NH2	37
43	Ac-AAVALVEAKQARSDIEKLKEAIRDITNKANH2	38
44	Ac-IEKLKEAIRDITNKAVQSVQSSIGNLIVA-NH2	40
45	Ac-IRDITNKAVQSVQSSIGNLIVAISVQDY-NH2	41
46	Ac-AVQSVQSSIGNLIVAISVQDYVNKEIV-NH2	42
47	Ac-QARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLARILAVERYLKDQ-NH2	43
48	Ac-QARQLLSGIVQQQNNLLRAIEAQQHLLQ-NH2	44
49	Ac-MTWMEMDREINNYTSLIGSLIEESQNQQEKNEQEELLELDKWASLWNWF-NH2	45
50	Ac-WMEWDREINNYTSLIGSLIEESQNQQEKNEQEELLE-NH2	46
51	Ac-INNYTSLIGSLIEESQNQQEKNEQEELLE-NH2	47
52	Ac-INNYTSLIGSLIEESQNQQEKNEQEELLELDKWASL-NH2	48
53	Ac-EWDREINNYTSLIGSLIEESQNQQEKNEQEGGC-NH2	49
54	Ac-QSRTLLAGIVQQQQQLLDVVKRQQELLR-NH2	50
55	Ac-NNDTWQEWERKVDLFLENITALLIEAQIQEKNMYELQKLNSWD-NH2	51

T No.	Sequence	Seq. ID No.
56	Ac-WQEWERKVDLFLEENITALLBEAQIQQEK-NH2	52
57	Ac-VDFLEENITALLBEAQIQQEKMYELQK-NH2	53
58	Ac-ITALLBEAQIQQEKMYELQKLNWDVF-NH2	54
59	Ac-SSESFTLLEQWNNWKLQLAEQWLEQINEKHYLEDIS-NH2	55
60	Ac-DKASLWNWF-NH2	56
61	Ac-NEQELLELDKWASLWNWF-NH2	57
62	Ac-EKNEQELLELDKWASLWNWF-NH2	58
63	Ac-NQEQKNEQELLELDKWASLWNWF-NH2	59
64	Ac-ESQNQEQKNEQELLELDKWASLWNWF-NH2	60
65	Ac-LIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	61
66	Ac-NDQKKLMSNNVQIVRQQSYSIMSIIKEE-NH2	62
67	Ac-DEFDASISQVNEKINQSLAFIRKSDELL-NH2	63
68	Ac-VSKGYSALRTGWYTSVITIELSNIKEN-NH2	64
69	Ac-VVSLSNGVSVLTSKVLDLKNYIDKQLL-NH2	65
70	Ac-VNKKISALLSTNKAVVSLSNGVSVLTSK-NH2	66
71	Ac-PIINFYDPLVFPSEFDASISQVNEKINQSLAFIR-NH2	67
72	Ac-NLVYAQLQFTYDTLRGYINRALAQIARA-NH2	68
73	Ac-LNQVDLTETLERYQQLNTYALVSKDASYSRS-NH2	69
74	Ac-ELLVLKKAQLNRHSYKDSDFLDAALD-NH2	70
75	Ac-LAEAGEESVTEDTEREDTEEREDEEE-NH2	71
76	Ac-ALLAEAGEESVTEDTEREDTEEREDEEEENBART-NH2	72
77	Ac-ETERSVDLVAALLAEAGEESVTEDTEREDTEEBRE-NH2	73
78	Ac-EESVTEDTEREDTEEREDEEEENBART-NH2	74
79	Ac-VDLVAALLAEAGEESVTEDTEREDTEEE-NH2	75
80	Ac-NSETERSVDLVAALLAEAGEESVTE-NH2	76
81	Ac-DISYAQLQFTYDVLKDYINDALRNIMDA-NH2	77
82	Ac-SNVFSKDEIMREYNSQKQHIRTLSAKVNDN-NH2	78
83	Biotin-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	1076
84	Dig-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	1076
85	Biotin-NNLLRAIEAQHLLQLTVWGKQLQARILAVERYLKDQ-NH2	16
86	Dig-NNLLRAIEAQHLLQLTVWGKQLQARILAVERYLKDQ-NH2	16
87	Ac-VLHQNLQKQYLETQERLLAGNRIAARQLQIWKDVA-NH2	83
88	Ac-LWHEQLNIAQRAQLQLINQALAVREKVLIRYDIQK-NH2	84
89	Ac-LLDNFESTWEQSKELWEQQEISQNLHKSALQBYW-NH2	85
90	Ac-LSNLLQISNNSDEWLEALEIEHEKWKLQWQSYEQF-NH2	86
91	Ac-KLEALEGKLEALEGKLEALEGKLEALEGKLEALEGK-NH2	87
92	Ac-ELRALRGELRALRGELRALRGELRALRGK-NH2	88
93	Ac-ELKAKELEGEGLAEGEBALKGLLEKAAKLEGLELLK-NH2	89
94	Ac-WEAAAREAAAREAAAREAAARA-NH2	90
95	Ac-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNAF-NH2	91
96	Ac-YTSLIHSLEESQNQEQKNEQELLELDKWASLANWF-NH2	92
97	Ac-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	93
98	Ac-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	94
99	Ac-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	95
100	Ac-RMKQLEDKVEELLSKNYHLENEVARLKKLVGER-NH2	96
101	Ac-QQLQLTVWGKQLQARILAVERYLKNQ-NH2	97
102	Ac-NEQELLELDKWASLWNWF-NH2	98
103	Ac-YTSLIHSLEESQNQEQKNEQELLELDKWASLWNWF-NH2	99
104	Ac-IINFYDPLVFPSEFDASISQVNEKINQSLAFIRK-NH2	100
105	Ac-INFYDPLVFPSEFDASISQVNEKINQSLAFIRKS-NH2	101

T No.	Sequence	Seq. ID No.
106	Ac-NFYDPLVFPSEFDASISQVNEKINQSLAFIRKSD-NH2	102
107	Ac-FYDPLVFPSEFDASISQVNEKINQSLAFIRKSDE-NH2	103
108	Ac-YDPLVFPSEFDASISQVNEKINQSLAFIRKSDEL-NH2	104
109	Ac-DPLVFPSEFDASISQVNEKINQSLAFIRKSDELL-NH2	105
110	Ac-PLVFPSEFDASISQVNEKINQSLAFIRKSDELLH-NH2	106
111	Ac-LVFPSEFDASISQVNEKINQSLAFIRKSDELLHN-NH2	107
112	Ac-VFPSEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	108
113	Ac-FPSEFDASISQVNEKINQSLAFIRKSDELLHNVN-NH2	109
114	Ac-PSDEFDASISQVNEKINQSLAFIRKSDELLHNVNA-NH2	110
115	Ac-SDEFDASISQVNEKINQSLAFIRKSDELLHNVNAG-NH2	111
116	Ac-DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK-NH2	112
117	Ac-EFDASISQVNEKINQSLAFIRKSDELLHNVNAGKS-NH2	113
118	Ac-FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST-NH2	114
119	Ac-DASISQVNEKINQSLAFIRKSDELLHNVNAGKSTT-NH2	115
120	Ac-ASGVAVSKVLHLEGEVNIKSALLSTNKAVVSLSN-NH2	116
121	Ac-SGVAVSKVLHLEGEVNIKSALLSTNKAVVSLSNG-NH2	117
122	Ac-GVAVSKVLHLEGEVNIKSALLSTNKAVVSLSNGV-NH2	118
123	Ac-VAVSKVLHLEGEVNIKSALLSTNKAVVSLSNGVSV-NH2	119
124	Ac-AVSKVLHLEGEVNIKSALLSTNKAVVSLSNGVSV-NH2	120
125	Ac-VSKVLHLEGEVNIKSALLSTNKAVVSLSNGVSVL-NH2	121
126	Ac-SKVLHLEGEVNIKSALLSTNKAVVSLSNGVSVLT-NH2	122
127	Ac-KVLHLEGEVNIKSALLSTNKAVVSLSNGVSVLTS-NH2	123
128	Ac-VLHLEGEVNIKSALLSTNKAVVSLSNGVSVLTSK-NH2	124
129	Ac-LHLEGEVNIKSALLSTNKAVVSLSNGVSVLTSKV-NH2	125
130	Ac-HLEGEVNIKSALLSTNKAVVSLSNGVSVLTSKVL-NH2	126
131	Ac-LEGEVNIKSALLSTNKAVVSLSNGVSVLTSKVLD-NH2	127
132	Ac-BGBVNIKSALLSTNKAVVSLSNGVSVLTSKVLDL-NH2	128
133	Ac-GBVNIKSALLSTNKAVVSLSNGVSVLTSKVLDLK-NH2	129
134	Ac-EVNIKSALLSTNKAVVSLSNGVSVLTSKVLDLKN-NH2	130
135	Ac-VNIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNY-NH2	131
136	Ac-NIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYI-NH2	132
137	Ac-KIKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYID-NH2	133
138	Ac-IKSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK-NH2	134
139	Ac-KSALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ-NH2	135
140	Ac-SALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQL-NH2	136
141	Ac-ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLL-NH2	137
142	Ac-YTSVTIELSNIKENKCNGTDAKVKLIKQELDKYK-NH2	138
143	Ac-TSVTIELSNIKENKCNGTDAKVKLIKQELDKYKN-NH2	139
144	Ac-SVTIELSNIKENKCNGTDAKVKLIKQELDKYKNA-NH2	140
145	Ac-VTIELSNIKENKCNGTDAKVKLIKQELDKYKNAV-NH2	141
146	Ac-ITIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE-NH2	142
147	Ac-TIELSNIKENKCNGTDAKVKLIKQELDKYKNAVTE-NH2	143
148	Ac-IELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEQ-NH2	144
149	Ac-ELSNIKENKCNGTDAKVKLIKQELDKYKNAVTEQL-NH2	145
150	Ac-LSNIKENKCNGTDAKVKLIKQELDKYKNAVTEQLQ-NH2	146
151	Ac-SNIKENKCNGTDAKVKLIKQELDKYKNAVTEQLQL-NH2	147
152	Ac-NIKENKCNGTDAKVKLIKQELDKYKNAVTEQLQLM-NH2	148
153	Ac-IKENKCNGTDAKVKLIKQELDKYKNAVTEQLQLMQ-NH2	149
154	Ac-KENKCNGTDAKVKLIKQELDKYKNAVTEQLQLMQS-NH2	150
155	Ac-ENKCNGTDAKVKLIKQELDKYKNAVTEQLQLMQST-NH2	151

T No.	Sequence	Seq. ID No.
156	Ac-LLDNFESTWEQSKELWELQHSIQNLHKSALQBYWN-NH2	152
157	Ac-ALGVATSAQITA AVALVEAKQARSDIEKLKEAIRD-NH2	153
158	Ac-LGVATSAQITA AVALVEAKQARSDIEKLKEAIRD-T-NH2	154
159	Ac-GVATSAQITA AVALVEAKQARSDIEKLKEAIRD-TN-NH2	155
160	Ac-VATSAQITA AVALVEAKQARSDIEKLKEAIRD-TNK-NH2	156
161	Ac-ATSAQITA AVALVEAKQARSDIEKLKEAIRD-TNKA-NH2	157
162	Ac-TSAQITA AVALVEAKQARSDIEKLKEAIRD-TNKAV-NH2	158
163	Ac-SAQITA AVALVEAKQARSDIEKLKEAIRD-TNKAVQ-NH2	159
164	Ac-AQITA AVALVEAKQARSDIEKLKEAIRD-TNKAVQS-NH2	160
165	Ac-QITA AVALVEAKQARSDIEKLKEAIRD-TNKAVQSV-NH2	161
166	Ac-ITAAVALVEAKQARSDIEKLKEAIRD-TNKAVQSVQ-NH2	162
167	Ac-TAAVALVEAKQARSDIEKLKEAIRD-TNKAVQSVQS-NH2	163
168	Ac-AAVALVEAKQARSDIEKLKEAIRD-TNKAVQSVQSS-NH2	164
169	Ac-AVALVEAKQARSDIEKLKEAIRD-TNKAVQSVQSSI-NH2	165
170	Ac-VALVEAKQARSDIEKLKEAIRD-TNKAVQSVQSSIG-NH2	166
171	Ac-ALVEAKQARSDIEKLKEAIRD-TNKAVQSVQSSIGN-NH2	167
172	Ac-LVEAKQARSDIEKLKEAIRD-TNKAVQSVQSSIGNL-NH2	168
173	Ac-VEAKQARSDIEKLKEAIRD-TNKAVQSVQSSIGNLI-NH2	169
174	Ac-EAKQARSDIEKLKEAIRD-TNKAVQSVQSSIGNLIV-NH2	170
175	Ac-KQARSDIEKLKEAIRD-TNKAVQSVQSSIGNLIVAI-NH2	171
176	Ac-QARSDIEKLKEAIRD-TNKAVQSVQSSIGNLIVAIK-NH2	172
177	Ac-ARSDIEKLKEAIRD-TNKAVQSVQSSIGNLIVAIKS-NH2	174
178	Ac-RSDIEKLKEAIRD-TNKAVQSVQSSIGNLIVAIKSV-NH2	175
179	Ac-SDIEKLKEAIRD-TNKAVQSVQSSIGNLIVAIKSVQ-NH2	176
180	Ac-DIEKLKEAIRD-TNKAVQSVQSSIGNLIVAIKSVQD-NH2	177
181	Ac-IEKLKEAIRD-TNKAVQSVQSSIGNLIVAIKSVQDY-NH2	178
182	Ac-EKLKEAIRD-TNKAVQSVQSSIGNLIVAIKSVQDYV-NH2	179
183	Ac-KLKEAIRD-TNKAVQSVQSSIGNLIVAIKSVQDYVN-NH2	180
184	Ac-LKEAIRD-TNKAVQSVQSSIGNLIVAIKSVQDYV-NK-NH2	181
185	Ac-KEAIRD-TNKAVQSVQSSIGNLIVAIKSVQDYVNKE-NH2	182
186	Ac-EAIRD-TNKAVQSVQSSIGNLIVAIKSVQDYVNKEI-NH2	183
187	Ac-AIRD-TNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV-NH2	184
188	Ac-IRD-TNKAVQSVQSSIGNLIVAIKSVQDYVNKEIV-NH2	185
189	Ac-YTPNDITLNNVALDPIDISIELNKA KSDLEESKE-NH2	186
190	Ac-TPNDITLNNVALDPIDISIELNKA KSDLEESKEW-NH2	187
191	Ac-PNDITLNNVALDPIDISIELNKA KSDLEESKEWI-NH2	188
192	Ac-NDITLNNVALDPIDISIELNKA KSDLEESKEWIR-NH2	189
193	Ac-DITLNNVALDPIDISIELNKA KSDLEESKEWIRR-NH2	190
194	Ac-ITLNNVALDPIDISIELNKA KSDLEESKEWIRRS-NH2	191
195	Ac-TLNNVALDPIDISIELNKA KSDLEESKEWIRRSN-NH2	192
196	Ac-LNNVALDPIDISIELNKA KSDLEESKEWIRRSNQ-NH2	193
197	Ac-NNNVALDPIDISIELNKA KSDLEESKEWIRRSNQK-NH2	194
198	Ac-NSVALDPIDISIELNKA KSDLEESKEWIRRSNQKL-NH2	195
200	Ac-SVALDPIDISIELNKA KSDLEESKEWIRRSNQKLD-NH2	197
201	Ac-VALDPIDISIELNKA KSDLEESKEWIRRSNQKLDS-NH2	198
202	Ac-ALDPIDISIELNKA KSDLEESKEWIRRSNQKLDSI-NH2	199
203	Ac-LDPIDISIELNKA KSDLEESKEWIRRSNQKLDSIG-NH2	200
204	Ac-DPIDISIELNKA KSDLEESKEWIRRSNQKLDSIGN-NH2	201
205	Ac-PIDISIELNKA KSDLEESKEWIRRSNQKLDSIGNW-NH2	202
206	Ac-IDISIELNKA KSDLEESKEWIRRSNQKLDSIGNWH-NH2	203

T No.	Sequence	Seq. ID No.
207	Ac-DISIELNKA KSDLEESKEWIRRSNQKLD SIGNWHQ-NH2	204
208	Ac-ISIELNKA KSDLEESKEWIRRSNQKLD SIGNWHQS-NH2	205
209	Ac-SIELNKA KSDLEESKEWIRRSNQKLD SIGNWHQSS-NH2	206
210	Ac-IELNKA KSDLEESKEWIRRSNQKLD SIGNWHQSST-NH2	207
211	Ac-ELNKA KSDLEESKEWIRRSNQKLD SIGNWHQSSTT-NH2	208
212	Ac-ELRALRGELRALRGELRALRGELRALRGELRALRGK-NH2	209
213	Ac-YTSLIHSLEESQNQQKNEQEELLELDKWASLWNWF-NH2	210
214	Ac-YTSLIHSLEESQNQQEKNEQEELLELNKWASLWNWF-NH2	211
215	Ac-YTSLIHSLEESQNQQEKNEQEELLELDKWASLWNWF-NH2	212
216	Ac-YTSLIHSLEESQNQQEKNEQEELLELDKWASLWNWF-NH2	213
217	Ac-YTSLIHSLEESQNQQKNNQQQLQLNKWASLWNWF-NH2	214
218	Ac-EQEELLELDKWASLWNWF-NH2	215
219	Ac-QEELLELDKWASLWNWF-NH2	216
220	Ac-ELLELDKWASLWNWF-NH2	217
221	Ac-LELDKWASLWNWF-NH2	218
222	Ac-ELDKWASLWNWF-NH2	219
226	Ac-WASLWNWF-NH2	223
227	Ac-ASLWNWF-NH2	224
229	Ac-YTSLIHSLEESQNQQEKNEQEELLELDKWASLANAA-NH2	226
230	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	227
231	Ac-YTSLIQSLEESQNQQEKNNQEELLELDKWASLWNWF-NH2	228
234	Ac-EAAAREAAAREAAARLELDKWASLWNWF-NH2	231
236	Ac-PSLRDPISAEISIQALSALGGDINKVLEKLGYSYG-NH2	233
237	Ac-SLRDPISAEISIQALSALGGDINKVLEKLGYSYGG-NH2	234
238	Ac-LRDPISAEISIQALSALGGDINKVLEKLGYSYGGD-NH2	235
239	Ac-RDPISAEISIQALSALGGDINKVLEKLGYSYGGDL-NH2	236
240	Ac-DPISAEISIQALSALGGDINKVLEKLGYSYGGDLL-NH2	237
241	Ac-PISAEISIQALSALGGDINKVLEKLGYSYGGDLLG-NH2	238
242	Ac-ISAEISIQALSALGGDINKVLEKLGYSYGGDLLGI-NH2	239
243	Ac-SAEISIQALSALGGDINKVLEKLGYSYGGDLLGIL-NH2	240
244	Ac-AEISIQALSALGGDINKVLEKLGYSYGGDLLGILE-NH2	241
245	Ac-EISIQALSALGGDINKVLEKLGYSYGGDLLGILES-NH2	242
246	Ac-ISIQALSALGGDINKVLEKLGYSYGGDLLGILES-R-NH2	243
247	Ac-SIQALSALGGDINKVLEKLGYSYGGDLLGILES-RG-NH2	244
248	Ac-IQALSALGGDINKVLEKLGYSYGGDLLGILES-RGI-NH2	245
249	Ac-QALSALGGDINKVLEKLGYSYGGDLLGILES-RGIK-NH2	246
250	Ac-ALSALGGDINKVLEKLGYSYGGDLLGILES-RGIKA-NH2	247
251	Ac-LSALGGDINKVLEKLGYSYGGDLLGILES-RGIKAR-NH2	248
252	Ac-PDAVYLHRIDLGPPISELERLDVGTNLGNAIAKLED-NH2	249
253	Ac-DAVYLHRIDLGPPISELERLDVGTNLGNAIAKLEDA-NH2	250
254	Ac-AVYLHRIDLGPPISELERLDVGTNLGNAIAKLEDAK-NH2	251
255	Ac-VYLHRIDLGPPISELERLDVGTNLGNAIAKLEDAKE-NH2	252
256	Ac-YLHRIDLGPPISELERLDVGTNLGNAIAKLEDAKEL-NH2	253
257	Ac-LHRIDLGPPISELERLDVGTNLGNAIAKLEDAKELL-NH2	254
258	Ac-HRIDLGPPISELERLDVGTNLGNAIAKLEDAKELLB-NH2	255
259	Ac-RIDLGPPISELERLDVGTNLGNAIAKLEDAKELLES-NH2	256
260	Ac-IDLGPPISELERLDVGTNLGNAIAKLEDAKELLESS-NH2	257
261	Ac-DLGPPISELERLDVGTNLGNAIAKLEDAKELLESSD-NH2	258
262	Ac-LGPPISELERLDVGTNLGNAIAKLEDAKELLESSDQ-NH2	259
263	Ac-GPPISELERLDVGTNLGNAIAKLEDAKELLESSDQI-NH2	260

T No.	Sequence	Seq. ID No.
264	Ac-PPISLERLDVGTNLGNAIAKLEDAKELLESSDQIL-NH2	261
265	Ac-PISLERLDVGTNLGNAIAKLEDAKELLESSDQILR-NH2	262
266	Ac-ISLERLDVGTNLGNAIAKLEDAKELLESSDQIRS-NH2	263
267	Ac-SLERLDVGTNLGNAIAKLEDAKELLESSDQILRSM-NH2	264
268	Ac-LERLDVGTNLGNAIAKLEDAKELLESSDQILRSMK-NH2	265
269	Ac-EWIRRSNQKLD SI-NH2	266
270	Ac-LBLDKWASLANAF-NH2	267
271	Ac-LBLDKWASLFNFF-NH2	268
272	Ac-LBLDKWASLANWF-NH2	269
273	Ac-LBLDKWASLWNAF-NH2	270
274	Ac-ELGNVNNSISNALDKLEESNSKLDKVN VKLTSTSA-NH2	271
275	Ac-TELG NVNNSISNALDKLEESNSKLDKVN VKLTST-NH2	282
276	Ac-STELGNVNNSISNALDKLEESNSKLDKVN VKLTST-NH2	273
277	Ac-ISTELGNVNNSISNALDKLEESNSKLDKVN VKLTS-NH2	274
278	Ac-DISTELGNVNNSISNALDKLEESNSKLDKVN VKLT-NH2	275
279	Ac-LDISTELGNVNNSISNALDKLEESNSKLDKVN VKL-NH2	276
280	Ac-NLDISTELGNVNNSISNALDKLEESNSKLDKVN VK-NH2	277
281	Ac-GNLDISTELGNVNNSISNALDKLEESNSKLDKVN V-NH2	278
282	Ac-TGNLDISTELGNVNNSISNALDKLEESNSKLDKVN-NH2	279
283	Ac-VTGNLDISTELGNVNNSISNALDKLEESNSKLDKV-NH2	280
284	Ac-IVTGNLDISTELGNVNNSISNALDKLEESNSKLDK-NH2	281
285	Ac-VIVTGNLDISTELGNVNNSISNALDKLEESNSKLD-NH2	282
286	Ac-QVIVTGNLDISTELGNVNNSISNALDKLEESNSKL-NH2	283
287	Ac-SQVIVTGNLDISTELGNVNNSISNALDKLEESNSK-NH2	284
288	Ac-DSQVIVTGNLDISTELGNVNNSISNALDKLEESNS-NH2	285
289	Ac-LDSQVIVTGNLDISTELGNVNNSISNALDKLEESN-NH2	286
290	Ac-ILDSQVIVTGNLDISTELGNVNNSISNALDKLEES-NH2	287
291	Ac-SILDSQVIVTGNLDISTELGNVNNSISNALDKLEE-NH2	288
292	Ac-ISILDSQVIVTGNLDISTELGNVNNSISNALDKLE-NH2	289
293	Ac-NISILDSQVIVTGNLDISTELGNVNNSISNALDKL-NH2	290
294	Ac-KNISILDSQVIVTGNLDISTELGNVNNSISNALDK-NH2	291
295	Ac-QKNISILDSQVIVTGNLDISTELGNVNNSISNALD-NH2	292
296	Ac-YQKNISILDSQVIVTGNLDISTELGNVNNSISNAL-NH2	293
297	Ac-TYQKNISILDSQVIVTGNLDISTELGNVNNSISNA-NH2	294
298	Ac-ATYQKNISILDSQVIVTGNLDISTELGNVNNSISN-NH2	295
299	Ac-DATYQKNISILDSQVIVTGNLDISTELGNVNNSIS-NH2	296
300	Ac-FDATYQKNISILDSQVIVTGNLDISTELGNVNNSI-NH2	297
301	Ac-EFDATYQKNISILDSQVIVTGNLDISTELGNVNNS-NH2	298
302	Ac-GEFDATYQKNISILDSQVIVTGNLDISTELGNVN-NH2	299
303	Ac-SGEFDATYQKNISILDSQVIVTGNLDISTELGNVN-NH2	300
304	Ac-LSGEFDATYQKNISILDSQVIVTGNLDISTELGNV-NH2	301
305	Ac-RLSGEFDATYQKNISILDSQVIVTGNLDISTELGN-NH2	302
306	Ac-LRLSGEFDATYQKNISILDSQVIVTGNLDISTELG-NH2	303
307	Ac-TLRLSGEFDATYQKNISILDSQVIVTGNLDISTEL-NH2	304
308	Ac-ITLRLSGEFDATYQKNISILDSQVIVTGNLDISTE-NH2	305
309	Ac-GITLRLSGEFDATYQKNISILDSQVIVTGNLDIST-NH2	306
310	Ac-TATIEAVHEVTDGLSQLAVAVGKMQQFVNDQFNNT-NH2	307
311	Ac-ITATIEAVHEVTDGLSQLAVAVGKMQQFVNDQFNN-NH2	308
312	Ac-SITATIEAVHEVTDGLSQLAVAVGKMQQFVNDQFN-NH2	309
314	Ac-KESITATIEAVHEVTDGLSQLAVAVGKMQQFVNDQ-NH2	310



T No.	Sequence	Seq. ID No.
315	Ac-LKESITATIEAVHEVTDGLSQLAVAVGKMQQFVND-NH2	311
316	Ac-RLKESITATIEAVHEVTDGLSQLAVAVGKMQQFVN-NH2	312
317	Ac-LRLKESITATIEAVHEVTDGLSQLAVAVGKMQQFV-NH2	313
318	Ac-ILRLKESITATIEAVHEVTDGLSQLAVAVGKMQQF-NH2	314
319	Ac-NILRLKESITATIEAVHEVTDGLSQLAVAVGKMQQ-NH2	315
320	Ac-ANILRLKESITATIEAVHEVTDGLSQLAVAVGKM-Q-NH2	316
321	Ac-AANILRLKESITATIEAVHEVTDGLSQLAVAVGKM-NH2	317
322	Ac-HKCDDECMNSVKNGTYDYPKYEEESKLNREIKGV-NH2	318
323	Ac-KCDDECMNSVKNGTYDYPKYEEESKLNREIKGVK-NH2	319
324	Ac-CDDECMNSVKNGTYDYPKYEEESKLNREIKGVKL-NH2	320
325	Ac-DDECMNSVKNGTYDYPKYEEESKLNREIKGVKLS-NH2	321
326	Ac-DECMNSVKNGTYDYPKYEEESKLNREIKGVKLSS-NH2	322
327	Ac-ECMNSVKNGTYDYPKYEEESKLNREIKGVKLSSM-NH2	323
328	Ac-CMNSVKNGTYDYPKYEEESKLNREIKGVKLSSMG-NH2	324
329	Ac-MNSVKNGTYDYPKYEEESKLNREIKGVKLSSMGV-NH2	325
330	Ac-NSVKNGTYDYPKYEEESKLNREIKGVKLSSMGVY-NH2	326
331	Ac-SVKNGTYDYPKYEEESKLNREIKGVKLSSMGVYQ-NH2	327
332	Ac-VKNGTYDYPKYEEESKLNREIKGVKLSSMGVYQI-NH2	328
333	Ac-KNGTYDYPKYEEESKLNREIKGVKLSSMGVYQIL-NH2	329
334	Ac-AFIRKSDELLHNV-NH2	330
335	Ac-VVLAGAALGVATAAQITAGIALHQSMNLNSQAIDNL-NH2	331
336	Ac-VLAGAALGVATAAQITAGIALHQSMNLNSQAIDNLR-NH2	332
337	Ac-LAGAALGVATAAQITAGIALHQSMNLNSQAIDNLR-NH2	333
338	Ac-AGAALGVATAAQITAGIALHQSMNLNSQAIDNLRAS-NH2	334
339	Ac-GAALGVATAAQITAGIALHQSMNLNSQAIDNLRASL-NH2	335
340	Ac-AALGVATAAQITAGIALHQSMNLNSQAIDNLRASLE-NH2	336
341	Ac-ALGVATAAQITAGIALHQSMNLNSQAIDNLRASLET-NH2	337
342	Ac-LGVATAAQITAGIALHQSMNLNSQAIDNLRASLETT-NH2	338
343	Ac-GVATAAQITAGIALHQSMNLNSQAIDNLRASLETTN-NH2	339
344	Ac-VATAAQITAGIALHQSMNLNSQAIDNLRASLETTNQ-NH2	340
345	Ac-ATAAQITAGIALHQSMNLNSQAIDNLRASLETTNQA-NH2	341
346	Ac-TAAQITAGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	342
347	Ac-AAQITAGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	343
348	Ac-AQITAGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	344
349	Ac-QITAGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	345
350	Ac-ITAGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	346
351	Ac-TAGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	347
352	Ac-AGIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	348
353	Ac-GIALHQSMNLNSQAIDNLRASLETTNQAI-NH2	349
354	Ac-IALHQSMNLNSQAIDNLRASLETTNQAI-NH2	350
355	Ac-ALHQSMNLNSQAIDNLRASLETTNQAI-NH2	351
356	Ac-LHQSMNLNSQAIDNLRASLETTNQAI-NH2	352
357	Ac-HQSMNLNSQAIDNLRASLETTNQAI-NH2	353
358	Ac-QSMNLNSQAIDNLRASLETTNQAI-NH2	354
359	Ac-SMLNSQAIDNLRASLETTNQAI-NH2	355
360	Ac-MLNSQAIDNLRASLETTNQAI-NH2	356
361	Ac-LNSQAIDNLRASLETTNQAI-NH2	357
362	Ac-NSQAIDNLRASLETTNQAI-NH2	358
363	Ac-SQAIDNLRASLETTNQAI-NH2	359
364	Ac-QAIDNLRASLETTNQAI-NH2	360

T No.	Sequence	Seq. ID No.
365	Ac-AIDNLRASLETTNQAIEAIRQAGQEMILAVQGVQD-NH2	361
366	Ac-IDNLRASLETTNQAIEAIRQAGQEMILAVQGVQDY-NH2	362
367	Ac-DNLRASLETTNQAIEAIRQAGQEMILAVQGVQDYI-NH2	363
368	Ac-NLRASLETTNQAIEAIRQAGQEMILAVQGVQDYIN-NH2	364
369	Ac-LRASLETTNQAIEAIRQAGQEMILAVQGVQDYINN-NH2	365
370	Ac-RASLETTNQAIEAIRQAGQEMILAVQGVQDYINNE-NH2	366
371	Ac-YTSVITIELSNIKENKUNGTD AVKLIKQELDKYK-NH2	367
372	Ac-TSVITIELSNIKENKUNGTD AVKLIKQELDKYKN-NH2	368
373	Ac-SVITIELSNIKENKUNGTD AVKLIKQELDKYKNA-NH2	369
374	Ac-SNIKENKUNGTD AKVLIKQELDKYKNAVTELQLL-NH2	370
375	Ac-KENKUNGTD AKVLIKQELDKYKNAVTELQLLMQS-NH2	371
376	Ac-CLELDKWASLWNWFC-NH2	372
377	Ac-CLELDKWASLANWFC-NH2	373
378	Ac-CLELDKWASLFNFFC-NH2	374
379	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASLFNFF-NH2	375
381	Ac-RMKQLEDKVEELLSKNYHLENELELDKWASLWNWF-NH2	376
382	Ac-KVEELLSKNYHLENELELDKWASLWNWF-NH2	377
383	Ac-RMKQLEDKVEELLSKLEWIRRSNQKLD SI-NH2	378
384	Ac-RMKQLEDKVEELLSKLAFIRKSDELHNV-NH2	379
385	Ac-ELEALRGELRALRGELELDKWASLWNWF-NH2	380
386	Ac-LDPIDISIELNKA KSDLEESKEWIRRSNQKLD SI-NH2	381
387	Ac-CNEQLSDSFPVEFFQV-NH2	382
388	Ac-MAEDDPYLRPEQMFHLDPSL-NH2	383
389	Ac-EDFSSIADMDFSALLSQISS-NH2	384
390	Ac-TWQEWERKVD FLEENITALL EEAQIQQEK NMYELQ-NH2	385
391	Ac-WQEWERKVD FLEENITALL EEAQIQQEK NMYELQK-NH2	386
392	Ac-QEWERKVD FLEENITALL EEAQIQQEK NMYELQKL-NH2	387
393	Ac-EWERKVD FLEENITALL EEAQIQQEK NMYELQKLN-NH2	388
394	Ac-WERKVD FLEENITALL EEAQIQQEK NMYELQKLNS-NH2	389
395	Ac-ERKVD FLEENITALL EEAQIQQEK NMYELQKLNSW-NH2	390
396	Ac-RKVD FLEENITALL EEAQIQQEK NMYELQKLNSWD-NH2	391
397	Ac-KVD FLEENITALL EEAQIQQEK NMYELQKLNSWDV-NH2	392
398	Ac-VDFLEENITALL EEAQIQQEK NMYELQKLNSWDVF-NH2	393
399	Ac-DFLEENITALL EEAQIQQEK NMYELQKLNSWDVFG-NH2	394
400	Ac-FLEENITALL EEAQIQQEK NMYELQKLNSWDVFGN-NH2	395
401	Ac-LEENITALL EEAQIQQEK NMYELQKLNSWDVFGNW-NH2	396
402	Ac-LEENITALL EEAQIQQEK NMYELQKLNSWDVFGNWF-NH2	397
403	Ac-NEQSEEKENELYWAKEQLLDLLFNIFNQTVGAWIMQ-NH2	398
405	Ac-QQQLLDVVKRQQELLRLTVWGTKNLQTRVTAIEKYLD-NH2	400
406	Ac-QQQLLDVVKRQQELLRLTVWGTKNLQTRVTAIEKYLDQ-NH2	401
407	Ac-QQQLLDVVKRQQELLRLTVWGPKNLQTRVTAIEKYLDQ-NH2	402
408	Ac-DERKQDKVLVVQQTGTLQLTLIQLEKTAKLQWVRLNRY-NH2	403
409	Ac-QQQLLDVVKRQQELLRLTVWGTKNLQTRVTAIEKY-NH2	404
410	Ac-QQQLLDVVKRQQELLRLTVWGTKNLQTRVTAIEKYL-NH2	405
411	Ac-QLLDVVKRQQELLRLTVWGTKNLQTRVTAIEKYK-NH2	406
412	Ac-LLDVVKRQQELLRLTVWGTKNLQTRVTAIEKYLD-NH2	407
413	Ac-LDVVKRQQELLRLTVWGTKNLQTRVTAIEKYLDQ-NH2	408
414	Ac-DVVVKRQQELLRLTVWGTKNLQTRVTAIEKYLDQA-NH2	409
415	Ac-VVKRQQELLRLTVWGTKNLQTRVTAIEKYLDQAQ-NH2	410
416	Ac-VKRQQELLRLTVWGTKNLQTRVTAIEKYLDQAQL-NH2	411

T No.	Sequence	Seq. ID No.
417	Ac-KRQQELLRLTVWGTKNLQTRVTAIEKYLDQAQLN-NH2	412
418	Ac-RQQELLRLTVWGTKNLQTRVTAIEKYLDQAQLNA-NH2	413
419	Ac-QQELLRLTVWGTKNLQTRVTAIEKYLDQAQLNAW-NH2	414
420	Ac-QELLRLTVWGTKNLQTRVTAIEKYLDQAQLNAWG-NH2	415
421	Ac-ELLRLTVWGTKNLQTRVTAIEKYLDQAQLNAWGC-NH2	416
422	Ac-NNLLRAIEAQQHLLQLTVWGPQLQARILAVERYLKDQ-NH2	417
423	Ac-SELEIKRYKNRVASRKCRAKFKQLLQHYREVAAAK-NH2	418
424	Ac-ELIKRYKNRVASRKCRAKFKQLLQHYREVAAAKS-NH2	419
425	Ac-LEIKRYKNRVASRKCRAKFKQLLQHYREVAAAKSS-NH2	420
426	Ac-EIKRYKNRVASRKCRAKFKQLLQHYREVAAAKSSE-NH2	421
427	Ac-IKRYKNRVASRKCRAKFKQLLQHYREVAAAKSSEN-NH2	422
428	Ac-KRYKNRVASRKCRAKFKQLLQHYREVAAAKSENDR-NH2	423
429	Ac-RYKNRVASRKCRAKFKQLLQHYREVAAAKSENDR-NH2	424
430	Ac-YKNRVASRKCRAKFKQLLQHYREVAAAKSENDR-L-NH2	425
431	Ac-KNRVASRKCRAKFKQLLQHYREVAAAKSENDR-LR-NH2	426
432	Ac-NRVASRKCRAKFKQLLQHYREVAAAKSENDR-LRL-NH2	427
433	Ac-RVASRKCRAKFKQLLQHYREVAAAKSENDR-LRLL-NH2	428
434	Ac-VASRKCRAKFKQLLQHYREVAAAKSENDR-LRLLL-NH2	429
435	Ac-ASRKCRAKFKQLLQHYREVAAAKSENDR-LRLLLK-NH2	430
436	Ac-SRKCRAKFKQLLQHYREVAAAKSENDR-LRLLLKQ-NH2	431
437	Ac-RKCRAKFKQLLQHYREVAAAKSENDR-LRLLLKQM-NH2	432
438	Ac-KCRAKFKQLLQHYREVAAAKSENDR-LRLLLKQMC-NH2	433
439	Ac-CRAKFKQLLQHYREVAAAKSENDR-LRLLLKQMCP-NH2	434
440	Ac-RAKFKQLLQHYREVAAAKSENDR-LRLLLKQMCP-S-NH2	435
441	Ac-AKFKQLLQHYREVAAAKSENDR-LRLLLKQMCP-SL-NH2	436
442	Ac-KFKQLLQHYREVAAAKSENDR-LRLLLKQMCP-SLD-NH2	437
443	Ac-FKQLLQHYREVAAAKSENDR-LRLLLKQMCP-SLDV-NH2	438
444	Ac-QQLLQHYREVAAAKSENDR-LRLLLKQMCP-SLDVD-NH2	439
445	Ac-QLLQHYREVAAAKSENDR-LRLLLKQMCP-SLDVDS-NH2	440
446	Ac-LLQHYREVAAAKSENDR-LRLLLKQMCP-SLDVDSI-NH2	441
447	Ac-LQHYREVAAAKSENDR-LRLLLKQMCP-SLDVDSII-NH2	442
448	Ac-QHYREVAAAKSENDR-LRLLLKQMCP-SLDVDSIIP-NH2	443
449	Ac-HYREVAAAKSENDR-LRLLLKQMCP-SLDVDSIIPR-NH2	444
450	Ac-YREVAAAKSENDR-LRLLLKQMCP-SLDVDSIIPRT-NH2	445
451	Ac-REVAAAKSENDR-LRLLLKQMCP-SLDVDSIIPRTP-NH2	446
452	Ac-EVAAAKSENDR-LRLLLKQMCP-SLDVDSIIPRTPD-NH2	447
453	Ac-VAAAKSENDR-LRLLLKQMCP-SLDVDSIIPRTPDV-NH2	448
454	Ac-AAAKSENDR-LRLLLKQMCP-SLDVDSIIPRTPDVL-NH2	449
455	Ac-AAKSENDR-LRLLLKQMCP-SLDVDSIIPRTPDVLH-NH2	450
456	Ac-AKSENDR-LRLLLKQMCP-SLDVDSIIPRTPDVLHE-NH2	451
457	Ac-KSENDR-LRLLLKQMCP-SLDVDSIIPRTPDVLHED-NH2	452
458	Ac-SENDR-LRLLLKQMCP-SLDVDSIIPRTPDVLHEDL-NH2	453
459	Ac-SENDER-LRLLLKQMCP-SLDVDSIIPRTPDVLHEDLL-NH2	454
460	Ac-ENDRLRLLLKQMCP-SLDVDSIIPRTPDVLHEDLLN-NH2	455
461	Ac-NDRLRLLLKQMCP-SLDVDSIIPRTPDVLHEDLLNF-NH2	456
534	Ac-PGYRWMCLRRFIIFLFIILLCLIFLLVLLDYQGML-NH2	458
535	Ac-GYRWMCLRRFIIFLFIILLCLIFLLVLLDYQGMLP-NH2	459
536	Ac-YRWMCLRRFIIFLFIILLCLIFLLVLLDYQGMLPV-NH2	460
537	Ac-RWMCLRRFIIFLFIILLCLIFLLVLLDYQGMLPVC-NH2	461
538	Ac-WMCLRRFIIFLFIILLCLIFLLVLLDYQGMLPVC-P-NH2	462

T No.	Sequence	Seq. ID No.
539	Ac-MCLRRFIIFLLFILLCLIFLLVLLDYQGMLPVCPL-NH2	463
540	Ac-CLRRFIIFLLFILLCLIFLLVLLDYQGMLPVCPLI-NH2	464
541	Ac-LRRFIIFLLFILLCLIFLLVLLDYQGMLPVCPLIP-NH2	465
542	Ac-RRFIIFLLFILLCLIFLLVLLDYQGMLPVCPLIPG-NH2	466
543	Ac-RFIIFLLFILLCLIFLLVLLDYQGMLPVCPLIPGS-NH2	467
544	Ac-FIIFLLFILLCLIFLLVLLDYQGMLPVCPLIPGSS-NH2	468
545	Ac-IIIFLLFILLCLIFLLVLLDYQGMLPVCPLIPGSST-NH2	469
546	Ac-IFLLFILLCLIFLLVLLDYQGMLPVCPLIPGSSTT-NH2	470
547	Ac-FLFILLCLIFLLVLLDYQGMLPVCPLIPGSSTTS-NH2	471
548	Ac-LFILLCLIFLLVLLDYQGMLPVCPLIPGSSTTST-NH2	472
549	Ac-FILLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTG-NH2	473
550	Ac-ILLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGP-NH2	474
551	Ac-LLLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPC-NH2	475
552	Ac-LLCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCR-NH2	476
553	Ac-LCLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRT-NH2	477
554	Ac-CLIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTC-NH2	478
555	Ac-LIIFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCM-NH2	479
556	Ac-IFLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMT-NH2	480
557	Ac-FLLVLLDYQGMLPVCPLIPGSSTTSTGPCRTCMTT-NH2	481
558	Ac-PPLVLQAGFFLLTRILTIQSLDSWWTSLNFLGGT-NH2	482
559	Ac-LLVLQAGFFLLTRILTIQSLDSWWTSLNFLGGTT-NH2	483
560	Ac-LVLQAGFFLLTRILTIQSLDSWWTSLNFLGGTTV-NH2	484
561	Ac-VLQAGFFLLTRILTIQSLDSWWTSLNFLGGTTVC-NH2	485
562	Ac-LQAGFFLLTRILTIQSLDSWWTSLNFLGGTTVCL-NH2	486
563	Ac-QAGFFLLTRILTIQSLDSWWTSLNFLGGTTVCLG-NH2	487
564	Ac-AGFFLLTRILTIQSLDSWWTSLNFLGGTTVCLGQ-NH2	488
565	Ac-GFFLLTRILTIQSLDSWWTSLNFLGGTTVCLGQN-NH2	489
566	Ac-FFLLTRILTIQSLDSWWTSLNFLGGTTVCLGQNS-NH2	490
567	Ac-FLLTRILTIQSLDSWWTSLNFLGGTTVCLGQNSQ-NH2	491
568	Ac-LLTRILTIQSLDSWWTSLNFLGGTTVCLGQNSQS-NH2	492
569	Ac-LTRILTIQSLDSWWTSLNFLGGTTVCLGQNSQSP-NH2	493
570	Ac-FWNWLSAWKDLELKSLEEVKDELQKMR-NH2	494
571	Ac-NNLLRAIEAQHLLQLTVW-NH2	495
572	Ac-CGGNNLLRAIEAQHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	496
573	Ac-YTSLIHSLIEESQNQKEKNEQELLELDKWASLWNWF-NH2	497
574	C13H27CO-YTSLIHSLIEESQNQKEKNEQELLELDKWASLWNWF-NH2	498
575	Ac-AVSKGYLSALRTGWYTSVTIELSNIKENKUNGIDA-NH2	499
576	Ac-SISNIETVIEFQQKNRLLHITREFSVNAGVTTPVS-NH2	500
577	Ac-DQQIKQYKRLLDRLIPLYDGLRQKDVTVSNQBSN-NH2	501
578	Ac-YSELTNIFGDNIGSLQEKGIKLQGIASLYRTNITEI-NH2	502
579	Ac-TSITLQVRLPLLTRLNLTQYRVDSISYNIQNREWY-NH2	503
580	Ac-VEIABYRRLRLTVLEPIRDALNAMTQNIQNPVQSV-NH2	504
581	Ac-SYFIVLSIAYPTLSBIKGVTVHRLEGVSYNIGSQEW-NH2	505
582	Ac-LKEAIRDTNKA VQSVQSSIGNLIVAIS-NH2	506
583	NNLLRAIEAQHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	507
583	NNLLRAIEAQHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	507
584	QKQEPIDKELYPLTSL	508
585	YPKFVKQNTLKLAT	509
586	QYIKANQKFIGITE	510
587	NGQIGNDPNRDILY	511

T No.	Sequence	Seq. ID No.
588	AC-RPDVY-OH	512
589	CLELDKWASLWNWFC-(cyclic)	513
590	CLELDKWASLANWFC-(cyclic)	514
591	CLELDKWASLANFFC-(cyclic)	515
594	Ac-NNLLRAIEAQQQHLLQLTVWGIKQLQARILAVEYLKDQ-NH2	516
595	Ac-CGGYTSLIHSLEESQNQQEKNEQEELLELDKWASLWNNWF-NH2	517
596	Ac-PLLVLQAGFFLLTRILTIQSLDSWWTSLNFLGGT-NH2	518
597	Ac-LLVLQAGFFLLTRILTIQSLDSWWTSLNFLGGTT-NH2	519
598	Ac-LVLQAGFFLLTRILTIQSLDSWWTSLNFLGGTTV-NH2	520
599	Ac-VLQAGFFLLTRILTIQSLDSWWTSLNFLGGTTVC-NH2	521
600	Ac-LQAGFFLLTRILTIQSLDSWWTSLNFLGGTTVCL-NH2	522
601	Ac-QAGFFLLTRILTIQSLDSWWTSLNFLGGTTVCLG-NH2	523
602	Ac-AGFFLLTRILTIQSLDSWWTSLNFLGGTTVCLGQ-NH2	524
603	Ac-GFFLLTRILTIQSLDSWWTSLNFLGGTTVCLGQN-NH2	525
604	Ac-FFLLTRILTIQSLDSWWTSLNFLGGTTVCLGQNS-NH2	526
605	Ac-FLLTRILTIQSLDSWWTSLNFLGGTTVCLGQNSQ-NH2	527
606	Ac-LLTRILTIQSLDSWWTSLNFLGGTTVCLGQNSQS-NH2	528
607	Ac-LTRILTIQSLDSWWTSLNFLGGTTVCLGQNSQSP-NH2	529
608	Ac-LELDKWASLWNWA-NH2	530
609	Ac-LELDKWASAWNWF-NH2	531
610	Ac-LELDKAASLWNWF-NH2	532
611	Ac-LKLDKWASLWNWF-NH2	533
612	Ac-LELKKWASLWNWF-NH2	534
613	Ac-DELLHNVNAGKST-NH2	535
614	Ac-KSDELLHNVNAGKST-NH2	536
615	Ac-IRKSDELLHNVNAGKST-NH2	537
616	Ac-AFIRKSDELLHNVNAGKST-NH2	538
617	Ac-FDASISQVNEKINQSLAFI-NH2	539
618	Ac-YAADKESTQKAFDGITNKVNSVIEKMNTQFEAVGKE-NH2	540
619	Ac-SVIEKMNTQFEAVGKEFGNLERLENLNRMEDGFL-NH2	541
620	Ac-VWTYNAELLVLMENERTLDHDSNVKNLYDKVRMQL-NH2	542
621	Ac-EWDREINNYTSLIHSLEESQNQQEKNEQEGGC-NH2	543
622	Ac-INNYTSLIHSLEESQNQQEKNEQEELLELDKWASL-NH2	544
623	Ac-INNYTSLIHSLEESQNQQEKNEQEELLE-NH2	545
624	Ac-WMEWDREINNYTSLIHSLEESQNQQEKNEQEELLE-NH2	546
625	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQEELLELDKWASLWNWF-NH2	547
626	Ac-IDISIELNKAASDLEESKEWIKKSNQKLDISGNWH-NH2	548
627	Ac-NQQEKNEQEELLELDKWASLWNWFNITNWLWYIKIFI-NH2	549
627	Ac-NQQEKNEQEELLELDKWASLWNWFNITNWLWYIKIFI-NH2	549
628	Ac-QNQQEKNEQEELLELDKWASLWNWFNITNWLWYIKIF-NH2	550
629	Ac-SQNQQEKNEQEELLELDKWASLWNWFNITNWLWYIKI-NH2	551
630	Ac-ESQNQQEKNEQEELLELDKWASLWNWFNITNWLWYIK-NH2	552
631	Ac-EESQNQQEKNEQEELLELDKWASLWNWFNITNWLWYI-NH2	553
632	Ac-IHESQNQQEKNEQEELLELDKWASLWNWFNITNWLWY-NH2	554
633	Ac-LIEESQNQQEKNEQEELLELDKWASLWNWFNITNWLW-NH2	555
634	Ac-SLIEESQNQQEKNEQEELLELDKWASLWNWFNITNWL-NH2	556
635	Ac-HSLIEESQNQQEKNEQEELLELDKWASLWNWFNITNW-NH2	557
636	Ac-IHSLIEESQNQQEKNEQEELLELDKWASLWNWFNITN-NH2	558
637	Ac-LIHSLEESQNQQEKNEQEELLELDKWASLWNWFNIT-NH2	559
638	Ac-SLHSLEESQNQQEKNEQEELLELDKWASLWNWFNI-NH2	560

T No.	Sequence	Seq. ID No.
639	Ac-TSLIHSLEESQNQQEKNEQELLELDKWASLWNWFF-NH2	561
640	Ac-NYTSLIHSLEESQNQQEKNEQELLELDKWASLWNW-NH2	562
641	Ac-NNYTSLIHSLEESQNQQEKNEQELLELDKWASLWN-NH2	563
642	Ac-INNYTSLIHSLEESQNQQEKNEQELLELDKWASLW-NH2	564
643	Ac-EINNYTSLIHSLEESQNQQEKNEQELLELDKWASL-NH2	565
644	Ac-REINNYTSLIHSLEESQNQQEKNEQELLELDKWAS-NH2	566
645	Ac-DREINNYTSLIHSLEESQNQQEKNEQELLELDKWA-NH2	567
646	Ac-WDREINNYTSLIHSLEESQNQQEKNEQELLELDKW-NH2	568
647	Ac-EWDREINNYTSLIHSLEESQNQQEKNEQELLELDK-NH2	569
648	Ac-MEWDREINNYTSLIHSLEESQNQQEKNEQELLELD-NH	570
649	Ac-WMEWDREINNYTSLIHSLEESQNQQEKNEQELLELD-NH2	572
650	Ac-TWMEWDREINNYTSLIHSLEESQNQQEKNEQELLE-NH2	573
651	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELL-NH2	574
652	Ac-NMTWMEWDREINNYTSLIHSLEESQNQQEKNEQEL-NH2	575
653	Ac-NNMTWMEWDREINNYTSLIHSLEESQNQQEKNEQE-NH2	576
654	Ac-WNNMTWMEWDREINNYTSLIHSLEESQNQQEKNEQ-NH2	577
655	Ac-IWNNMTWMEWDREINNYTSLIHSLEESQNQQEKNE-NH2	578
656	Ac-QIWNNMTWMEWDREINNYTSLIHSLEESQNQQEKN-NH2	579
657	Ac-EQIWNNMTWMEWDREINNYTSLIHSLEESQNQQEK-NH2	580
658	Ac-LEQIWNNMTWMEWDREINNYTSLIHSLEESQNQQE-NH2	581
659	Ac-SLEQIWNNMTWMEWDREINNYTSLIHSLEESQNQQ-NH2	582
660	Ac-KSLEQIWNNMTWMEWDREINNYTSLIHSLEESQNQ-NH2	583
661	Ac-NKSLEQIWNNMTWMEWDREINNYTSLIHSLEESQN-NH2	584
662	Ac-SLAFIRKSDHELLHNVNAGKST-NH2	585
663	Ac-FDASISQVNEKINQSLAFIRK-NH2	586
664	Ac-YTSLIHSLEESQQQEKQEELLELDKWASLWNWFF-NH2	587
665	Ac-FDASISQVNEKINQSLAFIRKSDHELLHNVNAGK-NH2	588
666	Ac-FDASISQVNEKINQSLAFIRKSDHELLHNVNA-NH2	589
667	Ac-FDASISQVNEKINQSLAFIRKSDHELLHNV-NH2	590
668	Ac-FDASISQVNEKINQSLAFIRKSDELLH-NH2	591
669	Ac-FDASISQVNEKINQSLAFIRKSD-EL-NH2	592
670	Ac-FDASISQVNEKINQSLAFIRKSD-NH2	593
671	Ac-ASISQVNEKINQSLAFIRKSDHELLHNVNAGKST-NH2	594
672	Ac-ISQVNEKINQSLAFIRKSDHELLHNVNAGKST-NH2	595
673	Ac-QVNEKINQSLAFIRKSDHELLHNVNAGKST-NH2	596
674	Ac-NEKINQSLAFIRKSDHELLHNVNAGKST-NH2	597
675	Ac-KINQSLAFIRKSDHELLHNVNAGKST-NH2	598
676	Ac-NQSLAFIRKSDHELLHNVNAGKST-NH2	599
677	Ac-FWNWLSAWKDLELYPGSLELDKWASLWNWFF-NH2	600
678	Ac-CGGNNLLRAIBAQHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	601
679	Ac-CGGYTSLIHSLEESQNQQEKNEQELLELDKWASLWNWFF-NH2	602
680	YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWFF	603
681	NNLLRAIBAQHLLQLTVWGIKQLQARILAVERYLKDQ	604
682	Ac-EKNMYELQKLNWDVFTNWLDFTSWVRYIQYIYGV-NH2	605
683	Ac-QEKNMYELQKLNWDVFTNWLDFTSWVRYIQYIYG-NH2	606
684	Ac-QQEKNNMYELQKLNWDVFTNWLDFTSWVRYIQYIY-NH2	607
685	Ac-IQQEKNMYELQKLNWDVFTNWLDFTSWVRYIQYI-NH2	608
686	Ac-QIQEKNMYELQKLNWDVFTNWLDFTSWVRYIQYI-NH2	609
687	Ac-AQIQEKNMYELQKLNWDVFTNWLDFTSWVRYIQY-NH2	610
688	Ac-QAQIQEKNMYELQKLNWDVFTNWLDFTSWVRYIQ-NH2	611

T No.	Sequence	Seq. ID No.
689	Ac-EQAQIQQEKNMYELQKLNSWDVFTNWLDFTSWVRYI-NH2	612
690	Ac-LEQAQIQQEKNMYELQKLNSWDVFTNWLDFTSWVRY-NH2	613
691	Ac-SLEQAQIQQEKNMYELQKLNSWDVFTNWLDFTSWVR-NH2	614
692	Ac-QSLEQAQIQQEKNMYELQKLNSWDVFTNWLDFTSWV-NH2	615
693	Ac-SQSLEQAQIQQEKNMYELQKLNSWDVFTNWLDFTSW-NH2	616
694	Ac-ISQSLEQAQIQQEKNMYELQKLNSWDVFTNWLDFTS-NH2	617
695	Ac-NISQSLEQAQIQQEKNMYELQKLNSWDVFTNWLDFT-NH2	618
696	Ac-ANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWLD-NH2	619
697	Ac-EANISQSLEQAQIQQEKNMYELQKLNSWDVFTNWLD-NH2	620
699	Ac-YLEANISQSLEQAQIQQEKNMYELQKLNSWDVFTNW-NH2	621
700	Ac-YTSLIHSLEESQNQQEKNEQEL-NH2	622
701	Ac-YTSLIHSLEESQNLQEKNEQELLELDKWASLWNWF-NH2	623
702	Ac-YTSLIHSLEESQNQQEKLEQELLELDKWASLWNWF-NH2	624
703	Ac-YTSLIHSLEESQNQQEKNEQELLEFDKWASLWNWF-NH2	625
704	Ac-YTSLIHSLEESQNQQEKNEQELLELDKPASLWNWF-NH2	626
705	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASPNWNWF-NH2	627
706	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNSR-NH2	628
707	Biotin NH(CH2)4CO-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	629
708	Biotin NH(CH2)6CO-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	630
709	FMOC-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF	92
710	FMOC-NNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ	16
711	Ac-EWDREINNYTSLIHSLEESQNQQEKNEQ-NH2	634
712	Ac-LIEESQNQQEKNEQELLELDKWASLWNWF-NH2	635
713	Ac-FWNWLSAWKDLELGGPGSGPGGLELDKWASLWNWF-NH2	636
714	Ac-LIHSLEESQNQQEKNEQELLELDKWASL-NH2	637
715	Ac-TSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	638
716	Ac-LIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	639
718	FMOC-GGGGGYTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	640
719	Ac-HSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	641
720	Ac-YTSLIYSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	642
721	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	643
722	Ac-YTSLIHSIEESQNQQEKNEQELLELDKWASLWNWF-NH2	644
723	Ac-LEANISQLLEQAQIQQEKNMYELQKLNSWDVFTNWL-NH2	645
724	Ac-SLEBCDSELEIKRYKNRVASRKCRAKFKQLLQHYR-NH2	646
725	Ac-LEBCDSELEIKRYKNRVASRKCRAKFKQLLQHYRE-NH2	647
726	Ac-EECDSELEIKRYKNRVASRKCRAKFKQLLQHYREV-NH2	648
727	Ac-ECDSELEIKRYKNRVASRKCRAKFKQLLQHYREVA-NH2	649
728	Ac-CDSELEIKRYKNRVASRKCRAKFKQLLQHYREVAA-NH2	650
729	Ac-DSELEIKRYKNRVASRKCRAKFKQLLQHYREVAAA-NH2	651
730	Desaminotyrosine-FDASISQVNEKINQSLAFIRKSDHELLHNVNAGKST-NH2	652
731	WASLWNWF-NH2	653
732	Ac-EAQQHLLQLTVWGIKQLQARILAVERYLKDQQLGIWG-NH2	654
733	Ac-IEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLGIW-NH2	655
734	Ac-AIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLGI-NH2	656
735	Ac-RAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQLG-NH2	657
736	Ac-LRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQL-NH2	658
737	Ac-LLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQQL-NH2	659
738	Ac-NLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKDQ-Q-NH2	660
739	Ac-QNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLKD-NH2	661
740	Ac-QQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYLK-NH2	662

T No.	Sequence	Seq. ID No.
741	Ac-QQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERYL-NH2	663
742	Ac-VQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY-NH2	664
743	Ac-IVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVERY-NH2	665
744	Ac-GIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAVE-NH2	666
745	Ac-SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARILAV-NH2	667
758	Ac-RSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTV-NH2	668
760	Ac-GARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQL-NH2	669
764	Ac-GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQH-NH2	670
765	Ac-GSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQH-NH2	671
766	Ac-EGSTMGARSMTLTVQARQLLSGIVQQQNNLLRAIEAQQ-NH2	672
767	Ac-RAKFKQLLQHYREVAAAKSSSENDRLRL-NH2	673
768	Ac-AKFKQLLQHYREVAAAKSSSENDRLRL-NH2	674
769	Ac-KFKQLLQHYREVAAAKSSSENDRLRL-NH2	675
770	Ac-FKQLLQHYREVAAAKSSSENDRLRL-NH2	676
771	Ac-RAKFKQLLQHYREVAAAKSSSENDRLRL-NH2	677
772	DKWASLWNWF-NH2	678
773	Biotin-FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST-NH2	679
774	Ac-YDASISQVNEKINQSLAFIRKSDELLHNVNAGKST-NH2	680
775	Ac-YDASISQVNEKINQSLAYIRKSDELLHNVNAGKST-NH2	681
776	Ac-FDASISQVNEKINQSLAYIRKSDELLHNVNAGKST-NH2	682
777	Ac-FDASISQVQEKIQSLAFIRKSDELLHQVQAGKST-NH2	683
778	Ac-FDASISQVNEKINQALAFIRKADELHNVNAGKST-NH2	684
779	Ac-FDASISQVNEKINQALAFIRKSDELLHNVNAGKST-NH2	685
780	Ac-FDASISQVNEKINQSLAFIRKADELHNVNAGKST-NH2	686
781	Ac-YDASISQVQEEIQALAFIRKADELLEQVQAGKST-NH2	687
782	Ac-FDASISQVNEKINQSLAFIRKSDELLHNVNAGKST-NH2	688
783	Ac-FDASISQVNEEINQSLAFIRKSDELLHNVNAGKST-NH2	689
784	Ac-VFPSDEFDASISQVNEKINQSLAFIRKSDELLENV-NH2	690
785	Ac-VFPSDEFDASISQVNEEINQSLAFIRKSDELLENV-NH2	691
786	Ac-VYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	692
787	Ac-VFPSDEFDASISQVNEEINQSLAFIRKSDELLHNV-NH2	693
788	Ac-SNKSLEQIWNNMTWMEWDREINNYTSLIHSLEESQ-NH2	694
789	Ac-WSNKSLEQIWNNMTWMEWDREINNYTSLIHSLEES-NH2	695
790	Ac-SWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLEES-NH2	696
791	Ac-ASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLE-NH2	697
792	Ac-NASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLE-NH2	698
793	Ac-WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLE-NH2	699
793	Ac-WNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHSLE-NH2	699
794	Ac-PWNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHS-NH2	700
795	Ac-VPWNASWSNKSLEQIWNNMTWMEWDREINNYTSLIHS-NH2	701
796	Ac-AVPWNASWSNKSLEQIWNNMTWMEWDREINNYTSLI-NH2	702
797	Ac-TAVPWNASWSNKSLEQIWNNMTWMEWDREINNYTSL-NH2	703
798	Ac-TTAVPWNASWSNKSLEQIWNNMTWMEWDREINNYTS-NH2	704
800	Ac-AAASDEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	705
801	Ac-VFPAAAFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	706
802	Ac-VFPSDEAAASISQVNEKINQSLAFIRKSDELLHNV-NH2	707
803	Ac-VFPSDEFDAAAAQVNEKINQSLAFIRKSDELLHNV-NH2	708
804	Ac-VFPSDEFDASISAAAEKINQSLAFIRKSDELLHNV-NH2	709
805	Ac-VFPSDEFDASISQVNAAANQSLAFIRKSDELLHNV-NH2	711
806	Ac-VFPSDEFDASISQVNEKIAAALAFIRKSDELLHNV-NH2	712



T No.	Sequence	Seq. ID No.
807	Ac-VFPSDEFDASISQVNEKINQSAAAIRKSDELLHNV-NH2	713
808	Ac-VFPSDEFDASISQVNEKINQSLAFAAASDELLHNV-NH2	714
809	Ac-VFPSDEFDASISQVNEKINQSLAFIRKAAALLHNV-NH2	715
810	Ac-VFPSDEFDASISQVNEKINQSLAFIRKSDEAAANV-NH2	716
811	Ac-VFPSDEFDASISQVNEKINQSLAFIRKSDELLAAA-NH2	717
812	Ac-VYPSDEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	718
813	Ac-AAAATHSLIEESQNQQEKNEQEELLELDKWASLWNWF-NH2	719
814	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASLWNWF-NH2	720
815	Ac-YTSLIHSLIEESQNQQEKQEELLELDKWASLWNWF-NH2	721
816	Ac-QIWNMTWMEWDREINNYTSLIHSLIEESQNQQEKQ-NH2	722
817	Ac-QIWNMTWMEWDREINNYTSLIHSLIEESQNQQEKN-NH2	723
818	Ac-QIWNMTWMEWDREINNYTSLIHSLIEESQNQQEKQ-NH2	724
819	Ac-NKSLEQIWNMTWMEWDREINNYTSLIHSLIEESQQ-NH2	725
820	Ac-FDASISQVNEKINQSLAFIEESDELLHNVNAGKST-NH2	726
821	Ac-ACIRKSDELCL-NH2	727
823	Ac-YTSLIHSLIEESQNQQEKDEQEELLELDKWASLWNWF-NH2	728
824	Ac-YTSLIHSLIEESQDQQEKNEQEELLELDKWASLWNWF-NH2	729
825	Ac-YTSLIHSLIEESQDQQEKDEQEELLELDKWASLWNWF-NH2	730
826	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASLWDF-NH2	731
841	Ac-LEANITQSLEQAQIQEKNMYELQKLNSWDVFTNWL-NH2	732
842	Ac-LEANISASLEQAQIQEKNMYELQKLNSWDVFTNWL-NH2	733
843	Ac-LEANISALLEQAQIQEKNMYELQKLNSWDVFTNWL-NH2	734
844	Ac-LEANTITALLEQAQIQEKNMYELQKLNSWDVFTNWL-NH2	735
845	Ac-LEANTTASLEQAQIQEKNMYELQKLNSWDVFTNWL-NH2	736
845	Ac-LEANTTASLEQAQIQEKNMYELQKLNSWDVFTNWL-NH2	736
846	Ac-RAKFKQLLQHYREVAAAKSSENDRLRLLLKQMUPS-NH2	737
847	Ac-Abu-DDE-Abu-MNSVKNGTYDYPKYEEESKLNREIKGVKL-NH2	738
856	Ac-WQEWQKVRYLEANISQSLEQAQIQEKNMYELQKL-NH2	739
860	Ac-DEYDASISQVNEKINQSLAFIRKSDELLHNVNAGK-NH2	740
861	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASLWN-NH2	741
862	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASLW-NH2	742
863	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASL-NH2	743
864	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWAS-NH2	744
865	Ac-QARQLLSGIVQQQNNLLRAIEAQHLLQLTVWGIKQLQARILAVERYLKDQ-NH2	745
866	Ac-DREINNYTSLIHSLIEESQNQQEKNEQEELLELDKWASLWNWF-NH2	746
867	Ac-NNMTWMEWDREINNYTSLIHSLIEESQNQQEKNEQEELLELDK-NH2	747
868	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWASLWAAA-NH2	748
869	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDKWAAAANWF-NH2	749
870	Ac-YTSLIHSLIEESQNQQEKNEQEELLELDAAAASLWNWF-NH2	750
871	Ac-YTSLIHSLIEESQNQQEKNEQEELAAAKWASLWNWF-NH2	751
872	Ac-YTSLIHSLIEESQNQQEKNEQAAAELELDKWASLWNWF-NH2	752
873	Ac-YTSLIHSLIEESQNQQEKAAAELELDKWASLWNWF-NH2	753
874	Ac-YTSLIHSLIEESQNQAAANEQEELLELDKWASLWNWF-NH2	754
875	Ac-YTSLIHSLIEESAAAQEKNQEELLELDKWASLWNWF-NH2	755
876	Ac-YTSLIHSLIAAAQNQQEKNEQEELLELDKWASLWNWF-NH2	756
877	Ac-YTSLIHAAAEESQNQQEKNEQEELLELDKWASLWNWF-NH2	757
878	Ac-YTSAASLIEESQNQQEKNEQEELLELDKWASLWNWF-NH2	758
879	Ac-EIWNMTWMEWDRENEKINQSLAFIRKSDELLHNV-NH2	759
880	Ac-YISEVNEEINQSLAFIRKADELLENVDKWASLWNWF-NH2	760
881	Ac-TSVITIELSNIKENKANGTDAKVLIKQELDKYKN-NH2	761

T No.	Sequence	Seq. ID No.
882	YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFMG-NH2	762
883	Ac-NEKINQSLAFIRKSDELLHNV-NH2	763
884	Biotin-YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL-NH2	764
885	Biotin-PLVFPSDEFDASISQVNEKINQSLAFIRKSDELLH-NH2	765
886	Biotin-VFPSDEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	766
887	Biotin-DEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK-NH2	767
888	Biotin-VYPSDEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	768
889	Biotin-VYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	769
890	Ac-VYPSDEFDASISQVQEEIQQALAFIRKADELLEQV-NH2	770
891	Ac-NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	771
892	Ac-NNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	772
893	Ac-INNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	773
894	Ac-EINNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	774
895	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN-NH2	775
896	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI-NH2	776
897	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNT-NH2	777
898	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNTN-NH2	778
899	Ac-YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDELLHNVNAGK-NH2	779
900	Ac-NYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFN-NH2	780
901	Ac-NNYTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWFNI-NH2	781
905	Ac-KCRAFKQLLQHYREVA AAKSSENDRLRLLLKQMCPSLDVDSIIPRTPD-NH2	782
906	Ac-RAKFKQLLQHYREVA AAKSSENDRLRLLLKQMCPSLDVDSIIPRTPD-NH2	783
907	Ac-VYPSDEYDASISQVNEEINQALAYIAADELLENV-NH2	784
909	Ac-YDASISQVNEEINQALAYIRKADELL-NH2	785
910	Ac-M-Nle-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL-NH2	786
911	Ac-KNGTYDYPKYEEESKLNREIKGVKLSSMGVYQI-NH2	787
912	Ac-VTEKIQM ASDNINDLIQSGVNTRLLTIQSHVQNYI-NH2	788
913	QNQQEKNEQELLELDKWASLWNWF-NH2	789
914	Ac-QNQQEKNEQELLELDKWASLWNWF-NH2	790
915	LWNWF-NH2	791
916	ELLELDKWASLWNWF-NH2	792
917	EKNEQELLELDKWASLWNWF-NH2	793
918	SLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	794
919	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNW	795
920	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWN	796
921	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLW	797
922	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASL	798
923	TSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	799
924	SLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	800
925	LIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	801
926	IHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	802
940	Ac-AAVALLPAVLLALLAPSELEIKRYKNRVASRKCRAFKQLLQHYREVA AAK-NH2	803
941	Ac-AAVALLPAVLLALLAPCRAKFKQLLQHYREVA AAKSSENDRLRLLLKQMCP-NH2	804
942	Ac-YTSLIHSLIEESQNQQEKNNIERDWEMWTMNNWIQ-NH2	805
944	VYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	806
945	Ac-LMQLARQLMQLARQMKQLADSLMQLARQVSRLESA-NH2	807
946	Ac-WMEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL-NH2	808
947	Ac-MEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL-NH2	809
948	Ac-EWDREINNYTSLIHSLIEESQNQQEKNEQELLEL-NH2	810
949	Ac-MEWDREINNYTSLIHSLIEESQNQQEKNEQELLEL-NH2	811

T No.	Sequence	Seq. ID No.
950	Biotin-W-Nle-EWDREINNYTSLIHSLEESQNQQEKNEQELLE-L-NH2	812
951	Ac-YLEYDREINNYTSLIHSLEESQNQQEKNEQELLE-L-NH2	813
952	Ac-IKQFINMWQEVGKAMYA-NH2	814
953	Ac-IRKSDELL-NH2	815
954	Decanoyl-IRKSDELL-NH2	815
955	Acetyl-Aca-Aca-IRKSDELL-NH2	815
956	Ac-YDASISQV-NH2	816
957	Ac-NEKINQSL-NH2	817
958	Ac-SISQVNEEINQALAYIRKADELL-NH2	818
959	Ac-QVNEEINQALAYIRKADELL-NH2	819
960	Ac-EEINQALAYIRKADELL-NH	820
961	Ac-NQALAYIRKADELL-NH2	821
962	Ac-LAYIRKADELL-NH2	822
963	FDASISQVNEKINQALAFIRKSDELL-NH2	823
964	Ac-W-Nle-EWDREINNYTSLIHSLEESQNQQEKNEQELLE-L-NH2	824
965	Ac-ASRKCRAKFKQLQHYREVAARKSSENDRLRLLLKQMCPSLDVDS-NH2	825
967	Ac-WLEWDREINNYTSLIHSLEESQNQQEKNEQELLE-L-NH2	827
968	Ac-VYKGBPIINFYDPLVFPSEDFDASISQVNEKINQSL-NH2	828
969	Ac-VYPSDEYDASISQVNEEINQSLAYIRKADELLENV-NH2	829
970	Ac-YDASISQVNEEINQALAYIRKADELLENV-NH2	830
971	Ac-YDASISQVNEEINQALAYIRKADELLE-NH2	831
972	Ac-VYPSDEYDASISQVNEEINQALAYIRKAAELLENV-NH2	832
973	Ac-VYPSDEYDASISQVNEEINQALAYIRKALELLENV-NH2	833
974	Decanoyl-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	834
975	Ac-VYPSDEYDASISQVNEEINQLLAYIRKLDELLENV-NH2	835
976	Ac-DEYDASISQVNEKINQSLAFIRKSDELL-NH2	836
977	Ac-SNDQSGGYAADKESTQKAFDGITNKVNSVIEKTNT-NH2	837
978	Ac-ESTQKAFDGITNKVNSVIEKTNTQFEAVGKEFGNLEKR-NH2	838
979	Ac-DGITNKVNSVIEKTNTQFEAVGKEFGNLEKRLNLN-NH2	839
980	Ac-DSNVKNLYDKVRSQLRDNVKELGNGAFEFYHK-NH2	840
981	Ac-RDNVKELGNGAFEFYHKADDEALNSVKNGTYPKY-NH2	841
982	Ac-EFYHKADDEALNSVKNGTYPKY-NH2	842
983	Ac-AAVALLPAVLLALLAPAADKESTQKAFDGITNKVNS-NH2	843
984	Ac-AAVALLPAVLLALLAPAADSNVKNLYDKVRSQLRDN-NH2	844
985	Ac-KESTQKAFDGITNKVNSV-NH2	845
986	Ac-IEKTNTQFEAVGKEFGNLER-NH2	846
987	Ac-RLENLNKRVEDGFLDVWTYNABELLVALENB-NH2	847
988	Ac-SNVKNLYDKVRSQLRDN-NH2	848
989	Ac-WMEWDREINNYTSLIHSLEESQNQQEKNEQEL-NH2	849
990	Ac-WMEWDREINNYTSLIHSLEESQNQQEKNEQB-NH2	850
991	Ac-MEWDREINNYTSLIHSLEESQNQQEKNEQEL-NH2	851
992	Ac-MEWDREINNYTSLIHSLEESQNQQEKNEQB-NH2	852
993	Ac-EWDREINNYTSLIHSLEESQNQQEKNEQELB-NH2	853
994	Ac-EWDREINNYTSLIHSLEESQNQQEKNEQELL-NH2	854
995	Ac-EWDREINNYTSLIHSLEESQNQQEKNEQEL-NH2	855
996	Ac-YTKFIYTLLEESQNQQEKNEQELLELDKWASLWNWF-NH2	856
997	Ac-YMKQLADSLMQLARQVSRLESA-NH2	857
998	Ac-YLMQLARQMKQLADSLMQLARQVSRLESA-NH2	858
999	Ac-YQEWERKVDLEENTALLERAIQQEKNMYELQKL-NH2	859
1000	Ac-WMAWAAAINNYTSLIHSLEESQNQQEKNEQEEEE-NH2	860

T No.	Sequence	Seq. ID No.
1001	Ac-YASLIAALIEESQNQQEKNEQELLELAKWAALWAWF-NH2	861
1002	[Ac-EWDREINNYTSLIHSLIEESQNQQEKNEQEGGC-NH2]dimer	862
1003	Ac-YDISIELNKA KSDLEESKEWIKKSNQKLD SIGNWH-NH2	863
1004	Biotinyl-IDISIELNKA KSDLEESKEWIKKSNQKLD SIGNWH-NH2	864
1005	Ac-YTSLI-OH	865
1006	Fmoc-HSLIEE-OH	866
1007	Fmoc-SQNQQEK-OH	867
1008	Fmoc-NEQELLEL-OH	868
1009	Fmoc-DKWASL-OH	869
1010	Fmoc-WNWF-OH	870
1011	Ac-AKTLERTWDTLNHLLFISSALYKLNKLSVAQITLSI-NH2	871
1012	Ac-NTTLQAKIKQFINMWQEVGKAMYA-NH2	872
1013	Ac-LENERTLDFHDSNVKNLYDKVRLQLRDN-NH2	873
1014	Ac-LENERTLDFHDSNVKNLYDKVRLQLRDNVKELGNG-NH2	874
1015	Ac-TLDFHDSNVKNLYDKVRLQLRDNVKELGNGAFEF-NH2	875
1016	Ac-IDISIELNKA KSDLEESKEWIKKSNQKLD SIGNWH-NH2	876
1021	Biotinyl-SISQVNEEINQALAYIRKADELL-NH2	877
1022	Biotinyl-SISQVNEEINQSLAYIRKSDELL-NH2	878
1023	Ac-SISQVNEEINQSLAYIRKSDELL-NH2	879
1024	Ac-IDISIELNKA KSDLEESKEWIKKSNQELDSIGNWE-NH2	39
1025	Ac-IDISIELNKA KSDLEESKEWIKKSNQELDSIGNWH-NH2	864
1026	Ac-IDISIELNKA KSDLEEAKEWIDDANQKLD SIGNWH-NH2	79
1027	Ac-IDISIELNKA KSDLEESKEWIKKANQKLD SIGNWH-NH2	80
1028	Ac-IDISIELNKA KSDLEEAKEWIKKSNQKLD SIGNWH-NH2	548
1029	Biotinyl-NSVALDPIDISIELNKA KSDLEESKEWIKKSNQKL-NH2	880
1030	Biotinyl-ALDPIDISIELNKA KSDLEESKEWIKKSNQKLD SI-NH2	881
1031	desAminoTyrosine-NSVALDPIDISIELNKA KSDLEESKEWIKKSNQKL-NH2	882
1032	desAminoTyrosine-ALDPIDISIELNKA KSDLEESKEWIKKSNQKLD SI-NH2	883
1033	Ac-YDASISQVNEEINQALAFIRKADEL-NH2	984
1034	Ac-YDASISQVNEEINQSLAYIRKADELL-NH2	985
1035	Biotinyl-YDASISQVNEEINQALAYIRKADELL-NH2	986
1036	Biotinyl-YDASISQVNEEINQSLAFIRKSDELL-NH2	987
1037	Ac-YDASISQVNEEINQSLAFIRKSDELL-NH2	988
1038	Ac-WLEWDREINNYTSLIHSLIEESQNQQEKNEQEL-NH2	989
1039	Biotinyl-IDISIELNKA KSDLEESKEWIRRSNQKLD SIGNWH-NH2	916
1044	Ac-YESTQKAFDGIITNKVNSVIEKTNTQFEAVGKEFGNLEKR-NH2	81
1045	Biotin-DEYDASISQVNEKINQSLAFIRKSDELL-NH2	82
1046	Ac-MEWDREINNYTSLIHSLIEESQNQQEKNEQELL-NH2	90
1047	Ac-WQEWQKVRYLEANISQSLEQAQIQQEKKNMYEL-NH2	892
1048	Ac-WQEWQKVRYLEANISQSLEQAQIQQEKNEYEL-NH2	893
1049	Ac-WQEWQKVRYLEANITALLEQAQIQQEKNEYEL-NH2	894
1050	Ac-WQEWQKVRYLEANITALLEQAQIQQEKKNMYEL-NH2	895
1051	Ac-WQEWQKVRYLEANISQSLEQAQIQQEKNEYELQKL-NH2	896
1052	Ac-WQEWQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	897
1053	Ac-WQEWQKVRYLEANITALLEQAQIQQEKKNMYELQKL-NH2	898
1054	Ac-IDISIELNKA KSDLEESKEWIKKSNQKLD SIGNWH-NH2	
1055	Ac-EFGNLEKRLENLNKRVEDGFLDVWVTYNAELLVALENE-NH2	899
1056	Ac-EDGFLDVWVTYNAELLVLMENERTLDFHDSNVKNLYDKVRMQL-NH2	900
1057	Ac-SISQVNEKINQSLAFIRKSDELL-NH2	901
1058	desaminoTyr-SISQVNEKINQSLAFIRKSDELL-NH2	902

T No.	Sequence	Seq. ID No.
1059	Ac-SISQVNEKINQSLAYIRKSDELL-NH2	903
1060	Ac-QQLLDVVKRQQEMLRLTVWGTKNLQARVTAIEKYLKDQ-NH2	904
1061	YTSLIHSLIEESQNQQEKNEQELLELDKASLWNWFC	905
1062	Ac-FDASISQVNEKINQSLAYIRKSDELL-NH2	906
1063	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWA	907
1064	Indole-3-acetyl-DEFDASISQVNEKINQSLAFIRKSDELL-NH2	908
1065	Indole-3-acetyl-DEFDESISQVNEKINQSLAFIRKSDELL-NH2	909
1066	Indole-3-acetyl-DEFDESISQVNEKIEQSLAFIRKSDELL-NH2	910
1067	Indole-3-acetyl-DEFDESISQVNEKIEESLAFIRKSDELL-NH2	911
1068	Indole-3-acetyl-DEFDESISQVNEKIEESLQFIRKSDELL-NH2	912
1069	Indole-3-acetyl-GGGGGDEFDASISQVNEKINQSLAFIRKSDELL-NH2	913
1070	2-Naphthoyl-DEFDASISQVNEKINQSLAFIRKSDELL-NH2	914
1071	desNH2Tyr-DEFDASISQVNEKINQSLAFIRKSDELL-NH2	915
1072	biotin-ALDPIDISIELNKAASDLEESKEWIRRSNQKLDSE-NH2	916
1073	Ac-YDASISQVNEKINQALAYIRKADELHNVNAGKST-NH2	917
1074	Ac-VYPSDEYDASISQVNEKINQALAYIRKADELHNV-NH2	918
1075	Ac-VYPSDEYDASISQVNEKINQSLAYIRKSDELLHNV-NH2	919
1076	Ac-WGWGYYGYG-NH2	920
1077	Ac-YGWGWGWGF-NH2	921
1078	Ac-WQEWQKVRYLEANITALQEQAQIAEKAIFYELQKL-NH2	922
1079	Ac-WQEWQKVRYLEAETITALQEEAQIAEKAIFYELQKL-NH2	923
1081	Ac-YTSLIHSLIEESQNQQEKNEQELLELDKAS	924
1082	Ac-VWPSDEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	925
1083	Ac-SKNISEQIDQIKKDEQKEGTGWGLGGKWWTSDWGV-NH2	926
1084	Ac-LSKNISEQIDQIKKDEQKEGTGWGLGGKWWTSDW-NH2	927
1085	Ac-DLSKNISEQIDQIKKDEQKEGTGWGLGGKWWTSDW-NH2	928
1086	Ac-EDLSKNISEQIDQIKKDEQKEGTGWGLGGKWWTS-NH2	929
1087	Ac-IEDLSKNISEQIDQIKKDEQKEGTGWGLGGKWWTS-NH2	930
1088	Ac-GIEDLSKNISEQIDQIKKDEQKEGTGWGLGGKWW-NH2	931
1089	Ac-IGIEDLSKNISEQIDQIKKDEQKEGTGWGLGGKWW-NH2	932
1090	2-Naphthoyl-PSDEFDASISQVNEKINQSLAFIRKSDELLHNV-NH2	933
1091	Ac-VYPSDEYDASISQVNEKINQALAYIRKADELHNV-NH2	934
1092	Ac-VYPSDEFDASISQVNEKINQALAFIRKADELHNV-NH2	935
1093	Ac-VYPSDEYDASISQVNEKINQALAYTREADELHNV-NH2	936
1094	Biotinyl-YDASISQVNEKINQSLAFIRESELL-NH2	937
1095	Ac-AIGIEDLSKNISEQIDQIKKDEQKEGTGWGLGGKWW-NH2	938
1096	Ac-AAIGIEDLSKNISEQIDQIKKDEQKEGTGWGLGGK-NH2	939
1097	Ac-DAAIGIEDLSKNISEQIDQIKKDEQKEGTGWGLGG-NH2	940
1098	Ac-PDAAIGIEDLSKNISEQIDQIKKDEQKEGTGWGLG-NH2	941
1099	Ac-NITDKIDQIHDFVDKTLPDQGDNDNWWTGWRQWI-NH2	942
1100	Ac-KNITDKIDQIHDFVDKTLPDQGDNDNWWTGWRQW-NH2	943
1101	Ac-TKNITDKIDQIHDFVDKTLPDQGDNDNWWTGWRQ-NH2	944
1102	Ac-WTKNITDKIDQIHDFVDKTLPDQGDNDNWWTGWR-NH2	945
1103	Ac-DWTKNITDKIDQIHDFVDKTLPDQGDNDNWWTGW-NH2	946
1104	Ac-HDWTKNITDKIDQIHDFVDKTLPDQGDNDNWWTG-NH2	947
1105	Ac-PHDWTKNITDKIDQIHDFVDKTLPDQGDNDNWW-NH2	948
1106	Ac-EPHDWTKNITDKIDQIHDFVDKTLPDQGDNDNWW-NH2	949
1107	Ac-IEPHDWTKNITDKIDQIHDFVDKTLPDQGDNDN-NH2	950
1108	Ac-AIEPHDWTKNITDKIDQIHDFVDKTLPDQGDNDN-NH2	951
1109	Ac-AAIEPHDWTKNITDKIDQIHDFVDKTLPDQGDND-NH2	

T No.	Sequence	Seq. ID No.
1110	Ac-DAAIEPHDWTKNITDKIDQIIHDFVDKTLDPDQGDN-NH2	952
1111	Ac-LSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIFF-NH2	953
1112	Ac-GLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPIF-NH2	1345
1113	Ac-VGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLLPI-NH2	1346
1114	Ac-FVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLL-NH2	1347
1115	Ac-WFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLPLL-NH2	1348
1116	Ac-QWFVFLSPTVWLSVIWMMWYWGPSLYSILSPFLPL-NH2	1349
1117	Ac-VQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFLP-NH2	1350
1118	Ac-FVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSPFL-NH2	1351
1119	Ac-PFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSP-NH2	1352
1120	Ac-VPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILSP-NH2	1353
1121	Ac-LVPFVQWFVGLSPTVWLSVIWMMWYWGPSLYSILS-NH2	1354
1122	H-NHTTWMEWDREINNYTSLIHSLIBESQNQQEKNEQELLELDKW-OH	954
1123	H-QARQLLSGIVQQNNLLRAIEAQQHLLQLTVWGKQLQARILAVERYLKDQ-OH	955
1124	Ac-VYPSDEFDASISQVNEKINQSLAFIRKADELLENV-NH2	956
1125	Ac-VFPSDEFDASISQVNEKINQSLAYIREADELLENV-NH2	957
1126	Ac-DEFDASISQVNEKINQSLAYIREADELL-NH2	958
1127	Ac-NEQELLELDKWASLWNWFGGGGDEFDASISQVNEKINQSLAFIRKSDELL-NH2	959
1128	Ac-LELDKWASLWNWFGGGGDEFDASISQVNEKINQSLAFIRKSDELL-NH2	960
1129	Naphthoyl-EGEGEGEGDEFDASISQVNEKINQSLAFIRKSDELL-NH2	961
1130	Ac-ASRKCRKFKQLLQHYREVAAAKXSENDRLRLLLKQMCPSLDV-NH2	962
1131	Naphthoyl-GDEEDASISQVNEKINQSLAFIRKSDELL-NH2	963
1132	Naphthoyl-GDEEDASESQVNEKINQSLAFIRKSDELL-NH2	964
1133	Naphthoyl-GDEEDASESQVNEKINQSLAFIRKSDELL-NH2	965
1134	Naphthoyl-GDEEDASESQVNEKQNSLAFIRKSDELL-NH2	966
1135	Naphthoyl-GDEEDASESQVNEKQNSLAFIRKSDELL-NH2	967
1136	Ac-WGDEFDESISQVNEKIEESLAFIRKSDELL-NH2	968
1137	Ac-YTSLGGDEFDESISQVNEKIEESLAFIRKSDELLGGWNWF-NH2	969
1138	Ac-YTSLIHSLGGDEFDESISQVNEKIEESLAFIRKSDELLGGWASLWNWF-NH	970
1139	2-Naphthoyl-GDEFDESISQVNEKIEESLAFIRKSDELL-NH2	971
1140	2-Naphthoyl-GDEEDSISQVNEKIEESLAFIRKSDELL-NH2	972
1141	2-Naphthoyl-GDEEDSISQVQEKIEESLAFIRKSDELL-NH2	973
1142	2-Naphthoyl-GDEEDSISQVQEKIEESLAFIRKSDELL-NH2	974
1143	Biotin-GDEYDESISQVNEKIEESLAFIRKSDELL-NH2	975
1144	2-Naphthoyl-GDEYDESISQVNEKIEESLAFIRKSDELL-NH2	976
1145	Ac-YTSLIHSLIDEQEKIEELAFIRKSDELLDKWNV-NH2	977
1146	VYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	978
1147	Ac-NNLLRAIEAQQHLLQLTVWGSKQLQARILAVERYLKDQ-NH2	979
1148	GGGVYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	980
1149	Ac-NNLLRAIEAQQHLLQLTVWGEKQLQARILAVERYLKDQ-NH2	981
1150	Ac-PTRVNYILIGVLVLABuEVTGVRADVHLL-NH2	982
1151	Ac-PTRVNYILIGVLVLABuEVTGVRADVHLLQPGNLW-NH2	983
1152	Ac-PEKTPLLPTRVNYILIGVLVLABuEVTGVRADVHLL-NH2	984
1153	AhaGGGVYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	985
1155	Ac-YTSLIHSLGGDEFDESISQVNEKIEESLAFIRKSDELL-NH2	986
1156	Ac-YTSLGGDEFDESISQVNEKIEESLAFIRKSDELL-NH2	987
1157	Ac-DEFDESISQVNEKIEESLAFIRKSDELLGGWASLWNWF-NH2	988
1158	Ac-DEFDESISQVNEKIEESLAFIRKSDELLGGWNWF-NH2	989
1159	Ac-YTSLIHSLIBESQNQQEKNEQHLELDKASLWNWF-NH2	990
1160	Ac-YTSLIHSLIBESQNQQEKNEQHLELDKSLWNWF-NH2	991

T No.	Sequence	Seq. ID No.
1161	Ac-YTSLIHSLEESQNQQEKNEQELLELDKLVNWF-NH2	992
1162	Ac-YTSLIHSLEESQNQQEKNEQELLELDKLVNWF-NH2	993
1163	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLELDKASLVNWF-NH2	994
1164	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLELDKSLVNWF-NH2	995
1165	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLELDKLVNWF-NH2	996
1166	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLELDKLVNWF-NH2	997
1167	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLELDKVASLVN-NH2	998
1168	Ac-MTWMEWDREINNYTSLIHSLEESQNQQEKNEQELLELDKVASLV-NH2	999
1169	(Pyr)HWSY(2-naphthyl-D-Ala)LRPG-NH2	1000
1170	Ac-WNWFDEFDESISQVNEKIEESLAFIRKSDELLVNWF-NH2	1001
1171	Ac-YTSLIHSLEESQNQQEKNEQELLELDKYASLYNYF-NH2	1002
1172	Ac-YTSLIHSLEESQNQQEKNEQELLELDKYAYLYNYF-NH2	1003
1173	2-Naphthoyl-AcaAcaAcaDEFDESISQVNEKIEESLAFIRKSDELLAcaAcaAcaW-NH2	1004
1174	2-Naphthoyl-AcaAcaAcaGDEFDESISQVNEKIEESLAFIRKSDELLGAcaAcaAcaW-NH2	1005
1175	2-Naphthoyl-GDEFDESISQVNEKIEESLAFIRESEDL-NH2	1006
1176	2-Naphthoyl-GDEFDESISQVNEKIEESLAFIESEDL-NH2	1007
1177	Ac-WQEWBQKVNYLEANITALLEQAQIQQEKNEYELQKL-NH2	1008
1178	Ac-WQEWBQKVDYLEANITALLEQAQIQQEKNEYELQKL-NH2	1009
1179	Ac-WQEWBQKVRWLEANITALLEQAQIQQEKNEYELQKL-NH2	1010
1180	Ac-WQEWBQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1011
1181	Ac-WQEWBHQVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1012
1182	Ac-WQEWBHKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1013
1183	Ac-WQEWBREVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1014
1184	Ac-WQEWBREVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1015
1185	Ac-WQEWBQVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1016
1186	Ac-WQEWBQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1017
1187	Ac-WQEWBQKVRLEANITALLEQAQIQQEKNEYELQKL-NH2	1018
1188	Ac-VNalPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	1019
1189	Ac-VNalPSDENalDASISQVNEEINQALAYIRKADELLENV-NH2	1020
1190	Ac-VNalPSDEYDASISQVNEEINQALANalIRKADELLENV-NH2	1021
1191	Ac-VYPSDEFDASISQVNEKINQSLAFIREADELLFNFF-NH2	1022
1192	Ac-VYPSDEYDASISQVNEEINQALAYIRKADELLENFNFF-NH2	1023
1193	Ac-YTSLITALLEQAQIQQEKNEYELQKLDKVASLVNWF-NH2	1024
1194	Ac-YTSLITALLEQAQIQQEKNEYELQKLDKVASLWVWF-NH2	1025
1195	Ac-YTSLITALLEQAQIQQEKNEYELQKLDWVASLWVWF-NH2	1026
1196	Ac-YTSLITALLEQAQIQQEKNEYELQELDEWVASLWVWF-NH2	1027
1197	Ac-YTSLITALLEQAQIQQEKNEYELQELDEWVASLWVWF-NH2	1028
1198	Naphthoyl-Aua-Aua-Aua-TALLEQAQIQQEKNEYELQKLAua-Aua-Aua-W-NH2	1029
1199	Ac-WAAWEQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1030
1200	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1031
1201	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1032
1202	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1033
1203	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1034
1204	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1035
1205	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1036
1206	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKL-NH2	1037
1207	Ac-WQEAQKVRYLEANITALLEQAQIQQEKNEYELQKLGGGWASLVNWF-NH2	1038
1208	2-Naphthoyl-GDEFDASISQVNEKINQSLAFIRKSELT-NH2	1039
1209	2-Naphthoyl-GDEFDASISQVNEKINQSLAFIRKSELT-NH2	1040
1210	2-Naphthoyl-GDEFDASISQVNEKINQSLAFIRKSELT-NH2	971

T No.	Sequence	Seq. ID No.
1211	2-Naphthoyl-GDEFDASISQTNEKTNQSLAFTRKSDELT-NH2	1038
1212	2-Naphthoyl-GDEFDASTSQTNEKTNQSLAFTRKSDELT-NH2	1039
1213	2-Naphthoyl-GDEYDASTSQTNEKTNQSLAFTRKSDELT-NH2	1040
1214	2-Naphthoyl-GDEFDEEISQVNEKIEESLAFIRKSDELL-NH2	1041
1215	2-Naphthoyl-GDEFDASISQVNEKINQSLAFIRKSDELA-NH2	1042
1216	2-Naphthoyl-GDEFDASASQANEKANQSLAFARKSDELA-NH2	1043
1217	2-Naphthoyl-GDEFDESISQVNEKIEESLAFTRKSDELL-NH2	1044
1218	2-Naphthoyl-GDEFDESISQVNEKTEESLAFIRKSDELL-NH2	1045
1219	2-Naphthoyl-GDEFDESISQTNEKIEESLAFIRKSDELL-NH2	1046
1220	2-Naphthoyl-GDEFDESTSQVNEKIEESLAFIRKSDELL-NH2	1047
1221	Ac-WNWFDEFDESTSQVNEKIEESLAFTRKSDELLWNWF-NH2	1048
1222	Ac-WNWFDEFDESTSQTNEKIEESLAFTRKSDELLWNWF-NH2	1049
1223	Ac-WNWFDEFDESTSQTNEKTEESLAFIRKSDELLWNWF-NH2	1050
1224	Ac-LQAGFFLLTRILTIQSLDSWWTSLNFLGGTTVAL-NH2	1355
1225	Ac-YTNLIYTLLEESQNQQEKNEQELLELDKWASLWSWF-NH2	1051
1226	Ac-WQEWBQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF-NH2	1052
1227	Ac-NNMTWQEWBQKVRYLEANITALLEQAQIQQEKNEYELQKLDKWASLWNWF-NH2	1053
1230	Ac-WNWFIEESDELLWNWF-NH2	1054
1231	2-Naphthoyl-GFIEESDELLW-NH2	1055
1232	Ac-WFIEESDELLW-NH2	1056
1233	2-Naphthoyl-GFNFFIEESDELLFNFF-NH2	1057
1234	2-Naphthoyl-GBSDELW-NH2	1058
1235	Ac-WNWFDEFDESISQVQEEIEESLAFIEESDELLGGWNWF-NH2	1059
1236	Ac-WNWFHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	1356
1237	Ac-YTSLITALLEQAQIQQEEENEYELQALDEWASLWEWF-NH2	1025
1238	Ac-YTSLIHSLLGGDEFDESISQVNEEIEESLAFIEESDELLGGWASLWNWF-NH2	1060
1239	2-Naphthoyl-GDEFDESISQVQEEIEESLAFIEESDELL-NH2	1061
1240	H-QARQLLSSIMQQNNLLRAIEAQHLLQLTVWGIKQLQARILAVERYLKDQ-OH	1062
1241	Ac-CPKYVKQNTLKLATGMRNVPEKQTR-NH2	1063
1242	Ac-GLFGAIAGFIENGWEGMIDGWYGFRHQNSC-NH2	1064
1243	Ac-LNFLGGT-NH2	1065
1244	Ac-LDSWWTSLNFLGGT-NH2	1066
1245	Ac-ILTIQSLDSWWTSLNFLGGT-NH2	1067
1246	Ac-GFFLLTRILTIQSLDSWWTSLNFLGGT-NH2	1068
1247	Ac-WQEWBQKITALLEQAQIQQEKNEYELQKLDKWASLWNWF-NH2	1069
1248	Ac-WNWFITALLEQAQIQQEKNEYELQKLDKWASLWNWF-NH2	1070
1249	Ac-WQEWBQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1071
1250	Ac-WQEWBQKVRYLEANITALLEQAQIQQEKIEYELQKL-NH2	1072
1251	Ac-WQEWBQKVRYLEAQITALLEQAQIQQEKIEYELQKL-NH2	1073
1252	Ac-KENKANGTDAKVLIKQELDKYKNAVTELQLMQS-NH2	1074
1253	Ac-NIKENKANGTDAKVLIKQELDKYKNAVTELQLLM-NH2	1075
1254	(FS)-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH2	1076
1255	2-Naphthoyl-GWNWFAcaDEFDESISQVQEEIEESLAFIEESDELLAcaWNWF-NH2	1077
1256	Ac-WNWFDEFDESISQVNEKIEESLAFIEESDELLGWNWF-NH2	1078
1257	Ac-WNWFDEFDESISQVNEKIEESLAFIRKSDELLGWNWF-NH2	1079
1258	Ac-WNWF-Aca-DEFDESISQVNEKIEESLAFIRKSDELL-Aca-WNWF-NH2	1080
1259	Ac-WNWF-Aca-DEFDESISQVNEKIEESLAFIEESDELL-Aca-WNWF-NH2	1081
1260	Ac-EESQNQQEKNEQELLELDKWA-NH2	1082
1261	EESQNQQEKNEQELLELDKWA	1083
1262	Ac-CGTIDRSAPTYSWGANDTDVFLNNTRPPLGNWFG-NH2	1084



T No.	Sequence	Seq. ID No.
1263	Ac-GVEHRLEAACNWTRGERADLEDNRSELSP-NH2	1085
1264	Ac-CVREGNASRAWVAVTPTVATRDGKLPT-NH2	1086
1265	Ac-CFSPRHHWTTQDANASTYPG-NH2	1087
1266	Ac-LQHYREVAAAKSSENDRLRLLLKQMCPSLDVDS-NH2	1088
1267	Ac-WQEWDRISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWF-NH2	1089
1268	Ac-CWQEWDRISNYTSLITALLEQAQIQQEKNEYELQKLDEWASLWEWFC-NH2	1090
1269	Ac-WQEWDRISNYTSLITALLEQAQIQQEKNEYELQKLDEWEWF-NH2	1091
1270	Ac-CWQEWDRISNYTSLITALLEQAQIQQEKNEYELQKLDEWEWFC-NH2	1092
1271	Ac-GQNSQSPTSNSPTSAPPTAPGYRWA-NH2	1093
1272	Ac-PGSSTTSTGPARTALTTAQTSLYPSA-NH2	1094
1273	Ac-PGSSTTSTGPARTALTTAQTSLYPSAAATKPSDGNATA-NH2	1095
1275	Ac-WQEWDRITALLEQAQIQQEKNEYELQKLDKASLWNWF-NH2	1097
1276	Ac-WQEWDRITALLEQAQIQQEKNEYELQKLDEWASLWEWF-NH2	1098
1277	Ac-WQEWDRITALLEQAQIQQEKNEYELQKLDEWEWF-NH2	1099
1278	Ac-WQEWDRITALLEQAQIQQEKNEYELQKLDEWEWF-NH2	1100
1279	Ac-WQEWERTALLEQAQIQQEKNEYELQKLIEWWF-NH2	1101
1280	Ac-WQEWERTALLEQAQIQQEKIEYELQKLDEWEWF-NH2	1102
1281	Ac-WQEWERTALLEQAQIQQEKNEYELQKLDEWEWF-NH2	1103
1282	Ac-WQEWERTALLEQAQIQQEKNEYELQKLIEWWF-NH2	1104
1283	Ac-WQEWERTALLEQAQIQQEKIEYELQKLDEWEWF-NH2	1105
1284	Ac-WQEWERTALLEQAQIQQEKIEYELQKLIEWWF-NH2	1106
1285	Ac-WQEWDRIDEYDASISQVNEKINQALAYIREADELWEWF-NH2	1107
1286	Ac-WQEWEREIDEYDASISQVNEKINQALAYIREADELWEWF-NH2	1108
1287	Ac-WQEWIDEYDASISQVNEKINQALAYIREADELWEWF-NH2	1109
1288	Ac-WQEWIDEYDASISQVNEEINQALAYIREADELWEWF-NH2	1110
1289	Ac-WQEWEREIDEYDASISQVNEEINQALAYIREADELWEWF-NH2	1111
1290	Ac-WQEWIDEYDASISQVNEEINQALAYIREADELWEWF-NH2	1112
1291	Ac-WQEWDEYDASISQVNEKINQALAYIREADELWEWF-NH2	1113
1292	Ac-WQEWDEYDASISQVNEEINQALAYIREADELWEWF-NH2	1114
1293	Ac-WQEWBQKITALLEQAQIQQEKIEYELQKLIEWWF-NH2	1115
1294	Ac-WQEWBQKITALLEQAQIQQEKIEYELQKLIEWASLWEWF-NH2	1116
1295	Ac-WQEWERTALLEQAQIQQEKIEYELQKLIEWASLWEWF-NH2	1117
1298	-VYPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	1160
1299	Ac-WVYPSDEYDASISQVNEEINQALAYIRKADELLENVWNWF-NH2	1120
1300	YTSLIHSLIEESQNQQEKNEQLLELDKASLWNWF-NH2	1121
1301	Ac-WQEWDEYDASISQVNEKINQALAYIREADELWAWF-NH2	1122
1302	Ac-WQAWDEYDASISQVNEKINQALAYIREADELWAWF-NH2	1123
1303	Ac-WQAWDEYDASISQVNEKINQALAYIREADELWEWF-NH2	1124
1304	Biotin-YDPLVFPSDEFDASISQVNEKINQSLAFIRKSDEL-NH2	1125
1305	Biotin-YDPLVFPSDEFDASISQVNEKINQSLAF-NH2	1126
1306	Biotin-QVNEKINQSLAFIRKSDELLHNVNAGKST-NH2	1127
1307	Ac-WMEWDREI-NH2	1128
1308	Ac-WQEWBQKI-NH2	1129
1309	Ac-WQEWBQKITALLEQAQIQQEKIEYELQKLIKASLWEWF-NH2	1130
1310	Ac-WQEWBQKITALLEQAQIQQEKIEYELQKLIEWASLWEWF-NH2	1131
1311	Ac-WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLIEWWF-NH2	1132
1312	Ac-WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKBWEWF-NH2	1133
1313	Ac-WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKBWEW-NH2	1134
1314	Ac-WQEWEREISAYTSLITALLEQAQIQQEKIEYELQKLIEWEWF-NH2	1135
1315	Ac-FNLSHDHSESIQKKFQLMKKHVNKIGVSDPIGSWLR-NH2	1136

T No.	Sequence	Seq. ID No.
1316	Ac-DHSESIQKKFQLMKKHVKNIGVSDPIGWSWLRGIF-NH2	1137
1317	Ac-WSVKQANLTTSLGDLDDVTSIRHAVLQNR-NH2	1138
1318	Biotin-WMEWDREI-NH2	1128
1319	Biotin-NNMTWMEWDREINNYTSL-NH2	1139
1320	Ac-GAASLTITVQARQLLSGIVQQQNNLLRAIEAQQHLL-NH2	1140
1321	Ac-ASLTITVQARQLLSGIVQQQNNLLRAIEAQQHLLQL-NH2	1141
1322	Ac-VSVGNTLYYVKNQEGKSLYVKGEPIINFYDPLVF-NH2	1142
1323	Ac-QHWSYGLRPG-NH2	1143
1324	Ac-WQEWQKIQHWSYGLRPGWASLWEWF-NH2	1144
1325	Ac-WQEWQKIQHWSYGLRPGWEWF-NH2	1145
1326	Ac-WNWFQHWSYGLRPGWNWF-NH2	1146
1327	Ac-FNFFQHWSYGLRPGFNFF-NH2	1147
1328	Ac-GAGAQHWSYGLRPGAGAG-NH2	1148
1329	PLLVLQAGFFLLTRILTIQSLDSWWTSLNFLGGT	482
1330	Ac-WQEWQKITALLEQAQIQQEKIEYELQKLAKWASLWEWF-NH2	1149
1331	Ac-WQEWQKITALLEQAQIQQEKIEYELQKLAEWASLWEWF-NH2	1150
1332	Ac-WQEWQKITALLEQAQIQQEKAEYELQKLAEWASLWEWF-NH2	1151
1333	Ac-WQEWQKITALLEQAQIQQEKAEYELQKLAEWASLWAWF-NH2	1152
1334	Ac-WQEWQKITALLEQAQIQQEKAEYELQKLAKWASLWAWF-NH2	1153
1335	Ac-TNKAVVSLNGVSVLTSKVLDLKNYIDKQLLPVKN-NH2	1154
1336	Ac-KAVVSLNGVSVLTSKVLDLKNYIDKQLLPVKNQS-NH2	1155
1337	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLIWEWF-NH2	1156
1338	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLIWEWF-NH2	1157
1339	Ac-WQEWQKITALLEQAQIQQEKIEYELQKLDKWEWF-NH2	1158
1340	Ac-YDPLVFPSDEFDASISQVNEKINQSLAF-NH2	1159
1341	Fluor-VYPSDEYDASISQVNEEQALAYIRKADBLENV-NH2	1160
1342	Fluor-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1161
1344	Ac-SGIVQQQNNLLRAIEAQQHLLQLTVWGKQLQARIL-NH2	1162
1345	Ac-QQQNNLLRAIEAQQHLLQLTVWGKQLQARILAVERYLKDQ-NH2	1163
1346	Ac-SGIVQQQNNLLRAIEAQQHLLQLTVWGKQLQARILAVERYLKDQ-NH2	1164
1347	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLAEWASLWAWF-NH2	1165
1348	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLAEWASLWAW-NH2	1166
1349	Ac-WQEWQKITALLEQAQIQQEKAEYELQKLAEWASLWAW-NH2	1167
1350	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLAEWAGLWAWF-NH2	1168
1351	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLAEWAGLWAW-NH2	1169
1352	Ac-WQEWQKITALLEQAQIQQEKAEYELQKLAEWAGLWAW-NH2	1170
1353	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLDKWAGLWEWF-NH2	1171
1354	Ac-WQEWQHWSYGLRPGWEWF-NH2	1172
1355	Ac-WQAWQHWSYGLRPGWAWF-NH2	1173
1356	Biotinyl-WQEWQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1174
1357	WQEWQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF	1175
1358	WQEWQKITALLEQAQIQQEKIEYELQKLIWEWF	1176
1361	Ac-AGSTMGARSMITLTVQARQLLSGIVQQQNNLLRAIEAQQ-NH2	1179
1362	Ac-AGSAMGAASLTLSAQSRITLAGIVQQQQQLLDVVKRQQ-NH2	1180
1363	Ac-AGSAMGAASTALTAQSRITLAGIVQQQQQLLDVVKRQQ-NH2	1181
1364	Ac-ALTAQSRITLAGIVQQQQQLLDVVKRQQELLRLTVWGT-NH2	1182
1365	Ac-TLSAQSRITLAGIVQQQQQLLDVVKRQQEMLRLTVWGT-NH2	1183
1366	Ac-TLTVQARQLLSGIVQQQNNLLRAIEAQQHLLQLTVWGI-NH2	1184
1367	Ac-WQAWIEYEAELSQVKEKIEQSLAYIREADELWAWF-NH2	1185
1368	Ac-WQAWIEYEAELSQAQEKIESKAYIREADELWAWF-NH2	1186

T No.	Sequence	Seq. ID No.
1369	Ac-WQAWIBYERLLVQAKLKIAIAKL YIAKELLEWAWF-NH2	1187
1370	Ac-WQAWIBYERLLVQVKLKIAIAL YIAKELLEWAWF-NH2	1188
1371	Ac-WQAWIELERLLVQVKLKLAIAKLEIAKELLEWAWF-NH2	1189
1372	Ac-GEWTYDDATKTFTVTEGGH-NH2	1190
1373	Ac-WQEBWQKIGEWTYDDATKTFTVTEGGHWASLWEWF-NH2	1191
1374	Ac-GEWTYDDATKTFTVTE-NH2	1192
1375	Ac-WQEBWQKIGEWTYDDATKTFTVTEWASLWEWF-NH2	1193
1376	Ac-MHRFDYRT-NH2	1194
1377	Ac-WQEBWQKIMHRFDYRTWASLWEWF-NH2	1195
1378	Ac-MHRFNWSTGGG-NH2	1196
1379	Ac-WQEBWQKIMHRFNWSTGGGWASLWEWF-NH2	1197
1380	Ac-MHRFNWST-NH2	1198
1381	Ac-WQEBWQKIMHRFNWSTWASLWEWF-NH2	1199
1382	Ac-LLVPLARIMTMSSVHGGG-NH2	1200
1383	Ac-WQEBWQKILLVPLARIMTMSSVHGGGWASLWEWF-NH2	1201
1384	Ac-LLVPLARIMTMSSVH-NH2	1202
1385	Ac-WQEBWQKILLVPLARIMTMSSVHWASLWEWF-NH2	1203
1386	TALLEQAQIQQEKN EYELQKLDK	1204
1387	Ac-TALLEQAQIQQEKN EYELQKLDK-NH2	1205
1388	Ac-TALLEQAQIQQEKN EYELQKLIB-NH2	1206
1389	TALLEQAQIQQEKN EYELQKLIB	1207
1390	Ac-QARQLLSGIVQQQNLLRAIEAQQHLLQLTVWGKQLQARILAVERY-NH2	1208
1391	Rhod-QARQLLSGIVQQQNLLRAIEAQQHLLQLTVWGKQLQARILAVERY-NH2	1209
1392	Ac-GAASLTLSAQSRLLAGIVQQQQQLLDVVKRQQEML-NH2	1210
1393	Ac-GSAMGAASLTLSAQSRLLAGIVQQQQQLLDVVKRQQEML-NH2	1211
1394	Ac-PALSTGLIHLHQNIVDVQFLFGVGSSIASWAIKWEY-NH2	1212
1395	Ac-PALSTGLIHLHQNIVDVQFLYGVGSSIASWAIK-NH2	1213
1396	Ac-LSTTQWQVLPUSFTTLPALSTGLIHLHQNIVDVQY-NH2	1214
1397	Ac-FRKFPEATFSRUGSGPRITPRUMVDFPRLWHY-NH2	1215
1398	Ac-DFPRLWHFPUTINYTFKVRFLVGGVEHRLEAAUNWTR-NH2 <sup>σ</sup>	1216
1399	Ac-YVGGVEHRLEAAUNWTRGERUDLED RDRSELSPL-NH2	1217
1400	MVYPSDEYDASISQVNEEINQALAYIRKADELLENV	1218
1402	Ac-GPLLVLQAGFFLLTRIL TIPQSLDSWWTSLNFLGG-NH2	1220
1403	Ac-LGPLLVLQAGFFLLTRIL TIPQSLDSWWTSLNFLG-NH2	1221
1404	Ac-FLGPLLVLQAGFFLLTRIL TIPQSLDSWWTSLNFL-NH2	1222
1405	Ac-YTNTIYTLLEESQNQQEKNEQELLELDK WASLWNWF-NH2	1223
1406	YTNTIYTLLEESQNQQEKNEQELLELDK WASLWNWF	1357
1407	Ac-YTGIIYNLLEESQNQQEKNEQELLELDK WANLWNWF-NH2	1358
1408	YTGIIYNLLEESQNQQEKNEQELLELDK WANLWNWF	1359
1409	Ac-YTSLIYSLLEKSQIQQEKN EYELQKLDK WASLWNWF-NH2	1360
1410	YTSLIYSLLEKSQIQQEKN EYELQKLDK WASLWNWF	1361
1411	Ac-EKSQIQQEKN EYELQKLDK WA-NH2	1362
1412	EKSQIQQEKN EYELQKLDK WA	1363
1413	Ac-EQAQIQQEKN EYELQKLDK WA-NH2	1364
1414	Ac-YTSLIGSLIHSQIQQERNBQELLELD RWASLWEWF-NH2	1365
1415	Ac-YTXLIHSLIXESQNQQXKNEQELXELDK WASLWNWF-NH2	1366
1416	Ac-YTXLIHSLIWESQNQQXKNEQELXELDK-NH2	1367
1417	Ac-YTSLIHSLSQIQQEKN EYELQKLD-NH2	1368
1418	Ac-WQEQEXKITALLXQAQIQQXKNEYELXKLDK WASLWEWF-NH2	1369
1419	Ac-XKITALLXQAQIQQXKNEYELXKLDK WASLWEWF-NH2	1370

T No.	Sequence	Seq. ID No.
1420	Ac-WQEWXXKITALLXQAQIQQXKNEYELXKLD-NH2	1371
1421	Ac-WEQKITALLEQAQIQQEKNEYELQKLD-NH2	1372
1422	Ac-WEXKITALLXQAQIQQXKNEYELXKLD-NH2	1373
1423	Ac-XKITALLXQAQIQQXKNEYELXKLD-NH2	1374
1425	Ac-QKITALLEQAQIQQEKNEYELQKLD-NH2	1375
1426	Ac-QKITALLEQAQIQQEKNEYELQKLDKWSLWEWF-NH2	1381
1427	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLD-NH2	1379
1428	Ac-VYPSDEYDASISQVNEEINQALAYIRKADELLEN-OH	1377
1429	Ac-VYPSDEYDASISQVNEEINQALAYIRKADELLE-OH	1380
1430	Ac-VYPSDEYDASISQVNEEINQALAYIRKADELL-OH	1376
1431	Ac-VYPSDEYDASISQVNEEINQALAYIRKADEL-OH	1378
1432	YPSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	1227
1433	PSDEYDASISQVNEEINQALAYIRKADELLENV-NH2	1228
1434	SDEYDASISQVNEEINQALAYIRKADELLENV-NH2	1229
1435	DEYDASISQVNEEINQALAYIRKADELLENV-NH2	1230
1436	Ac-VYPSDEYDASISQVDEEINQALAYIRKADELLENV-NH2	1231
1437	Ac-VYPSDEYDASISQVNEEIDQALAYIRKADELLENV-NH2	1232
1438	Ac-VYPSDEYDASISQVNEEINQALAYIRKADELLEDV-NH2	1233
1439	Ac-VYPSDEYDASISQVDEEIDQALAYIRKADELLENV-NH2	1234
1440	Ac-LLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLP-NH2	1235
1441	Ac-LSSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLP-NH2	1236
1442	Ac-STNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1382
1443	Ac-TNKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1383
1444	Ac-NKAVVSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1384
1445	Ac-KAVVSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1385
1446	Ac-AVVSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1386
1447	Ac-VVSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1387
1448	Ac-VSLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1388
1449	Ac-SLSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	13389
1450	Ac-LSNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1390
1451	Ac-SNGVSVLTSKVLDLKNYIDKQLLPV-NH2	1391
1452	Ac-NGVSVLTSKVLDLKNYIDKQLLPV-NH2	1392
1453	Ac-GVSVLTSKVLDLKNYIDKQLLPV-NH2	1393
1454	Ac-VSVLTSKVLDLKNYIDKQLLPV-NH2	1394
1455	Ac-SVLTSKVLDLKNYIDKQLLPV-NH2	1395
1456	Ac-VLTSKVLDLKNYIDKQLLPV-NH2	1396
1457	Ac-LTSKVLDLKNYIDKQLLPV-NH2	1397
1458	Ac-TSKVLDLKNYIDKQLLPV-NH2	1398
1459	Ac-SKVLDLKNYIDKQLLPV-NH2	1399
1460	Ac-KVLDLKNYIDKQLLPV-NH2	1400
1461	Ac-VLDLKNYIDKQLLPV-NH2	1401
1462	Ac-LDLKNYIDKQLLPV-NH2	1402
1463	Ac-DLKNYIDKQLLPV-NH2	1403
1464	Ac-LKNYIDKQLLPV-NH2	1404
1465	Ac-KNYIDKQLLPV-NH2	1405
1466	Ac-NYIDKQLLPV-NH2	1406
1467	Ac-YIDKQLLPV-NH2	1407
1468	Ac-IDKQLLPV-NH2	1408
1469	Ac-DKQLLPV-NH2	1409
1470	Ac-KQLLPV-NH2	1410

T No.	Sequence	Seq. ID No.
1471	Ac-QLLPVINKQSUSISNIETVIEFQQKNNRLLBITRE-NH2	1411
1472	Ac-VYPSDEYDASISQVNEEINQALA	1412
1473	QVNEEINQALAYIRKADELLENV-NH2	1413
1474	VYPSDEYDASISQVNEEINQALAYIRKADELLENV	1414
1475	Ac-DEYDASISQVNEEINQALAYIREADEL-NH2	1415
1476	Ac-DEYDASISQVNEKINQALAYIREADEL-NH2	1416
1477	Ac-DDECLNSVKNGTYDFPKFEEESKLNRRNEIKGVKLS-NH2	1417
1478	Ac-DDE-Abu-LNSVKNGTYDFPKFEEESKLNRRNEIKGVKLS-NH2	1718
1479	Ac-YHKCDDCLNSVKNGTYDFPKFEEESKLNRRNEIKGVKLSS-NH2	1719
1480	Ac-YHK-Abu-DDE-Abu-LNSVKNGTYDFPKFEEESKLNRRNEIKGVKLSS-NH2	1420
1481	Ac-YTSLIHSLIBESQIQQEKNEQELLELDKWASLWNWF-NH2	1344
1482	Ac-YTSLIHSLIBESQNQQEKNEYELLELDKWASLWNWF-NH2	1345
1483	Ac-YTSLIHSLIBESQIQQEKNEYELLELDKWASLWNWF-NH2	1346
1484	Ac-YTSLIHSLIBESQIQQEKNEYELQKLDKWASLWNWF-NH2	1347
1485	Ac-YTSLIHSLIBESQNQQEKNEQELQKLDKWASLWNWF-NH2	1348
1486	Ac-YTSLIHSLIBESQNQQEKNEYELQKLDKWASLWNWF-NH2	1421
1487	Ac-YTSLIHSLIBESQIQQEKNEQELQKLDKWASLWNWF-NH2	1422
1488	Ac-YTSLIHSLIBESQNQQEKNEQELLELDKWASLWEWF-NH2	1423
1489	Ac-YTSLIHSLIBESQIQQEKNEQELLELDKWASLWEWF-NH2	1424
1490	Ac-YTSLIHSLIBESQNQQEKNEYELLELDKWASLWEWF-NH2	1425
1491	Ac-YTSLIHSLIBESQIQQEKNEYELLELDKWASLWEWF-NH2	1426
1492	Ac-YTSLIHSLIBESQIQQEKNEYELQKLDKWASLWEWF-NH2	1427
1493	Ac-YTSLIHSLIBESQNQQEKNEQELQKLDKWASLWEWF-NH2	1428
1494	Ac-YTSLIHSLIBESQNQQEKNEYELQKLDKWASLWEWF-NH2	1429
1495	Ac-YTSLIHSLIBESQIQQEKNEQELQKLDKWASLWEWF-NH2	1430
1496	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLDKEWWF-NH2	1431
1497	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLIWASLWEWF-NH2	1432
1498	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLAKWASLWEWF-NH2	1256
1499	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLIKWASLWEWF-NH2	1257
1500	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLIWAGLWEWF-NH2	1258
1501	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLAKWAGLWEWF-NH2	1259
1502	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLIKWAGLWEWF-NH2	1260
1503	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLIWAGLWAWF-NH2	1261
1504	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLAKWAGLWAWF-NH2	1262
1505	Ac-WQEQEQKITALLEQAQIQQEKNEYELQKLIKWAGLWAWF-NH2	1263
1506	Ac-WQEQEQKITALLEQAQIQQEKGEYELQKLDKQEQF-NH2	1264
1507	Ac-WQEQEQKITALLEQAQIQQEKGEYELLELDKWEEF-NH2	1265
1508	Ac-WQEQEQKITALLEQAQIQQEKGEYELQKLAKWEEF-NH2	1266
1509	Ac-WQEQEQKITALLEQAQIQQEKGEYELQKLDWQWER-NH2	1267
1510	Ac-WQEQEQKITALLEQAQIQQEKGEYELLELAKWEEF-NH2	1268
1511	Ac-WQEQEQKITALLEQAQIQQEKNEYELLELDKWEEF-NH2	1269
1512	Ac-WQEQEQKITALLEQAQIQQEKNEYELLEELIEWASLWEWF-NH2	1270
1513	Ac-WQEQEQKITALLEQAQIQQEKNEYELLELIEWAGLWEWF-NH2	1271
1514	Ac-WQEQEQKITALLEQAQIQQEKNEYELLELIEWAGLWAWF-NH2	1272
1515	Ac-WQEWERTALLEQAQIQQEKNEYELQKLIWASLWEWF-NH2	1273
1516	Ac-WQEWERTIQQEKNEYELQKLDKWASLWEWF-NH2	1274
1517	Ac-WQEWERTIQQEKGEYELQKLIWEEF-NH2	1275
1518	Ac-WQEWQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1276
1519	Ac-WQEWQAQIQQEKGEYELQKLIWEEF-NH2	1277
1520	PEG-GWQEQEQKITALLEQAQIQQERNEYELQRLDEWASLWEWF-NH2	1437

T No.	Sequence	Seq. ID No.
1521	Ac-GWQWEQRITALLEQAQIQQERNEYELQRLDEWASLWEWF-NH2	1438
1522	PEG-YTSLITALLEQAQIQQERNEQELLEDEWASLWEWF-NH2	1439
1523	Ac-YTSLITALLEQAQIQQERNEQELLEDEWASLWEWF-NH2	1440
1526	PEG-GWQWEQRITALLEQAQIQQERNEYELQELDEWASLWEWF-NH2	1441
1527	Ac-GWQWEQRITALLEQAQIQQERNEYELQELDEWASLWEWF-NH2	1442
1528	PEG-YTSLIGSLIEESQIQQERNEQELLELDRAWASLWEWF-NH2	1443
1529	PEG-GWQWEQRITALLEQAQIQQERNEYELQRLDRAWASLWEWF-NH2	1444
1530	Ac-GWQWEQRITALLEQAQIQQERNEYELQRLDRAWASLWEWF-NH2	1445
1531	PEG-GWQWEQRITALLEQAQIQQERNEYELQELDRAWASLWEWF-NH2	1446
1532	Ac-GWQWEQRITALLEQAQIQQERNEYELQELDRAWASLWEWF-NH2	1447
1533	PEG-YTSLIGSLIEESQIQQERNEQELLELDRAWASLWNWF-NH2	1448
1534	Ac-YTSLIGSLIEESQIQQERNEQELLELDRAWASLWNWF-NH2	1449
1538	Ac-YTSLIHSLEESQIQQEK-OH	1450
1539	NEQELLELDK	1451
1540	WASLWNWF-NH2	1452
1542	Ac-AAAWQKITALLEQAQIQQEKNEYELQKLDKASLWEWF-NH2	1453
1543	Ac-WQEAQKITALLEQAQIQQEKNEYELQKLDKASLWEWF-NH2	1454
1544	Ac-WQEWQAAAAALLEQAQIQQEKNEYELQKLDKASLWEWF-NH2	1455
1545	Ac-WQEWQKITAAAEQAQIQQEKNEYELQKLDKASLWEWF-NH2	1456
1546	Ac-WQEWQKITALLAAQAQIQQEKNEYELQKLDKASLWEWF-NH2	1457
1547	Ac-WQEWQKITALLEQAQAAAAQEKNEYELQKLDKASLWEWF-NH2	1458
1548	Ac-WQEWQKITALLEQAQAAAAQEKNEYELQKLDKASLWEWF-NH2	1459
1549	Ac-WQEWQKITALLEQAQIQQEKAAAAHQKLDKASLWEWF-NH2	1460
1550	Ac-WQEWQKITALLEQAQIQQEKNEYAAAAKLDKASLWEWF-NH2	1461
1551	Ac-WQEWQKITALLEQAQIQQEKNEYELQAAAAKASLWEWF-NH2	1462
1552	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLDAAASLWEWF-NH	1463
1553	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLDKAAAAEWF-NH	1464
1554	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLDKASLWAAA-NH	1465
1556	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1466
1557	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1467
1558	Ac-ERTLDFHDS-NH2	1468
1559	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWN(W)F-NH2	1469
1563	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1470
1564	Ac-YTSLIHSLEESQIQQDKASLWNWF-NH2	1471
1566	Ac-FYEIMDIEQNNVQGGKGIQQLQKWEDWVGWIGNI-NH2	1472
1567	Ac-INQTIWNHGNITLGEWYNQTKDLQQKFYEIMDIE-NH2	1473
1568	Ac-WNHGNITLGEWYNQTKDLQQKFYEIMDIEQNNVQ-NH2	1474
1572	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1475
1573	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1476
1574	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1477
1575	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1478
1576	Ac-YTSLIHSLEESQIQQEKDEQELLELDKASLWNWF-NH2	1479
1577	Ac-LGEWYNQTKDLQQKFYEIMDIEQNNVQGGKGIQQ-NH2	1480
1578	Ac-WYNQTKDLQQKFYEIMDIEQNNVQGGKGIQQLQK-NH2	1481
1579	Ac-YTSLIHSLEESQIQQEKNEEELLELDKASLWNWF-NH2	1482
1580	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWDWF-NH2	1483
1586	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWX-NH2	1484
1588	Ac-YNQTKDLQQKFYEIMDIEQNNVQGGKGIQQLQKW-NH2	1485
1598	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF	1486
1600	Ac-TLTVQARQLLSGIVQQNNLLRAIEAQHLLQLTVWGKQLQAR-NH2	1487
1603	Ac-LQQKFYEIMDIEQNNVQGGKGIQQLQKWEDWVGW-NH2	1488
1627	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1489
1628	Ac-YTSLIHSLEESQIQQEKNEQELLELDKASLWNWF-NH2	1490

T No.	Sequence	Seq. ID No.
1629	Ac-YTSLIHSLEESQNQQEKNEQELLEAKWASLWNWF-NH2	1491
1630	Ac-YTSLIHSLEESQNQQEKABQELLELDKWASLWNWF-NH2	1492
1631	Ac-YTSLIHSLEESQNQQEKNAQELLELDKWASLWNWF-NH2	1493
1632	Ac-YTSLIHSLEESQNQQEKNEAELLELDKWASLWNWF-NH2	1494
1634	Ac-WQEWQKITALLEQAQIQQEKNEQELQKLDKWASLWEWF-NH2	1495
1635	Ac-WQEWQKITALLEQAQIQQEKABEYELQKLDKWASLWEWF-NH2	1496
1636	Ac-WQEWQKITALLEQAQIQQEKNAEYELQKLDKWASLWEWF-NH2	1497
1637	Ac-WQEWQKITALLEQAQIQQEKNEAELQKLDKWASLWEWF-NH2	1498
1644	Ac-EYDLRRWBK-NH2	1499
1645	Ac-EQELLELDK-NH2	1500
1646	Ac-EYELQKLDK-NH2	1501
1647	Ac-WQEWQKITALLEQAQIQQEKNEQELKLDKWASLWEWF-NH2	1502
1648	Ac-WQEWQKITALLEQAQIQQEKNEQELLELDKWASLWEWF-NH2	1503
1649	Ac-WQEWQKITALLEQAQIQQEKNDKWASLWEWF-NH2	1504
1650	Ac-YTSLIHSLEESQNQAQKNEQELLELDKWASLWNWF-NH2	1505
1651	Ac-YTSLIHSLEESQNQAQKNEQELLELDKWASLWNWF-NH2	1506
1652	Ac-YTSLIHSLEESQNQQAQNEQELLELDKWASLWNWF-NH2	1507
1653	Ac-YTSLIHSLEESANQQAQNEQELLELDKWASLWNWF-NH2	1508
1654	Ac-YTSLIHSLEESQAQQEKNEQELLELDKWASLWNWF-NH2	1509
1655	Ac-YTSLIHSLEESQNAQEKNEQELLELDKWASLWNWF-NH2	1510
1656	Ac-YTSLIHALIEESQNQQEKNEQELLELDKWASLWNWF-NH2	1511
1657	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1512
1658	Ac-VYPSDEYDASISQVNEINQALAYIRKADELLENV-NH2	1513
1659	Ac-YTSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1514
1660	Ac-YTSAIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1515
1661	Ac-YTSLAHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1516
1662	Ac-YTSLIASLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1517
1663	Ac-ATSLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1518
1664	Ac-YASLIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1519
1665	Ac-YTALIHSLEESQNQQEKNEQELLELDKWASLWNWF-NH2	1520
1666	Ac-RIQDLEKYVEDTKIDLWSYNAELLVALENQ-NH2	1521
1667	Ac-HTIDLTDSEMKNLFKTRRQLREN-NH2	1522
1668	Ac-SEMKNLFKTRRQLREN-NH2	1523
1669	Ac-VFPSDEADASISQVNEKINQSLAFIRKSDELLHNV-NH2	1524
1670	Ac-VFPSDEFDAASISQVNEKINQSLAFIRKSDELLHNV-NH2	1525
1671	Ac-VFPSDEFDASISAVNEKINQSLAFIRKSDELLHNV-NH2	1526
1672	Ac-VFPSDEFDASISQANEKINQSLAFIRKSDELLHNV-NH2	1527
1673	Ac-VFPSDEFDASISQVAEKINQSLAFIRKSDELLHNV-NH2	1528
1674	Ac-WQEWQKITAALEQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1529
1675	Ac-WQEWQKITALAEQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1530
1676	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1531
1677	Ac-WQEWQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF-NH2	1532
1678	Ac-WQEWQKITALLEQAQIAQEKNEYELQKLDKWASLWEWF-NH2	1533
1679	Ac-WQEWQKITALLEQAQIAQEKNEYELQKLDKWASLWEWF-NH2	1534
1680	Ac-VFPSDEFDASISQVNEKINQSAFIRKSDELLHNV-NH2	1535
1681	Ac-VFPSDEFDASISQVNEKINQSLAIRKSDELLHNV-NH2	1536
1682	Ac-VFPSDEFDASISQVNEKINQSLAFIRKSDEALHNV-NH2	1537
1683	Ac-VFPSDEFDASISQVNEKINQSLAFIRKSDELAHNV-NH2	1538
1684	Ac-VFPSDEFDASISQVNEKINQSLAFIRKSDELLANV-NH2	1539
1685	Ac-WQEWQKITALLEQAQIQQAKNEYELQKLDKWASLWEWF-NH2	1540
1687	Ac-WQEWQKITALLEQAQIQQEKNEYELQALDKWASLWEWF-NH2	1541
1688	Ac-WQEWQKITALLEQAQIQQEKNEYELQKADKWASLWEWF-NH2	1542

It is to be understood that the peptides listed in Table 2 are also intended to fall within the scope of the present invention. As discussed above, those peptides depicted in Table 2 that do not already contain enhancer peptide sequences (that is, do not represent hybrid polypeptides) can be utilized in connection with the enhancer peptide sequences and teaching provided herein to generate hybrid polypeptides. Further, the core polypeptides and the core polypeptide of the hybrid polypeptides shown in Table 2 and FIG. 13 can be used with any of the enhancer peptide sequences described herein to routinely produce additional hybrid polypeptides, which are also intended to fall within the scope of the present invention.

It is noted that while a number of the polypeptides listed in Table 2 and FIG. 13 are depicted with modified, e.g., blocked amino and/or carboxy termini or d-isomeric amino acids (denoted by residues within parentheses), it is intended that any polypeptide comprising a primary amino acid sequence as depicted to Table 2 and FIG. 13 is also intended to be part of the present invention.

The core polypeptide sequences, per se, shown in Table 2 and FIG. 13, as well as the hybrid polypeptides comprising such core polypeptides, can exhibit antiviral, and/or anti-fusogenic activity and/or can exhibit an ability to modulate interacellular processes that involve coiled-coil peptide structures. Among the core polypeptide sequences are, for example, ones which have been derived from individual viral protein sequences. Also among the core polypeptide sequences are, for example, ones whose amino acid sequences are derived from greater than one viral protein sequence (e.g., an HIV-1, HIV-2 and SIV -derived core polypeptide).

In addition, such core polypeptides can exhibit amino acid substitutions, deletions and/or insertions as discussed, above, for enhancer polypeptide sequences as long as the particular core polypeptide's antiviral and/or antifusogenic activity (either per se or as part of a hybrid polypeptide) is not abolished.



With respect to amino acid deletions, it is preferable that the resulting core polypeptide is at least about 4-6 amino acid residues in length. With respect to amino acid insertions, preferable insertions are no greater than about 50 amino acid residues, and, more preferably no more than about 15 amino acid residues. It is also preferable that core polypeptide insertions be amino- and/or carboxy-terminal insertions.

Among such amino and/or carboxy-terminal insertions are ones which comprise amino acid sequences amino and/or carboxy to the endogenous protein sequence from which the core polypeptide is derived. For example, if the core polypeptide is derived from gp41 protein, such an insertion would comprise an amino and/or carboxy-terminal insertion comprising a gp41 amino acid sequence adjacent to the gp41 core polypeptide sequence. Such amino and/or carboxy terminal insertions can typically range from about 1, 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 amino acid residues amino to and/or carboxy to the original core polypeptide.

The hybrid polypeptides of the invention can still further comprise additional modifications that readily allow for detection of the polypeptide. For example, the hybrid polypeptides can be labeled, either directly or indirectly. Peptide labeling techniques are well known to those of skill in the art and include, but are not limited to, radioactive, fluorescent and colorimetric techniques. Indirect labeling techniques are also well known to those of skill in the art and include, but are not limited to, biotin/streptavidin labeling and indirect antibody labeling.

The invention further relates to the association of the enhancer polypeptide sequences to types of molecules other than peptides. For example, the enhancer peptide sequences may be linked to nucleic acid molecules (e.g., DNA or RNA) or any type of small organic molecule for the purpose of enhancing the pharmacokinetic properties of said molecules.

30

## 5.2. SYNTHESIS OF PEPTIDES

The enhancer, core and hybrid polypeptides of the invention may be synthesized or prepared by techniques well known in the art. See, for example, Creighton, 1983, Proteins: Structures and Molecular Principles, W.H. Freeman and Co., NY, which is incorporated herein by reference in its entirety. Hybrid polypeptides may be prepared using conventional step-wise solution or solid phase synthesis, fragment condensation, F-MOC or T-BOC chemistry. (see, e.g., Chemical Approaches to the Synthesis of Peptides and Proteins, Williams et al., Eds., 1997, CRC Press, Boca Raton Florida, and references cited therein; Solid Phase Peptide Synthesis: A Practical Approach, Atherton & Sheppard, Eds., 1989, IRL Press, Oxford, England, and references cited therein). Likewise the amino- and/or carboxy-terminal modifications.

The enhancer, core and hybrid polypeptides of the invention can be purified by art-known techniques such as normal and reverse phase high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion, precipitation and the like. The actual conditions used to purify a particular polypeptide will depend, in part, on synthesis strategy and on factors such as net charge, hydrophobicity, hydrophilicity, solubility, stability etc., and will be apparent to those having skill in the art.

Hybrid, enhancer and core polypeptides may also be made using recombinant DNA techniques. Here, the nucleotide sequences encoding the polypeptides of the invention may be synthesized, and/or cloned, and expressed according to techniques well known to those of ordinary skill in the art. See, for example, Sambrook, et al., 1989, Molecular Cloning, A Laboratory Manual, Vols. 1-3, Cold Spring Harbor Press, NY.

One may obtain the DNA segment encoding the polypeptide of interest using a variety of molecular biological techniques, generally known to those skilled in the art. For

example, polymerase chain reaction (PCR) may be used to generate the DNA fragment encoding the protein of interest. Alternatively, the DNA fragment may be obtained from a commercial source.

5 The DNA encoding the polypeptides of interest may be recombinantly engineered into a variety of host vector systems that also provide for replication of the DNA in large scale. These vectors can be designed to contain the necessary elements for directing the transcription and/or translation of the DNA sequence encoding the hybrid polypeptide.

10 Vectors that may be used include, but are not limited to, those derived from recombinant bacteriophage DNA, plasmid DNA or cosmid DNA. For example, plasmid vectors such as pCDNA3, pBR322, pUC-19/18, pUC-118, 119 and the M13 mp series of vectors may be used. Bacteriophage vectors may include  $\lambda$ gt10,  $\lambda$ gt11,  $\lambda$ gt18-23,  $\lambda$ ZAP/R and the EMBL series of  
15 bacteriophage vectors. Cosmid vectors that may be utilized include, but are not limited to, pJB8, pCV 103, pCV 107, pCV 108, pTM, pMCS, pNNL, pHSG274, COS202, COS203, pWE15, pWE16 and the charomid 9 series of vectors.

Alternatively, recombinant virus vectors including, but not limited to, those derived from viruses such as herpes  
20 virus, retroviruses, vaccinia viruses, adenoviruses, adeno-associated viruses or bovine papilloma viruses plant viruses, such as tobacco mosaic virus and baculovirus may be engineered.

In order to express a biologically active polypeptide, the nucleotide sequence coding for the protein may be  
25 inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for the transcription and translation of the inserted coding sequences. Methods which are well known to those skilled in the art can be used to construct expression vectors having the hybrid polypeptide coding sequence operatively associated  
30 with appropriate transcriptional/translational control

signals. These methods include *in vitro* recombinant DNA techniques and synthetic techniques. See, for example, the techniques described in Sambrook, et al., 1992, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y. and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates & Wiley Interscience, N.Y., each of which are incorporated herein by reference in its entirety.

The nucleic acid molecule encoding the hybrid, enhancer and core polypeptides of interest may be operatively associated with a variety of different promoter/enhancer elements. The promoter/enhancer elements may be selected to optimize for the expression of therapeutic amounts of protein. The expression elements of these vectors may vary in their strength and specificities. Depending on the host/vector system utilized, any one of a number of suitable transcription and translation elements may be used. The promoter may be in the form of the promoter which is naturally associated with the gene of interest. Alternatively, the DNA may be positioned under the control of a recombinant or heterologous promoter, i.e., a promoter that is not normally associated with that gene. For example, tissue specific promoter/enhancer elements may be used to regulate the expression of the transferred DNA in specific cell types.

Examples of transcriptional control regions that exhibit tissue specificity which have been described and could be used include, but are not limited to, elastase I gene control region which is active in pancreatic acinar cells (Swift et al., 1984, Cell 38:639-646; Ornitz et al., 1986, Cold Spring Harbor Symp. Quant. Biol. 50:399-409; MacDonald, 1987, Hepatology 7:42S-51S); insulin gene control region which is active in pancreatic beta cells (Hanahan, 1985, Nature 315:115-122); immunoglobulin gene control region which is active in lymphoid cells (Grosschedl et al., 1984, Cell

38:647-658; Adams et al., 1985, Nature 318:533-538; Alexander et al., 1987, Mol. Cell. Biol. 7:1436-1444): albumin gene control region which is active in liver (Pinkert et al., 1987, Genes and Devel. 1:268-276) alpha-fetoprotein gene control region which is active in liver (Krumlauf et al., 1985, Mol. Cell. Biol. 5:1639-1648; Hammer et al., 1987, Science 235:53-58); alpha-1-antitrypsin gene control region which is active in liver (Kelsey et al., 1987, Genes and Devel. 1:161-171); beta-globin gene control region which is active in myeloid cells (Magram et al., 1985, Nature 315:338-340; Kollias et al., 1986, Cell 46:89-94); myelin basic protein gene control region which is active in oligodendrocyte cells in the brain (Readhead et al., 1987, Cell 48:703-712); myosin light chain-2 gene control region which is active in skeletal muscle (Shani, 1985, Nature 314:283-286); and gonadotropic releasing hormone gene control region which is active in the hypothalamus (Mason et al., 1986, Science 234:1372-1378). Promoters isolated from the genome of viruses that grow in mammalian cells, (e.g., vaccinia virus 7.5K, SV40, HSV, adenoviruses MLP, MMTV, LTR and CMV promoters) may be used, as well as promoters produced by recombinant DNA or synthetic techniques.

In some instances, the promoter elements may be constitutive or inducible promoters and can be used under the appropriate conditions to direct high level or regulated expression of the nucleotide sequence of interest. Expression of genes under the control of constitutive promoters does not require the presence of a specific substrate to induce gene expression and will occur under all conditions of cell growth. In contrast, expression of genes controlled by inducible promoters is responsive to the presence or absence of an inducing agent.

Specific initiation signals are also required for sufficient translation of inserted protein coding sequences.

These signals include the ATG initiation codon and adjacent sequences. In cases where the entire coding sequence, including the initiation codon and adjacent sequences are inserted into the appropriate expression vectors, no additional translational control signals may be needed.

- 5 However, in cases where only a portion of the coding sequence is inserted, exogenous translational control signals, including the ATG initiation codon must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the protein coding sequences to ensure translation of the entire insert. These exogenous
- 10 translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of transcription attenuation sequences, enhancer elements, etc.

15 5.3. USES OF THE ENHANCER PEPTIDE SEQUENCES; CORE POLYPEPTIDES AND HYBRID POLYPEPTIDES OF THE INVENTION

As discussed above, the enhancer peptide sequences of the invention can be utilized to enhance the pharmacokinetic properties of any core polypeptide through linkage of the core polypeptide to the enhancer peptide sequences to form

20 hybrid polypeptides. The observed enhancement of pharmacokinetic properties is relative to the pharmacokinetic properties of the core polypeptide alone. Standard pharmacokinetic character parameters and methods for determining and characterizing the pharmacokinetic properties of an agent such as a polypeptide are well known to those of

25 skill in the art. Non-limiting examples of such methods are presented in the Examples provided below.

The enhancer peptide sequences of the invention can, additionally, be utilized to increase the in vitro or ex-vivo half-life of a core polypeptide to which enhancer peptide sequences have been attached. For example, enhancer peptide

30 sequences can increase the half life of attached core polypeptides when the resulting hybrid polypeptides are

present in cell culture, tissue culture or patient samples, (e.g., cell samples, tissue samples biopsies, or other sample containing bodily fluids).

The core polypeptides and hybrid polypeptides of the invention can also be utilized as part of methods for  
5 modulating (e.g., decreasing, inhibiting, disrupting, stabilizing or enhancing) fusogenic events. Preferably, such peptides exhibit antifusogenic or antiviral activity. The peptides of the invention can also exhibit the ability to modulate intracellular processes involving coiled-coil peptide interactions.

10 In particular embodiments, the hybrid polypeptides and core polypeptides of the invention that exhibit antiviral activity can be used as part of methods for decreasing viral infection. Such antiviral methods can be utilized against, for example, human retroviruses, particularly HIV (human immunodeficiency virus), e.g., HIV-1 and HIV-2, and the human  
15 T-lymphocyte viruses (HTLV-I and HTLV-II), and non-human retroviruses, such as bovine leukosis virus, feline sarcoma and leukemia viruses, simian immunodeficiency viruses (SIV), sarcoma and leukemia viruses, and sheep progress pneumonia viruses.

The antiviral methods of the invention can also be  
20 utilized against non-retroviral viruses, including, but not limited to, respiratory syncytial virus (RSV), canine distemper virus, newcastle disease virus, human parainfluenza virus, influenza viruses, measles viruses, Epstein-Barr viruses, hepatitis B viruses and Mason-Pfizer viruses.

The above-recited viruses are enveloped viruses. The  
25 antiviral methods of the invention can also be utilized against non-enveloped viruses, including but not limited to picornaviruses such as polio viruses, hepatitis A virus, enterovirus, echoviruses, and coxsackie viruses, papovaviruses such as papilloma virus, parvoviruses, adenoviruses and reoviruses.

30 Other antifusogenic activities that can be modulated via methods that utilize the peptides of the invention include,

but are not limited to modulation of neurotransmitter exchange via cell fusion, and sperm-egg fusion. Among the intracellular disorders involving coiled-coil interactions that can be ameliorated via methods that utilize the peptides of the invention are disorder involving, for example,  
5 bacterial toxins.

The antifusion or antiviral activity of a given core polypeptide or hybrid polypeptide can routinely be ascertained via standard in vitro, ex vivo and animal model assays that, with respect to antiviral activity, can be specific or partially specific for the virus of interest and  
10 are well known to those of skill in the art.

The above description relates mainly to antiviral and antifusion-related activities of core and hybrid polypeptides of the invention. ~~The hybrid polypeptides of the invention~~ can also be utilized as part of any method for which administration or use of the core polypeptide alone might be  
15 contemplated. Use of hybrid polypeptides as part of such methods is particularly preferable in instances wherein an increase in the pharmacokinetic properties of the core polypeptide is desired. For example, insulin is utilized as part of treatment for certain types of diabetes. A hybrid polypeptide comprising an insulin or insulin fragment as the  
20 core polypeptide can, therefore, also be utilized as part of methods for ameliorating symptoms of forms of diabetes for which insulin is used and/or contemplated.

In addition to the above therapeutic methods, the peptides of the invention can still further be utilized as part of prognostic methods for preventing disorders,  
25 including, but not limited to disorders involving fusion events, intracellular processes involving coiled-coil peptides and viral infection that involves cell-cell and/or virus-cell fusion. For example, the core and hybrid polypeptides of the invention can be utilized as part of prophylactic methods of preventing viral infection.

30 The hybrid polypeptides of the invention can still further be utilized as part of diagnostic methods. Such



methods can be either in vivo or in vitro methods. Any diagnostic method that a particular core polypeptide can be utilized can also be performed using a hybrid polypeptide comprising the core polypeptide and a modification or primary amino acid sequence that allows detection of the hybrid polypeptide. Such techniques can reflect an improvement over diagnostic methods in that the increased half life of the hybrid polypeptide relative to the core polypeptide alone can increase the sensitivity of the diagnostic procedure in which it is utilized. Such diagnostic techniques include, but are not limited to imaging methods, e.g., in vivo imaging methods. In a non-limiting example of an imaging method, a structure that binds the core polypeptide of a hybrid polypeptide can be detected via binding to the hybrid polypeptide ~~and imaging (either directly or indirectly) the~~ bound hybrid polypeptide.

15                   5.4.   PHARMACEUTICAL FORMULATIONS, DOSAGES  
                    AND MODES OF ADMINISTRATION

The peptides of the invention may be administered using techniques well known to those in the art. Preferably, agents are formulated and administered systemically. Techniques for formulation and administration may be found in "Remington's Pharmaceutical Sciences", latest edition, Mack Publishing Co., Easton, PA. Suitable routes may include oral, rectal, vaginal, lung (e.g., by inhalation), transdermal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as, intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few. For intravenous injection, the agents of the invention may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or physiological saline buffer to name a few. In addition, infusion pumps may be used to deliver the peptides of the invention. For transmucosal administration,

penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.

In instances wherein intracellular administration of the peptides of the invention or other inhibitory agents is preferred, techniques well known to those of ordinary skill in the art may be utilized. For example, such agents may be encapsulated into liposomes, or microspheres then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are effectively delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, when small molecules are to be administered, direct intracellular administration may be achieved.

Nucleotide sequences encoding the peptides of the invention which are to be intracellularly administered may be expressed in cells of interest, using techniques well known to those of skill in the art. For example, expression vectors derived from viruses such as retroviruses, vaccinia viruses, adeno-associated viruses, herpes viruses, or bovine papilloma viruses, may be used for delivery and expression of such nucleotide sequences into the targeted cell population. Methods for the construction of such vectors and expression constructs are well known. See, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Cold Spring Harbor NY, and Ausubel et al., 1989, Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley Interscience, NY.

Effective dosages of the peptides of the invention to be administered may be determined through procedures well known to those in the art which address such parameters as biological half-life, bioavailability, and toxicity. In particularly preferred embodiments, an effective hybrid

polypeptide dosage range is determined by one skilled in the art using data from routine *in vitro* and *in vivo* studies well known to those skilled in the art. For example, *in vitro* cell culture assays of antiviral activity, such as the exemplary assays described in Section 7, below, for T1249, will provide data from which one skilled in the art may readily determine the mean inhibitory concentration (IC) of the peptide of the polypeptide necessary to block some amount of viral infectivity (e.g., 50%, IC<sub>50</sub>; or 90%, IC<sub>90</sub>). Appropriate doses can then be selected by one skilled in the art using pharmacokinetic data from one or more routine animal models, such as the exemplary pharmacokinetic data described in Section 10, below, for T1249, so that a minimum plasma concentration (C<sub>min</sub>) of the peptide is obtained which is equal to or exceeds the determined IC value.

Exemplary polypeptide dosages may be as low as 0.1 µg/kg body weight and as high as 10 mg/kg body weight. More preferably an effective dosage range is from 0.1 - 100 µg/kg body weight. Other exemplary dosages for peptides of the invention include 1-5 mg, 1-10 mg, 1-30 mg, 1-50 mg, 1-75 mg, 1-100 mg, 1-125 mg, 1-150 mg, 1-200 mg, or 1-250 mg of peptide. A therapeutically effective dose refers to that amount of the compound sufficient to result in amelioration of symptoms or a prolongation of survival in a patient. Toxicity and therapeutic efficacy of such compounds can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD<sub>50</sub> (the dose lethal to 50% of the population) and the ED<sub>50</sub> (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD<sub>50</sub>/ED<sub>50</sub>. Compounds which exhibit large therapeutic indices are preferred. The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such compounds lies preferably within a range of

circulating concentrations that include the  $ED_{50}$  with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized. For any compound used in the method of the invention, the therapeutically effective dose can be  
5 estimated initially from cell culture assays. A dose may be formulated in animal models to achieve a circulating plasma concentration range that includes the  $IC_{50}$  (e.g., the concentration of the test compound which achieves a half-maximal inhibition of the fusogenic event, such as a half-maximal inhibition of viral infection relative to the amount  
10 of the event in the absence of the test compound) as determined in cell culture. Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by high performance liquid chromatography (HPLC) or any biological or immunological assay capable of measuring peptide levels.

15 The hybrid polypeptides of the invention can be administered in a single administration, intermittently, periodically, or continuously. For example, the polypeptides of the invention can be administered in a single administration, such as a single subcutaneous, a single intravenous infusion or a single ingestion. The polypeptides  
20 of the invention can also be administered in a plurality of intermittent administrations, including periodic administrations. For example, in certain embodiments the polypeptides of the invention can be administered once a week, once a day, twice a day (e.g., every 12 hours), every six hours, every four hours, every two hours, or every hour.  
25 The polypeptides of the invention may also be administered continuously, such as by a continuous subcutaneous or intravenous infusion pump or by means of a subcutaneous or other implant which allows the polypeptides to be continuously absorbed by the patient.

30 The hybrid polypeptides of the invention can also be administered in combination with at least one other

therapeutic agent. Although not preferred for HIV therapy, administration for other types of therapy (e.g., cancer therapy) can be performed concomitantly or sequentially, including cycling therapy (that is, administration of a first compound for a period of time, followed by administration of  
5 a second antiviral compound for a period of time and repeating this sequential administration in order to reduce the development of resistance to one of the therapies).

In the case of viral, e.g., retroviral, infections, an effective amount of a hybrid polypeptide or a pharmaceutically acceptable derivative thereof can be  
10 administered in combination with at least one, preferably at least two, other antiviral agents.

Taking HIV infection as an example, such antiviral agents can include, ~~but are not limited to~~ DP-107 (T21), DP-178 (T20), any other core polypeptide depicted in Table 2 derived from HIV-1 or HIV-2, any other hybrid polypeptide  
15 whose core polypeptide is, at least in part, derived from HIV-1 or HIV-2, cytokines, e.g., RIFN  $\alpha$ , RIFN  $\beta$ , RIFN  $\gamma$ ; inhibitors of reverse transcriptase, including nucleoside and non-nucleoside inhibitors, e.g., AZT, 3TC, D4T, ddI, adefovir, abacavir and other dideoxynucleosides or dideoxyfluoronucleosides, or delaviridine mesylate,  
20 nevirapine, efavirenz; inhibitors of viral mRNA capping, such as ribavirin; inhibitors of HIV protease, such as ritonavir, nelfinavir mesylate, amprenavir, saquinavir, saquinavir mesylate, indinavir or ABT378, ABT538 or MK639; amphotericin B as a lipid-binding molecule with anti-HIV activity; and castanospermine as an inhibitor of glycoprotein processing.

25 The hybrid and/or core polypeptides of the invention may, further, be utilized prophylactically for the prevention of disease. Hybrid and/or core polypeptides can act directly to prevent disease or, alternatively, can be used as vaccines, wherein the host raises antibodies against the hybrid polypeptides of the invention, which then serve to  
30 neutralize pathogenic organisms including, for example, inhibiting viral, bacterial and parasitic infection.

For all such treatments described above, the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., 1975, in "The Pharmacological Basis of Therapeutics", Ch. 1 p. 1).

5 It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an  
10 administered dose in the management of the oncogenic disorder of interest will vary with the severity of the condition to be treated and the route of administration. The dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in  
15 veterinary medicine.

Use of pharmaceutically acceptable carriers to formulate the compounds herein disclosed for the practice of the invention into dosages suitable for systemic administration is within the scope of the invention. With proper choice of carrier and suitable manufacturing practice, the compositions  
20 of the present invention, in particular, those formulated as solutions, may be administered parenterally, such as by subcutaneous injection, intravenous injection, by subcutaneous infusion or intravenous infusion, for example by pump. The compounds can be formulated readily using pharmaceutically acceptable carriers well known in the art  
25 into dosages suitable for oral administration. Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.

Pharmaceutical compositions suitable for use in the  
30 present invention include compositions wherein the active ingredients are contained in an effective amount to achieve

its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.

In addition to the active ingredients, these  
5 pharmaceutical compositions may contain suitable  
pharmaceutically acceptable carriers comprising excipients  
and auxiliaries which facilitate processing of the active  
compounds into preparations which can be used  
pharmaceutically. The preparations formulated for oral  
administration may be in the form of tablets, dragees,  
10 capsules, or solutions. For oral administration of peptides,  
techniques such of those utilized by, e.g., Emisphere  
Technologies well known to those of skill in the art and can  
routinely be used.

The pharmaceutical compositions of the present invention  
may be manufactured in a manner that is itself known, e.g.,  
15 by means of conventional mixing, dissolving, granulating,  
dragee-making, levigating, spray drying, emulsifying,  
encapsulating, entrapping or lyophilizing processes.

Pharmaceutical formulations for parenteral  
administration include aqueous solutions of the active  
compounds in water-soluble form. Additionally, emulsions and  
20 suspensions of the active compounds may be prepared as  
appropriate oily injection mixtures. Suitable lipophilic  
solvents or vehicles include fatty oils such as sesame oil,  
or synthetic fatty acid esters, such as ethyl oleate or  
triglycerides, liposomes or other substances known in the art  
for making lipid or lipophilic emulsions. Aqueous injection  
25 suspensions may contain substances which increase the  
viscosity of the suspension, such as sodium carboxymethyl  
cellulose, sorbitol, or dextran. Optionally, the suspension  
may also contain suitable stabilizers or agents which  
increase the solubility of the compounds to allow for the  
preparation of highly concentrated solutions.

30 Pharmaceutical preparations for oral use can be obtained  
by combining the active compounds with solid excipient,

optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, trehalose, mannitol, or sorbitol; 5 cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic 10 acid or a salt thereof such as sodium alginate.

Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic 15 solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.

Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, 20 sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active compounds may be dissolved or suspended 25 in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.

In instances where an enhancement of the host immune response is desired, the hybrid polypeptides may be formulated with a suitable adjuvant in order to enhance the 30 immunological response. Such adjuvants may include, but are not limited to mineral gels such as aluminum hydroxide;



surface active substances such as lysolecithin, pluronic polyols, polyanions; other peptides; oil emulsions; and potentially useful adjuvants such as BCG and Corynebacterium parvum. Many methods may be used to introduce the vaccine formulations described here. These methods include but are not limited to oral, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, and intranasal routes.

6. EXAMPLE: IDENTIFICATION OF CONSENSUS AMINO ACID SEQUENCES THAT COMPRISE ENHANCER PEPTIDE SEQUENCES

The retroviral gp41 protein contains structural domains referred to as the  $\alpha$ -helix region located in the C-terminal region of the protein and the leucine zipper region located in the N-terminal region of the protein. Alignment of the enhancer peptide sequence regions contained within gp41 (FIG. 2A and 2B) of gp41 from all currently published isolate sequences of HIV-1, HIV-2 and SIV identified the consensus amino acid sequences shown in FIG. 1.

As described in detail in the Examples presented below, such sequences represent enhancer peptide sequences in that linkage of these peptide sequences to a variety of different core polypeptides enhances the pharmacokinetic properties of the resultant hybrid polypeptides.

7. EXAMPLE: HYBRID POLYPEPTIDES THAT FUNCTION AS POTENT INHIBITORS OF HIV-1 INFECTION

T1249, as depicted in FIG. 13, is a hybrid polypeptide comprising enhancer peptide sequences linked to an HIV core polypeptide. As demonstrated below, the T1249 hybrid polypeptide exhibits enhanced pharmacokinetic properties and potent *in vitro* activity against HIV-1, HIV-2, and SIV isolates, with enhanced activity against HIV-1 clinical isolates in HuPBMC infectivity assays *in vitro* as well as in the HuPBMC SCID mouse model of HIV-1 infection *in vivo*. In the biological assays described below, the activity of the

T1249 is compared to the potent anti-viral T20 polypeptide. The T20 polypeptide, also known as DP-178, is derived from HIV-1 gp41 protein sequence, and is disclosed and claimed in U.S. patent No. 5,464,933.

5

## 7.1. MATERIALS AND METHODS

### 7.1.1. PEPTIDE SYNTHESIS AND PURIFICATION

Peptides were synthesized using Fast Moc chemistry. Generally, unless otherwise noted, the peptides contained amidated carboxyl termini and acetylated amino termini. Purification was carried out by reverse phase HPLC.

10

T1249 (Ac-WQEWKQKITALLEQAQIQQEKNEYELQKLDKWASLWEWF-NH<sub>2</sub>) is a 39 amino acid peptide (MW = 5036.7) composed entirely of naturally occurring amino acids and is blocked at the amino terminus by an acetyl group and the carboxyl terminus is blocked by an amido group to enhance stability. T1387 is a 23 amino acid peptide lacking enhancer peptide sequences (Ac-TALLEQAQIQQEKNEYELQKLDK-NH<sub>2</sub>). Thus, T1387 represents the

15

core polypeptide of the T1249 hybrid polypeptide. T1387 is blocked at its amino- and carboxy- termini in the same manner as T1249.

In particular, T1249 was synthesized using standard solid-phase synthesis techniques. The identity of the

20

principal peak in the HPLC trace was confirmed by mass spectroscopy to be T1249.

T1249 was readily purified by reverse phase chromatography on a 6-inch column packed with a C18, 10 micron, 120A support.

25

### 7.1.2. VIRUS

The HIV-1<sub>LA1</sub> virus (Popovic, M. et al., 1984, Science 224:497-508) was propagated in CEM cells cultured in RPMI 1640 containing 10% fetal calf serum. Supernatant from the infected CEM cells was passed through a 0.2µm filter and the infectious titer estimated in a microinfectivity assay using

30

the AA5 cell line to support virus replication. For this purpose, 20µl of serially diluted virus was added to 20µl CEM

cells at a concentration of  $6 \times 10^5/\text{ml}$  in a 96-well microtitre plate. Each virus dilution was tested in triplicate. Cells were cultured for seven days by addition of fresh medium every other day. On day 7 post infection, supernatant samples were tested for virus replication as evidenced by reverse transcriptase activity released to the supernatant. The  $\text{TCID}_{50}$  was calculated according to the Reed and Muench formula (Reed, L.J. et al., 1938, Am. J. Hyg. 27:493-497).

#### 7.1.3. CELL FUSION ASSAY

Approximately  $7 \times 10^4$  Molt-4 cells were incubated with  $1 \times 10^4$  CEM cells chronically infected with the HIV-1<sub>LAI</sub> virus in 96-well tissue culture plates in a final volume of 100  $\mu\text{l}$  culture medium (RPMI 1640 containing 10% heat inactivated FBS, supplemented with 1% L-glutamine and 1% Pen-Strep) as previously described (Matthews, T.J. et al., 1987, Proc. Natl. Acad. Sci. USA 84: 5424-5428). Peptide inhibitors were added in a volume of 10  $\mu\text{l}$  and the cell mixtures were incubated for 24 hr. at 37°C in 5%  $\text{CO}_2$ . At that time, multinucleated giant cells (syncytia, five cell widths or larger) were counted by microscopic examination at 10x and 40x magnification which allowed visualization of the entire well in a single field. Treated cells were compared to infected, untreated controls and results expressed as percent inhibition of infected controls.

#### 7.1.4. MAGI-CCR-5 INFECTIVITY ASSAYS

Approximately  $1 \times 10^6$  Magi-CCR-5 cells (obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID; Chackerian, B. et al., 1997, J. Virol. 71: 3932-3939) were seeded into a 48-well tissue culture plate (approximately  $2 \times 10^4$  cells/well in a volume of 300  $\mu\text{l}$ /well selective growth medium consisting of DMEM supplemented with 10% heat inactivated FBS, 1% L-glutamine, 1% Pen/Strep, Hygromycin B, Geneticin, and Puromycin) and allowed to attach overnight at 37°C, 5%  $\text{CO}_2$ . Cell confluency was approximately

30% by the following day. Seeding medium was removed and diluted peptide inhibitor added in volumes of 50  $\mu$ l/well (media only in untreated controls), followed by 100  $\mu$ l/well of diluted virus (desired input virus titre of 100 - 200 pfu/well). Finally, 250  $\mu$ l of selective growth medium was  
5 added to each well and the plate incubated for 2 days at 37°C, 5% CO<sub>2</sub>. Fixing and staining were done according to the protocol provided by NIAID with the MAGI-CCR5 cells. Briefly, medium was removed from the plate and 500  $\mu$ l of fixative added to each well. Plates were allowed to fix for 5 minutes at room temp. Fixative was removed, each well  
10 washed twice with DPBS, and 200  $\mu$ l of staining solution added to each well. The plate was then incubated at 37°C, 5% CO<sub>2</sub>, for 50 minutes, staining solution removed, and each well washed twice with DPBS. The plate was allowed to air dry before blue cells were counted by microscopic, enumerating the entire well. Treated wells were compared to infected,  
15 untreated controls and results expressed as percent inhibition of infected controls.

#### 7.1.5. REVERSE TRANSCRIPTASE ASSAY

The micro-reverse transcriptase (RT) assay was adapted from Goff et al. (Goff, S. et al., 1981, J. Virol. 38: 239-  
20 248) and Willey et al. (Willey, R. et al., 1988, J. Virol. 62: 139-147). Supernatants from virus/cell cultures were adjusted to 1% Triton-X100. 10  $\mu$ l of each supernatant/Triton X-100 sample were added to 50  $\mu$ l of RT cocktail (75 mM KCl, 2 mM Cleavelands reagent, 5 mM MgCl<sub>2</sub>, 5  $\mu$ g/ml poly A, 0.25 units/ml oligo dT, 0.05% NP40, 50 mM Tris-HCl, pH 7.8, 0.5  $\mu$ M  
25 non-radioactive dTTP, and 10 cCi/ml <sup>32</sup>P-dTTP) in a 96-well U-bottom microtitre plate and incubated at 37°C for 90 min. After incubation, 40  $\mu$ l of reaction mixture from each well was transferred to a Schleicher and Schuell (S+S) dot blot apparatus, under partial vacuum, containing a gridded 96-well filter-mat (Wallac catalog #1450-423) and filter backing  
30 saturated with 2x SSC buffer (0.3M NaCl and 0.003M sodium citrate). Each well was washed 4 times with at least 200  $\mu$ l

2x SSC using full vacuum. Minifold was disassembled and gridded filter paper removed and washed 3 times with 2x SSC. Finally, the filter membrane was drained on absorbent paper, allowed to air dry, and sealed in heat sealable bags. Samples were placed in a phosphorscreen cassette and an  
5 erased (at least 8 min) phosphorscreen applied and closed. Exposure was for 16 hr. Pixel Index Values (PIV), generated in volume reporting format retrieved from phosphorimaging (Molecular Dynamics Phosphorimager) blots, were used to determine the affected or inhibited fraction (Fa) for all doses of inhibitor(s) when compared to untreated, infected  
10 controls (analyzed by ImageQuant volume report, corrected for background).

#### 7.1.6. HUMAN PBMC INFECTIVITY/NEUTRALIZATION ASSAY

The prototypic assay used cell lines where the primary  
15 isolate assay utilizes PBMC, obtained through Interstate Blood Bank, activated for 2-3 days with a combination of OKT3 (0.5 µg/ml) and CD28 antibodies (0.1 µg/ml). The target cells were banded on lymphocyte separation medium (LSM), washed, and frozen. Cells were thawed as required and activated as indicated above a minimum of 2-3 days prior to  
20 assay. In this 96-well format assay, cells were at a concentration of  $2 \times 10^6$ /ml in 5% IL-2 medium and a final volume of 100 µl. Peptide stock solutions were made in DPBS (1 mg/ml). Peptide dilutions were performed in 20% FBS RPMI 1640/5% IL-2 complete medium.

#### 25 7.1.7. IN VIVO HU-PBMC SCID MODEL OF HIV-1 INFECTION

Female SCID mice (5-7 weeks old) received  $5-10 \times 10^7$  adult human PBMC injected intraperitoneally. Two weeks after reconstitution, mice were infected IP on day 0 with  $10^3$  TCID<sub>50</sub> HIV-1 9320 (AZT-sensitive isolate A018). Treatment with  
30 peptides was IP, bid, beginning day -1 and continuing through day 6. The extent of infection in blood cells, splenocytes,

lymph nodes, and peritoneal cells was assayed by quantitative co-culture with human PBMC blasts weekly for three consecutive weeks following animal exsanguinations and tissue harvest (day 7, approximately 12-18 hours following the last drug treatment). Co-culture supernatants were evaluated for HIV-1 p24 antigen production as a measure of virus infection (Immunotek Coulter kits and protocol).

#### 7.1.8. RAT PHARMACOKINETIC STUDIES

250-300 g male CD rats, double jugular catheter, obtained from Charles River Laboratories were used. Peptides were injected in one jugular catheter in a volume of 200  $\mu$ l of peptide solution (approximately 3.75 mg/ml), dosing solution concentration was determined using the Edelhoch method, (Edelhoch, 1967, Biochemistry 6:1948-1954) method and adjusted based on animal weight such that each animal received a dose of 2.5 mg/kg). Approximately 250-300  $\mu$ l of blood was removed at predetermined time intervals (0, 15, 30 min and 1, 2, 4, 6, and 8 hours) and added to EDTA capiject tubes. Plasma was removed from pelleted cells upon centrifugation and either frozen or immediately processed for fluorescence HPLC analysis.

#### 7.1.9. FLUORESCENCE HPLC ANALYSIS OF PLASMA SAMPLES

100  $\mu$ l of sample plasma was added to 900  $\mu$ l of precipitation buffer (acetonitrile, 1.0% TFA, detergent) resulting in precipitation of the majority of plasma proteins. Following centrifugation at 10,000 rpm for 10 min, 400  $\mu$ l of the supernatant was removed and added to 600  $\mu$ l of HPLC grade water. Serial dilutions were performed as dictated by concentration of peptide present in each sample in dilution buffer comprised of 40% precipitation buffer and 60% HPLC water. In addition to sample dilutions, serial dilutions of dosing solution were performed in buffer as well as in plasma and used to generate a standard curve relating peak area to known concentration of peptide. This curve was

then used to calculate concentration of peptide in plasma taking into account all dilutions performed and quantity injected onto column.

#### 7.1.10. XTT PROTOCOL

5 In order to measure cytotoxic/cytostatic effects of peptides, XTT assays (Weislow, O.S. et al., 1989, J. Natl. Cancer Inst. 81:577-586) were performed in the presence of varying concentrations of peptide in order to effectively establish a selective index (SI). A  $TC_{50}$  was determined in this assay by incubating cells in the presence and absence of  
10 serially diluted peptide followed by the addition of XTT. In surviving/metabolizing cells XTT is reduced to a soluble brown dye, XTT-formazan. Absorbance is read and comparisons made between readings in the presence and absence of peptide to determine a  $TC_{50}$  utilizing the Karber method (see. e.g., Lennette, E.H. et al., eds., 1969, "Diagnostic Procedures for  
15 Viral and Rickettsial Infections," American Public Health Association, Inc., fourth ed., pp. 47-52). Molt 4, CEM (80,000 cells/well) and a combination of the two cell types (70,000 and 10,000 respectively) were plated and incubated with serially diluted peptide for 24 hours in a total volume of 100  $\mu$ l. Following incubation, 25  $\mu$ l of XTT working stock  
20 (1 mg/ml XTT, 250  $\mu$ M PMS in complete medium containing 5% DMSO) was added to each well and the plates incubated at 37°C. Color development was read and results used to express values generated from peptide containing wells as a percentage of the untreated control wells.

25

#### 7.2. RESULTS

##### 7.2.1. ANTIVIRAL ACTIVITY - FUSION ASSAYS

T1249 was directly compared to T20 in virus mediated cell-cell fusion assays conducted using chronically infected CEM cells mixed with uninfected Molt-4 cells, as shown in Table 3, below. T1249 fusion inhibition against lab isolates  
30 such as IIIb, MN, and RF is comparable to T20, and displays

an approximately 2.5-5-fold improvement over T20. T1249 was also more active (3-28 fold improvement) than T20 against several syncytia-inducing clinical isolates, including an AZT resistant isolate (G691-2), a pre-AZT treatment isolate (G762-3), and 9320 (isolate used in HuPBMC-SCID studies).

5 Most notably, T1249 was over 800-fold more potent than T20 against HIV-2 NIHZ.

**TABLE 3**

10	Virus Isolate	T20 (ng/ml)	n	T1249 (ng/ml)	n	Fold Differenc e
	HIV-1 IIIB	2.5	9	1.0	9	2.5
	HIV-1 G691-2 (AZT-R)	406.0	1	16.0	1	25
	HIV-1 G762-3 (Pre-AZT)	340.1	1	12.2	1	28
	HIV-1 MN	20.0	7	3.1	7	6
15	HIV-1 RF	6.1	7	2.1	7	3
	HIV-1 9320	118.4	1	34.5	1	3
	HIV-2 NIHZ	3610.0	>10	4.3	2	840

#### 7.2.2. ANTIVIRAL ACTIVITY - Magi-CCR-5 INFECTIVITY ASSAYS

20 Magi-CCR-5 infectivity assays allow direct comparisons to be made of syncytia and non-syncytia inducing virus isolates, as well as comparisons between laboratory and clinical isolates. The assay is also a direct measure of virus infection (TAT expression following infection,

25 transactivating an LTR driven beta-galactosidase production), as opposed to commonly used indirect measures of infectivity such as p24 antigen or reverse transcriptase production. Magi-CCR-5 infectivity assays (see Table 4 below) reveal that T1249 is consistently more effective than T20 against all isolates tested, in terms of both  $EC_{50}$  and  $V_n/V_o = 0.1$

30 inhibition calculations. T1249 shows considerable improvement in potency against the clinical isolate HIV-1



301714 (>25-fold), which is one of the least sensitive isolates to T20. In addition, T1249 is at least 100-fold more potent than T20 against the SIV isolate B670. These data, along with fusion data suggest that T1249 is a potent peptide inhibitor of HIV-1, HIV-2, and SIV.

5

**TABLE 4**

Virus Isolate	T20		T1249			
	EC-50	Vn/Vo=0.1	E C-50	Vn/Vo=0.1	EC-50 Fold Difference	Vn/Vo=0.1 Fold Difference
HIV-1 IIIIB	42	80	8	10	5	8
HIV-1 9320	11	50	1	6	11	8
HIV-1 301714 (subtype B, NSI)	1065	4000	43	105	25	38
HIV-1 G691-2 (AZT-R)	13	200	0.3	20	43	10
HIV-1 pNL4-3	166	210	1	13	166	16
SIV-B670	2313	>10000	21	100	110	>100

### 7.2.3. ANTIVIRAL ACTIVITY - HuPBMC INFECTIVITY ASSAYS

T1249 was directly compared to T20 in HuPBMC infectivity assays (Table 5, below), which represent a recognized surrogate *in vitro* system to predict plasma drug concentrations required for viral inhibition *in vivo*. These comparisons revealed that T1249 is more potent against all HIV-1 isolates tested to date, with all Vn/Vo = 0.1 (dose required to reduce virus titer by one log) values being reduced to sub-microgram concentrations. Many of the least

sensitive clinical isolates to T20 exhibited 10-fold or greater sensitivity to T1249. It is noteworthy that HIV-1 9320, the isolate used in the HuPBMC SCID mouse model of infection, is 46-fold less sensitive to T20 than to T1249, indicating a very good correlation with the *in vivo* results.

5

**TABLE 5**

	Virus Isolate (HIV-1)	T20	T1249	Fold Difference
		Vn/Vo = 0.1 (ng/ml)	Vn/Vo = 0.1 (ng/ml)	
10	IIIB	250	80	3
	9320	6000	130	46
	301714 (subtype B, NSI)	8000	700	11
	302056 (subtype B, NSI)	800	90	9
15	301593 (subtype B, SI)	3500	200	18
	302077 (subtype A)	3300	230	14
	302143 (SI)	1600	220	7
	G691-2 (AZT-R)	1300	400	3

20

#### 7.2.4. ANTIVIRAL ACTIVITY - T20 RESISTANT LAB ISOLATES

T1249 was directly compared to T20 in virus mediated cell-cell fusion assays conducted using chronically infected CEM cells mixed with uninfected Molt-4 cells (Table 6, below). T1249 was nearly 200-fold more potent than T20 against a T20-resistant isolate.

25

**TABLE 6**

	Virus Isolate	T20 (ng/ml)	n	T1249 (ng/ml)	n	Fold Difference
30	HIV-1 pNL4-3 SM (T20 Resistant)	405.3	3	2.1	3	193

In Magi-CCR-5 assays (see Table 7, below), T1249 is as much as 50,000-fold more potent than T20 against T20-resistant isolates such as pNL4-3 SM and pNL4-3 STM (Rimsky, I. and Matthews, T., 1998, J. Virol. 72:986-993).

5

**TABLE 7**

Virus Isolate (HIV-1)	T20		T1249			
	EC-50	Vn/Vo = 0.1	EC-50	Vn/Vo=0.1	EC-50 Fold Difference	Vn/Vo=0.1 Fold Difference
pNL4-3	166	210	1	13	166	16
pNL4-3 SM (T20-R)	90	900	4	11	23	82
pNL4-3 SM (T20-R) Duke	410	2600	4	11	103	236
pNL4-3 STM (T20/T649-R)	>50 000	>5000 0	1	13	>50000	>3846

T1249 was directly compared to T20 in HuPBMC infectivity assays (see Table 8, below), evaluating differences in potency against a resistant isolate. T1249 is greater than 250-fold more potent than T20 against the resistant isolate pNL4-3 SM.

20

**TABLE 8**

Virus Isolate (HIV-1)	T20		T1249	
	Vn/Vo = 0.1 (ng/ml)	Vn/Vo = 0.1 (ng/ml)	Fold Difference	
pNL4-3	3500	30	117	
pNL4-3 SM (T20-R)	>10000	40	>250	

30

7.2.5. ANTIVIRAL ACTIVITY - IN VIVO SCID-  
HuPBMC MODEL

In vivo antiviral activity of T1249 was directly compared to T20 activity in the HuPBMC-SCID mouse model of HIV-1 9320 infection (FIG. 3). Two weeks after  
5 reconstitution with HuPBMCs, mice were infected IP on day 0 with  $10^3$  TCID<sub>50</sub> HIV-1 9320 passed in PBMCs (AZT-sensitive isolate A018). Treatment with peptides was IP, bid, for total daily doses of 67 mg/kg (T20), 20 mg/kg (T1249), 6.7 mg/kg (T1249), 2.0 mg/kg (T1249), and 0.67 mg/kg (T1249), for  
10 cells, splenocytes, lymph nodes, and peritoneal cells was assayed by quantitative co-culture with human PBMC blasts weekly for three consecutive weeks following animal exsanguinations and tissue harvest (day 7, approx. 12 to 18 hours following last drug treatment). Co-culture supernatants were evaluated for HIV-1 p24 antigen production  
15 as a measure of virus infection. Infectious virus was not detectable in the blood or lymph tissues of the T20-treated animals, although, virus was detected in the peritoneal washes and spleen preparation. All compartments were negative for infectious virus at the 6.7 mg/kg dose of T1249, indicating at least a 10-fold improvement over T20 treatment.  
20 At the 2.0 mg/kg dose of T1249, both the lymph and the spleen were completely free of detectable infectious virus, with a 2 log<sub>10</sub> reduction in virus titer in the peritoneal wash and a 1 log<sub>10</sub> reduction in virus titer in the blood, compared to infected controls. At the lowest dose of T1249, 0.67 mg/kg, the peritoneal washes and blood were equivalent to infected  
25 control; however, at least a 1 log<sub>10</sub> drop in infectious virus titer was observed in both the lymph and the spleen tissues. Overall, the results indicate that T1249 is between 30 and 100-fold more potent against HIV-1 9320, in vivo, under these conditions.

#### 7.2.6. PHARMACOKINETIC STUDIES - RAT

Cannulated rats were used to further define the pharmacokinetic profile of T1249. Male CD rats, 250-300 g, were dosed IV through a jugular catheter with T1249 and T20 (FIGS. 4A-5). The resulting plasma samples were evaluated  
5 using fluorescence HPLC to estimate peptide quantities in extracted plasma. The beta-phase half-life and total AUC of T1249 was nearly three times greater than T20 (FIG. 5).

#### 7.2.7. CYTOTOXICITY

No overt evidence of T1249 cytotoxicity has been  
10 observed *in vitro*, as demonstrated in FIG. 6.

In addition, T1249 is not acutely toxic (death within 24 hours) at 167 mg/kg (highest dose tested) given IV through jugular cannula (0.3 ml over 2-3 min).

#### 7.2.8. DIRECT BINDING TO gp41 CONSTRUCT M41 Δ 178

15 T1249 was radiolabelled with  $^{125}\text{I}$  and HPLC- purified to maximum specific activity. T20 was iodinated in the same manner. Saturation binding of to M41Δ178 (a truncated gp41 ectodomain fusion protein lacking the T20 amino acid sequence) immobilized on microtitre plates at 0.5 mg/ $\mu\text{l}$  is  
20 shown in FIG.7. Nonspecific binding was defined as binding of the radioligand in the presence of 1  $\mu\text{M}$  unlabeled peptide. Specific binding was the difference between total and nonspecific binding. The results demonstrate that  $^{125}\text{I}$ -T1249 and  $^{125}\text{I}$ -T20 have similar binding affinities of 1-2 nM. Linear inverse Scatchard plots suggests that each ligand  
25 binds to a homogeneous class of sites.

The kinetics of  $^{125}\text{I}$ -T1249 and  $^{125}\text{I}$ -T20 binding was determined on scintillating microtitre plates coated with 0.5  $\mu\text{g/ml}$  M41Δ178. The time course for association and dissociation is shown in FIG.8. Dissociation of bound radioligand was measured following the addition of unlabeled  
30 peptide to a final concentration of 10  $\mu\text{M}$  in one-tenth of the total assay volume. Initial on- and off-rates for  $^{125}\text{I}$ -T1249

were significantly slower than those of  $^{125}\text{I}$ -T20.

Dissociation patterns for both radioligands were unchanged when dissociation was initiated with the other unlabeled peptide (i.e.,  $^{125}\text{I}$ -T1249 with T20).

5 To further demonstrate that both ligands compete for the same target site, unlabeled T1249 and T20 were titrated in the presence of a single concentration of either  $^{125}\text{I}$ -T1249 or  $^{125}\text{I}$ -T20. Ligand was added just after the unlabeled peptide to start the incubation. The competition curves shown in FIG.9 suggest that although both ligands have similar  
10 affinities, a higher concentration of either unlabeled T20 or T1249 is required to fully compete for bound  $^{125}\text{I}$ -T1249.

#### 7.2.9. DIRECT BINDING TO THE HR1 REGION OF GP41

Circular dichroism (CD) spectroscopy was used to measure the secondary structure of T1249 in solution (phosphate-  
15 buffered saline, pH 7) alone and in combination with a 45-residue peptide (T1346) from the HR1 (heptad repeat 1) binding region of gp 41. FIG. 14A illustrates the CD spectrum of T1249 alone in solution (10  $\mu\text{M}$ , 1°C). The spectrum is typical of peptides which adopt an alpha-helical structure. In particular, deconvolution of this spectrum  
20 using single value decomposition with a basis set of 33 protein spectra predicts the helix content of T1249 (alone in solution) to be 50%. FIG. 14B illustrates a representative CD spectrum of T1249 mixed with T1346. The closed squares (■) represent a theoretical CD spectrum predicted for a "non-interaction model" wherein the peptides are hypothesized  
25 to not interact in solution. The actual experimental spectrum (●) differs markedly from this theoretical "non-interaction model" spectrum, demonstrating that the two peptides do, indeed, interact, producing a measurable structural change which is observed in the CD spectrum.

7.2.10. PROTEASE PROTECTION OF THE T1249  
BINDING REGION WITHIN GP41

The susceptibility of the chimeric protein M41Δ178, described in Section 7.2.8 above, to proteinase-K digestion was determined and analyzed by polyacrylamide gel electrophoresis. The results are illustrated in FIG. 15.

When either M41Δ178 (untreated; FIG 15, lane 2) or T1249 (untreated; FIG. 15, lane 4) are incubated individually with proteinase K (FIG. 15, lanes 3 and 5, respectively), both are digested. However, when T1249 is incubated with M41Δ178 prior to addition of proteinase-K (FIG. 15, lane 7), a protected HR-1 fragment of approximately 6500 Daltons results. Sequencing of the protected fragment demonstrates that it corresponds to a region of primary sequence located within the ectodomain of gp41. The protected fragment encompasses the soluble HR1 peptide (T1346) used in the CD studies described in Section 7.2.9 above, and further contains an additional seven amino acid residues located on the amino terminus. This protection can be attributed to the binding of T1249 to a specific sequence of gp41 which is contained in the M41Δ178 construct.

8. EXAMPLE: RESPIRATORY SYNCYTIAL  
VIRUS HYBRID POLYPEPTIDES

The following example describes respiratory syncytial virus (RSV) hybrid polypeptides with enhanced pharmacokinetic properties. In addition, results are presented, below, which demonstrate that the RSV hybrid polypeptides represent potent inhibitors of RSV infection.

8.1. MATERIALS AND METHODS

8.1.1. PEPTIDE-SYNTHESIS AND PURIFICATION

RSV polypeptides were synthesized using standard Fast Moc chemistry. Generally, unless otherwise noted, the peptides contained amidated carboxyl termini and acetylated amino termini. Purification was carried out by reverse phase HPLC.

### 8.1.2. RESPIRATORY SYNCYTIAL VIRUS PLAQUE REDUCTION ASSAY

All necessary dilutions of peptides were performed in clean, sterile 96-well TC plate. A total of eleven dilutions for each peptide and one control well containing no peptide were assembled. The final concentration range of peptide started at 50µg/ml or 100µg/ml, with a total of eleven two-fold dilutions. The RSV was prepared at a concentration of 100PFU/well in 100µl 3% EMEM, as determined by a known titer of RSV. The virus is then added to all of the wells.

The media was removed from one sub-confluent 96-well plate of Hep2 cells. The material from the dilution plate was transferred onto the cell plates starting with row 1 and then transferring row 12, row 11, etc. until all rows were transferred. Plates were placed back into the incubator for 48 hours.

The cells were checked to ensure that syncytia were present in the control wells. Media was removed and approximately 50 µls of 0.25% Crystal Violet in methanol was added to each well. The wells were rinsed immediately in water to remove excess stain and allowed to dry. Using a dissecting microscope, the number of syncytia in each well was counted.

20

### 8.2. RESULTS

Pharmacokinetic studies with the RSV hybrid peptides T1301 (Ac-WQEWDEYDASISQVNEKINQALAYIREADELWA WF-NH<sub>2</sub>) and T1302 (Ac-WQAWDEYDASISQVNEKINQALAYIREADELW AWF-NH<sub>2</sub>) containing enhancer peptide sequences demonstrated a greatly enhanced half-life relative to core peptide T786 (Ac-VYPSDEYDASISQVNEKINQALAYIRKADELLENV-NH<sub>2</sub>), as demonstrated in FIG. 10A-10B. Hybrid polypeptides T1301, T1302 and T1303 (Ac-WQAWDEYDASISDVNEKINQALAYIREADELWEWF-NH<sub>2</sub>) also showed a greatly enhanced half-size relative to core peptide T1476 (Ac-DEYDASISQVNEKINQALAYIREADEL-NH<sub>2</sub>).

RSV hybrid polypeptides T1301, T1302 and T1303, as well as polypeptide T786 and T1293, were tested for their ability



to inhibit RSV plaque formation of HEp2 cells. As indicated in FIGS. 11A and 11B, both the tested hybrid RSV polypeptides, as well as the T786 core polypeptide were able to inhibit RSV infection. Surprisingly, the T1293 hybrid polypeptide was also revealed to be a potent anti-RSV compound (FIG. 13).

9. EXAMPLE: LUTEINIZING HORMONE  
HYBRID POLYPEPTIDES

The example presented herein describes luteinizing hormone (LH) hybrid proteins with enhanced pharmacokinetic properties. The following LH hybrid peptides were synthesized and purified using the methods described above: core peptide T1323 (Ac-QHWSYGLRPG-NH<sub>2</sub>) and hybrid polypeptide T1324 (Ac-WQEWQKIQHWSYGLRPGWASLWEWF-NH<sub>2</sub>) which comprises the core polypeptide T1323 amino acid sequence coupled with enhancer peptides at its amino- and carboxy-termini. As demonstrated in FIG. 12A and 12B, the T1324 hybrid peptide exhibited a significantly increased half-life when compared to the T1323 core peptide which lacks the enhancer peptide sequences.

10. EXAMPLE: PHARMACOLOGY OF HYBRID  
POLYPEPTIDE T1249

T1249, depicted in FIG. 13, is a hybrid polypeptide comprising enhancer peptide sequences linked to a core polypeptide derived from a mix of viral sequences. As demonstrated in the Example presented in Section 7 above, the T1249 hybrid polypeptide exhibits enhanced pharmacokinetic properties and potent *in vitro* as well as *in vivo* activity against HIV-1. In the example presented below, the pharmacological properties of T1249 in both rodent and primate animal models are further described.

### 10.1. MATERIALS AND METHODS

#### 10.1.1. SINGLE-DOSE ADMINISTRATION TO RODENTS

T1249 was administered to Sprague-Dawley albino rats in a single dose administered by continuous subcutaneous infusion (SCI), subcutaneous (SC) injection or intravenous (IV) injection. Each treatment group consisted of nine rats per sex per group. The groups received sterile preparations of T1249 bulk drug substance at a dose of 0.5, 2.0, or 6.5 mg/kg by CSI. One group received 50mM carbonate-bicarbonate, pH 8.5, administered as a control. The peptides were given for 12 hours via a polyvinyl chloride/polyethylene catheter surgically implanted subcutaneously in the nape of the neck. Two groups received a single dose of T1249 at a dose of 1.2 or 1.5 mg/kg by subcutaneous injection into the intrascapular region. Two groups received a single dose of T1249 at a dose of 1.5 or 5 mg/kg via intravenous injection. The actual milligram amount of T1249 was calculated using the peptide content that was determined for the batch administrated.

Endpoints for analysis included cageside observations (twice daily for mortality and moribundity), clinical observations, clinical laboratory parameters, body weight and necropsy. Blood samples were obtained by a sparse sampling technique over a 12 hour time period from three rats per sex per group at each of the following times: 0.5, 1, 2, 4, 6, 8, 19, and 12 hours after dose administration. Sample analysis was performed using a PcAb ECLIA assay (Blackburn, G. et al., 1991, Clin. Chem. 37:1534-1539; Deaver, D., 1995, Nature 377:758).

For plasma and lymphatic pharmacokinetic analysis of T1249 in rats, T1249 was prepared as a sterile solution in bicarbonate buffer and administered as a single dose, bolus intravenous injection into the lateral tail vein at a dose of 20 mg/kg. Blood was collected from the animal from an indwelling jugular catheter. Samples were collected immediately after dosing and at 5, 15, and 30 minutes, and 1, 2, 4, and 6 hours after drug administration. For the

analysis of lymphatic fluids, samples were taken immediately before dosing and every 20 minutes for the first six hours after dosing. Lymphatic fluid was collected from a catheter placed directly into the thoracic lymphatic duct as previously described (Kirkpatrick and Silver, 1970, *The*  
5 *Journal of Surgical Research* 10:147-158). The concentrations of T1249 in plasma and lymphatic fluid were determined using a standard T1249 Competitive ELISA assay (Hamilton, G. 1991, p. 139, in "Immunochemistry of Solid-Phase Immunoassay," Butler, J., ed., CRC Press, Boston).

10

#### 10.1.2. SINGLE-DOSE ADMINISTRATION TO PRIMATES

Sterile preparations of T1249 bulk drug substance were administered to cynomolgus monkeys in single doses administered by subcutaneous (SC), intramuscular (IM) or intravenous (IV) injection. In a sequential crossover  
15 design, one group of animals consisting of two per sex received a single bolus dose of T1249 by IV (0.8 mg/kg), IM (0.8 mg/kg) or SC (0.4, 0.8, and 1.6 mg/kg) injection. A washout period of at least three days separated each dosing day. Lyophilized T1249 was reconstituted in sterile phosphate buffered saline pH 7.4 immediately prior to dosing.  
20 The actual milligram amount of test article was calculated using the peptide content that was determined for the batch administered.

Endpoints for analysis included cageside observations, physical examinations and body weight. For the IV phase of the study, blood samples were collected into heparinized  
25 tubes at the following time points: immediately after dosing, 0.25, 0.5, 1.5, 3, 6, 12, and 24 hours after dosing. For the IM and SC phases of the study blood samples were collected in heparinized tubes from each animal at the following time points: 0.5, 1, 2, 3, 6, 12, and 24 hours  
30 after dosing. Plasma samples were prepared within one hour of collection and flash frozen in liquid nitrogen. Samples analysis was performed using a PcAb ECLIA assay (Blackburn,

G. et al., 1991, Clin. Chem. 37:1534-1539; Deaver, D., 1995, Nature 377:758).

#### 10.1.3. BRIDGING PHARMACOKINETIC STUDY

Six male cynomolgus monkeys were randomly assigned to  
5 three groups consisting of two animals per group. All doses  
of T1249 were given by bolus subcutaneous injection. The  
study was divided into two sessions. In Session 1, animals  
in groups 1, 2 and 3 received a sterile preparation of T1249  
bulk drug substance (i.e., bulk +1249 dissolved in carbonate-  
bicarbonate, pH 8.5) twice daily for four consecutive days  
10 (Study Days 1-4) at doses of 0.2, 0.6 and 2.0 mg/kg/dose,  
respectively. A ten day washout period separated Session 1  
and Session 2. In Session 2, animals in groups 1, 2, and 3  
received a sterile preparation of T1249 drug product (i.e.,  
in aqueous solution, pH 6.5, plus mannitol) twice daily for  
four consecutive days (Study Days 15-18) at doses of 0.2, 0.6  
15 and 2.0 mg/kg/dose, respectively.

Blood samples for pharmacokinetic analyses were  
collected on Study Days 1 and 15 to assess single-dose  
pharmacokinetic parameters, and on Study Days 4 and 18 to  
assess steady-state plasma pharmacokinetic parameters.  
Samples were collected at the following times: immediately  
20 pre-dose, and 0.5, 1.5, 3.0, 4.0, 6.0, 8.0 and 12.0 hours  
post-dose. Animals were monitored during Sessions 1 and 2  
for clinical signs and changes in body weight.

### 10.2. RESULTS

#### 10.2.1. PHARMACOKINETICS OF T1249 ADMINISTERED TO RATS

25 Rat models were used to perform an initial assessment of  
plasma pharmacokinetics and distribution of T1249. For  
animals in all dose groups, there were no changes in body  
weight, physical observations, hematology and clinical  
chemistry parameters or macroscopic pathology observations  
30 related to the administration of T1249.

Rats that received T1249 by CSI achieved steady-state plasma peptide concentrations approximately four hours after administration. Both the steady-state concentration in plasma ( $C_{p_{ss}}$ ) and calculated area under the plasma concentration versus time curve (AUC) were directly proportional to the administered dose, indicating that T1249 displays linear pharmacokinetics within the tested dose range of 0.5 to 6.5 mg/kg. Both the calculated pharmacokinetic parameters and the plasma concentration versus time curves for the CSI route of administration are presented in Table 9 and in FIG. 16A, respectively.

TABLE 9

Parameter	Dose Groups		
	0.5 mg/kg	2.0 mg/kg	6.5 mg/kg
$C_{p_{ss}}$ ( $\mu\text{g/ml}$ )	0.80	2.80	10.9
$AUC_{(0-12h)}$ ( $\mu\text{g}\cdot\text{h/ml}$ )	7.99	25.9	120

Administration of T1249 by bolus IV injection resulted in linear dose-dependent pharmacokinetics within the doses tested. In contrast, exposure to T1249 by SC injection was not dose-dependent within the dose range studied. The calculated pharmacokinetic parameters and plasma concentration versus time curves for both SC and IV administration of T1249 are shown in Table 10 and FIG. 16B respectively.

TABLE 10

Parameter	Dose Groups/Administration			
	(SC)		(IV)	
	1.2 mg/kg	15 mg/kg	1.5 mg/kg	5.0 mg/kg
$t_{1/2, \text{ terminal}}$ (hours)	2.02	2.00	2.46	1.86

	$t_{\max}$ (hours)	1.09	1.88	-	-
	$C_{\max}$ ( $\mu\text{g}/\text{ml}$ )	6.37	21.5	15.7	46.3
	$\text{AUC}_{(0-12\text{h})}$ ( $\mu\text{g}\cdot\text{h}/\text{ml}$ )	27.0	107	45.6	118
5	$\text{AUC}_{(0-\infty)}$ ( $\mu\text{g}\cdot\text{h}/\text{ml}$ )	27.6	110	47.1	120

The bioavailability of T1249 administered to rats by subcutaneously was determined relative to IV administration. The results are shown in Table 11 below. At low dose (1.2 mg/kg) T1249 exhibited a relative bioavailability ( $F_R$ ) of 73% for subcutaneous administration. Relative bioavailability was 30% when high-dose (15 mg/kg) administration of T1249 concentration was greater than the concentration that inhibits 90% ( $\text{IC}_{90}$ ) of HIV infectivity for the full 12 hours of the study at all doses examined.

15

TABLE 11

	Route	Dose (mg/kg)	$\text{AUC}_{(0-\infty)}$ ( $\mu\text{g}\cdot\text{h}/\text{ml}$ )	Normalized $\text{AUC}_{(0-\infty)}$ ( $\mu\text{g}\cdot\text{h}/\text{ml}$ )	$F_R$ (%)
	Low Dose				
20	SC	1.2	27.6	34.5 <sup>(a)</sup>	73
	IV	1.5	47.1	-	-
	High Dose				
	SC	15	110	36.5 <sup>(b)</sup>	30
	IV	5	120	-	-

25 <sup>(a)</sup> Normalized from a 1.2 mg/kg dose to a 1.5 mg/kg dose by multiplying  $\text{AUC}_{(0-\infty)}$  by 1.25.

<sup>(b)</sup> Normalized from a 15 mg/kg dose to a 5 mg/kg dose by dividing  $\text{AUC}_{(0-\infty)}$  by 3.

The kinetic data for both plasma and lymph concentrations of T1249 are illustrated in FIG. 16C and tabulated below in Table 12. T1249 rapidly penetrated into the lymphatic system and equilibrated with the plasma reservoir of drug within approximately one hour after

30

administration. Following equilibration between the two compartments, plasma and lymph levels of drug were comparable out to three hours post-dosing in four out of five animals. One animal had consistently lower concentrations of T1249 in the lymph than the other animals, however this animal's lymph  
 5 elimination profile was indistinguishable from other members of the group. Comparison of the elimination phase half-life ( $t_{1/2}$ ) for plasma and lymph suggest that the transit of T1249 between these two compartments is a diffusion-controlled process. After three hours, there appeared to be a second, more rapid elimination phase from the lymphatic system. This  
 10 difference could be mechanism-based (e.g., due to redistribution or accelerated peptide degradation in the lymph) or due to other factors. The concentration of T1249 in lymphatic fluid six hours post-injection is greater than the  $IC_{90}$  for viral infectivity for common laboratory strains and for primary clinical isolates of HIV-1.

15 The extent of penetration of T1249 into cerebrospinal fluid (CSF) was also assessed. T1249 concentrations were below the limit of detection (LOD; 2.0 ng T1249/ml CSF) at all measurable time points, indicating that T1249 does not penetrate the central nervous system after a single dose administration.

20

TABLE 12

Parameter	T1249	
	Plasma	Lymph
25 $t_{1/2}$ , elimination(hours)	2.6±0.41	1.3±0.27
$C_{max}$ (µg/ml)	291	133 <sup>(a)</sup> /155 <sup>(b)</sup>
AUC <sub>(0-6h)</sub> (µg•h/ml)	506	348 <sup>(a)</sup> /411 <sup>(b)</sup>
AUC <sub>(0-∞)</sub> (µg•h/ml)	598	390 <sup>(a)</sup> /449 <sup>(b)</sup>
30 Cl (ml/h)	7.8	11.5

(a) Calculated averages include one animal (Rat #1) that exhibited significantly lower lymph concentrations but a similar kinetic profile by comparison to the other animals in the group.

(b) Calculated averages that exclude Rat #1.

5

#### 10.2.2. PHARMACOKINETICS OF T1249 ADMINISTERED TO PRIMATES

Primate models were used to evaluate the relationship between dose level and various pharmacokinetic parameters associated with the parenteral administration of T1249. Plasma concentrations greater than 6.0 µg/ml of T1249 were achieved by all routes of administration and quantifiable levels (i.e., levels greater than 0.5 µg/ml) were detected at 10 24 hours after SC and IV administration. The elimination  $t_{1/2}$  was comparable for all routes of administration (5.4 hours, 4.8 hours and 5.6 hours for IV, SC and IM administration, respectively). Plasma concentrations of T1249 that exceed the  $IC_{90}$  values for laboratory strains and clinical isolates 15 of HIV-1 were observed at all measured time points throughout the 24 hour sampling period.

A comparison of the data obtained for the parenteral administration of 0.8 mg/kg T1249 via all routes of administration (SC, IV, and IM) is presented in FIG. 17A. FIG. 15B illustrates a comparison of the data obtained from 20 SC injection at three different dose levels of T1249 (0.4 mg/kg, 0.8 mg/kg, and 1.6 mg/kg). The insert in FIG. 17B contains a plot of the calculated AUC versus administered dose.

T1249 displays linear pharmacokinetics in cynomolgus 25 monkeys following SC administration within the range of administered doses, indicating that saturation of the clearance mechanism or mechanisms has not occurred within this range. A summary of the pharmacokinetic data following parenteral administration of T1249 to cynomolgus monkeys is provided in Table 13, below. A comparison of the plasma AUC 30 values indicates that, relative to intravenous administration, the bioavailability of T1249 is approximately



64% when given by intramuscular injection and 92% when given by subcutaneous injection.

Table 13

Parameter	Administration Route (Dose Level, mg/kg)				
	SC (0.4)	SC (0.8)	SC (1.6)	IM (0.8)	IV (0.8)
$t_{1/2, \text{ terminal}}$ (h)	6.23±0.52	4.83±0.48	5.55±0.92	5.57±0.24	5.35±0.95
$t_{\text{max}}$ (h)	3.97±1.18	4.58±1.45	4.72±1.81	2.32±0.43	-
$C_{\text{max}}$ (µg/ml)	3.17±0.09	6.85±1.01	13.3±2.55	6.37±1.69	26.7±0.25
$AUC_{(0-24)}$ (µg·h/ml)	37.5±6.6	8.12±11.4	168±34.0	56.4±12.3	87.4±25.0
$AUC_{(0-\infty)}$ (µg·h/ml)	40.9±8.2	85.3±13.6	181±44.0	59.5±13.1	92.5±25.0
$F_R$ (%)	-	92.3	-	64.4	-

#### 10.2.3. BRIDGING PHARMACOKINETIC STUDY

Bridging pharmacokinetic studies were performed in order to compare the plasma pharmacokinetic profiles of the T1249 bulk drug substances used in the nonclinical trials described above to the formulated T1249 drug product which would be administered to an actual subject or patient, e.g., to treat HIV infection. The study was designed as a parallel group, one-way, cross-over comparison of three dose levels of T1249 bulk drug substance and three dose levels of formulated drug product. Plasma pharmacokinetics were assessed after single-dose administration and after steady state was achieved.

Administration of T1249 by subcutaneous injection resulted in measurable levels of peptide in all dose groups. The plasma concentration-time curves were roughly parallel within all dose groups following the initial dose (Days 1 and 15) and at steady state (Days 4 and 18) for both T1249 bulk drug substance and formulated T1249 drug product.

Furthermore  $AUC_{(0-12hr)}$  values varied in direct proportion to

the dose level for both drug formulations. Calculated  $AUC_{(0-12hr)}$  values for the drug product ranged from 43% to 80% of the  $AUC_{(0-12hr)}$  values calculated for drug substance following single dose administration, and from 36% to 71% at steady state.

5 T1249 bulk drug substance and drug product demonstrated similar pharmacokinetic profiles in cynomolgus monkeys following bolus subcutaneous administration at the dose levels and dose volume tested. A direct comparison of the shapes of the plasma concentration-time curves in the present study and the shapes of curves from a previous study in  
10 cynomolgus monkeys suggests that there is a depot effect when T1249 is administered by subcutaneous injection. This is suggested by the increases in time at which maximal plasma concentration ( $t_{max}$ ) is achieved and  $t_{1/2}$ .

These results indicate that the formulation of bulk drug substance used in the pharmacology program yields comparable  
15 AUC values and other kinetic parameters to those observed following the administration of the formulated drug product. These observations indicate that clinical administration of T1249 will result in total patient exposure to T1249.

The present invention is not to be limited in scope by  
20 the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in  
25 the art from the foregoing description and accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

WHAT IS CLAIMED IS:

1. A hybrid polypeptide comprising an enhancer peptide sequence linked to a core polypeptide.
2. The hybrid polypeptide of Claim 1, wherein the  
5 enhancer peptide sequence comprises: WXXWXXXI, WXXWXXX,  
WXXWXX, WXXWX, WXXW, WXXXWXXW, XXXWXXW, XXWXXW, XWXXW, WXXW,  
WXXXWXXW, WXXXW, IXXXWXXW, XXXWXXW, XXWXXW, XWXXW, XWXXXW,  
XWXWXXX, XWXWXX, XWXXW, XWXW, WXWXXXW or XWXXXW.
3. The hybrid polypeptide of Claim 1 wherein the  
10 enhancer peptide sequence comprises WQEWQKI or WASLWEP.
4. The hybrid polypeptide of Claim 1, wherein the  
enhancer peptide sequence is linked to the amino-terminal end  
of the core polypeptide.
5. The hybrid polypeptide of Claim 4, further  
15 comprising an enhancer peptide sequence linked to the  
carboxy-terminal end of the core polypeptide.
6. The hybrid polypeptide of Claim 1, wherein the  
enhancer peptide sequence is linked to the carboxy-terminal  
20 end of the core polypeptide.
7. The hybrid polypeptide of Claim 1 wherein the core  
polypeptide is a therapeutic reagent.
8. The hybrid polypeptide of Claim 1 wherein the core  
25 polypeptide is a bioactive peptide, a growth factor,  
cytokine, differentiation factor, interleukin, interferon,  
colony stimulating factor, hormone or angiogenic factor amino  
acid sequence.
9. The hybrid polypeptide of Claim 1, wherein the core  
30 polypeptide comprises the following amino acid sequence:  
YTSLIHSLIEESQNOQEKNEQELLELDK; LEENITALLEEAIQOQEKMYELOKINS;

LEANISQSLEQAQIQQEKKNMYELQKLNS; NNYTSLIHSLIEESQNQQEKNEQELLEL;  
 DFLEENITALLEEAQIQQEKKNMYELQKL; RYLEANISQSLEQAQIQQEKKNMYELQKL;  
 RYLEANITALLEQAQIQQEKNEVELQKL; NNYTSLIHSLIEESQNQQEKNEQELLELDK;  
 TALLEQAQIQQEKNEVELQKLDK;  
 TALLEQAQIQQEKNEVELQKLDE;  
 5 TALLEQAQIQQEKNEVELQKLIE;  
 TALLEQAQIQQEKIEVELQKLDK;  
 TALLEQAQIQQEKIEVELQKLDE;  
 TALLEQAQIQQEKIEVELQKLIE;  
 TALLEQAQIQQEKIEVELQKLE;  
 TALLEQAQIQQEKIEVELQKLAK;  
 10 TALLEQAQIQQEKIEVELQKLAE;  
 TALLEQAQIQQEKAEVELQKLE;  
 TALLEQAQIQQEKNEVELQKLE;  
 TALLEQAQIQQEKGEVELQKLE;  
 TALLEQAQIQQEKAEVELQKLAK;  
 TALLEQAQIQQEKNEVELQKLAK;  
 15 TALLEQAQIQQEKGEVELQKLAK;  
 TALLEQAQIQQEKAEVELQKLAE;  
 TALLEQAQIQQEKNEVELQKLAE;  
 TALLEQAQIQQEKGEVELQKLAE;  
 DEFDAISQVNEKINQSLAFIRKSDELL;  
 DEYDASISQVNEKINQALAYIREADEL;  
 20 DEYDASISQVNEEINQALAYIRKADEL; DEFDESISQVNEKIEESLAFIRKSDELL;  
 DEFDESISQVNEKIEESLAFIRKSDEL; or  
 QHWSYGLRPG.

10. The hybrid polypeptide of Claim 9, wherein the  
 enhancer peptide sequence is linked to the amino-terminal end  
 25 of the core polypeptide.

11. The hybrid polypeptide of Claim 10, further  
 comprising an enhancer peptide sequence linked to the  
 carboxy-terminal end of the core polypeptide.

30

12. The hybrid polypeptide of Claim 9, wherein the enhancer peptide sequence is linked to the carboxy-terminal end of the core polypeptide.

13. The hybrid polypeptide of Claim 9, wherein the  
5 enhancer peptide sequence comprises WQEWQKI or WASLWFW.

14. The hybrid polypeptide of Claim 9, wherein the hybrid polypeptide comprises the amino acid sequence:  
WQEWQKITALLEQAQIQQEKNEYELQKLDKWASLWFW,  
WQEWQKITALLEQAQIQQEKIEYELQKLIEWFW or  
10 VYPSDEYDASISQVNEEINQALAYIRKADELLENV.

15. The hybrid polypeptide of Claim 14, further comprising an amino terminal acetyl group and a carboxy terminal amido group.

16. A core polypeptide comprising:  
YTSLIHSLIEESQNQQEKNEQELLELDK; LEENITALLEEAQIQQEKKNMYELQKLNS;  
LEANISQSLEQAQIQQEKKNMYELQKLNS; NNYTSLIHSLIEESQNQQEKNEQELLEL;  
DFLEENITALLEEAQIQQEKKNMYELQKL; RYLEANISQSLEQAQIQQEKKNMYELQKL;  
RYLEANITALLEQAQIQQEKNEYELQKL; NNYTSLIHSLIEESQNQQEKNEQELLELDK;  
TALLEQAQIQQEKNEYELQKLDK;  
20 TALLEQAQIQQEKNEYELQKLDE;  
TALLEQAQIQQEKNEYELQKLIE;  
TALLEQAQIQQEKIEYELQKLDK;  
TALLEQAQIQQEKIEYELQKLDE;  
TALLEQAQIQQEKIEYELQKLIE;  
TALLEQAQIQQEKIEYELQKLE;  
25 TALLEQAQIQQEKIEYELQKLAK;  
TALLEQAQIQQEKIEYELQKLAE;  
TALLEQAQIQQEKAEYELQKLE;  
TALLEQAQIQQEKNEYELQKLE;  
TALLEQAQIQQEKGEYELQKLE;  
TALLEQAQIQQEKAEYELQKLAK;  
30 TALLEQAQIQQEKNEYELQKLAK;  
TALLEQAQIQQEKGEYELQKLAK;

TALLEQAQIQQEKA EYELQKLAE;  
TALLEQAQIQQEKNEYELQKLAE;  
TALLEQAQIQQEKGEYELQKLAE;  
DEFDASISQVNEKINQSLAFIRKSDELL;  
DEYDASISQVNEKINQALAYIREADEL;  
5 DEYDASISQVNEEINQALAYIRKADEL; DEFDESISQVNEKIEESLAFIRKSDELL;  
DEFDESISQVNEKIEESLAFIRKSDEL; or  
QHWSYGLRPG.

17. The core polypeptide of Claim 16, further  
comprising an amino terminal acetyl group and a carboxy  
10 terminal amido group.

18. A method for enhancing the pharmacokinetic  
properties of a core polypeptide comprising linking a  
consensus enhancer peptide sequence to a core polypeptide to  
form a hybrid polypeptide, such that, when introduced into a  
15 living system, the hybrid polypeptide exhibits enhanced  
pharmacokinetic properties relative those exhibited by the  
core polypeptide.

19. The method of Claim 18 wherein the core polypeptide  
is a therapeutic reagent.  
20

20. The method of Claim 18 wherein the core polypeptide  
is a bioactive peptide, growth factor, cytokine,  
differentiation factor, interleukin, interferon, colony  
stimulating factor, hormone or angiogenic factor.  
25

30



2/29

SIV AND HIV-2 SEQUENCES				HIV-1 SEQUENCES				HIV-1 SEQUENCES				HIV-1 SEQUENCES												
	WQEW	EQK	I	WLQ	WDK	E	I	W	I	Q	WD	R	E	I	W	M	Q	W	K	R	E	I		
SIV	WLEW	ERQ	I	WMD	WER	E	I	W	I	Q	WE	K	E	I	W	M	E	W	N	R	E	I		
	WLEW	EKQ	I	WME	WEK	E	I	W	M	Q	WE	K	E	I	W	R	E	W	D	R	E	I		
HIV-2	WQQW	EQQ	I	WME	WD	R	E	I	W	Q	Q	WD	Q	H	I	W	T	E	W	E	R	E	I	
	WQQW	EKQ	I	WME	WER	E	I	W	M	Q	WE	R	E	I	W	L	E	W	E	R	E	I		
	WQEW	EHK	I	WIE	WER	E	I	W	Q	E	WD	R	Q	I	W	M	G	W	E	R	E	I		
	WQEW	EKG	I	WIE	WD	R	E	I	W	Q	Q	WD	Q	Q	I	W	Q	E	W	D	Q	Q	I	
	WQEW	EQQ	I	WMQ	WD	R	E	I	W	I	E	W	K	R	E	I	W	M	K	W	E	R	E	I
	WQKW	EQQ	I	WIQ	WER	E	I	W	M	E	W	E	M	E	I									
	WQEW	EQR	I	WGI	WR	WG	I		W	I	E	W	E	K	E	I	W	X	X	W	X	X	X	I

FIG.2A

SIV SEQUENCES				HIV-2 SEQUENCES				HIV-1 SEQUENCES				HIV-1 SEQUENCES				HIV-1 SEQUENCES																										
	W	A	G	L	W	E	W	F	W	D	V	F	G	N	W	F	W	A	N	L	W	N	W	F	W	T	S	L	W	S	W	F	W	A	G	L	W	N	W	F		
SIV	W	S	N	F	W	S	W	F	W	D	V	F	T	N	W	L	W	A	S	L	W	N	W	F	W	A	S	I	W	N	W	L	W	T	N	L	W	N	W	F		
	W	D	S	L	W	S	W	F	W	D	I	F	G	N	W	F	W	E	N	L	W	N	W	F	W	Q	N	L	W	N	W	F	W	P	S	L	W	N	W	F		
	W	S	G	F	W	S	W	F	W	D	V	F	G	N	W	L	W	A	S	L	W	N	W	V	W	Q	N	L	W	S	W	F	W	A	G	L	W	S	W	F		
	W	S	S	L	W	N	W	F	W	D	I	F	G	N	W	S	W	W	E	N	L	W	S	W	F	W	P	N	L	W	N	W	F	W	A	S	L	W	T	W	S	
	W	S	D	F	W	S	W	F	W	D	V	F	S	N	W	F	W	D	S	L	W	G	W	F	W	A	S	L	W	S	W	F	W	A	S	L	W	S	W	F		
	W	S	D	I	W	S	W	V	W	D	I	L	G	N	W	F	W	D	S	L	W	N	W	F	W	S	S	L	W	N	W	F	W	X	X	X	W	X	W	X	W	X
	W	A	S	L	W	N	W	F									W	A	S	L	W	T	W	F	W	G	S	L	W	S	W	F										
	W	S	S	F	W	S	W	F									W	K	N	L	W	N	W	F	W	A	N	L	W	S	W	F										

FIG.2B



3/29




FIG. 3

4/29




FIG. 4A

5/29





FIG. 4B

6/29



PHARMACOKINETIC PARAMETERS	T20BQ1	T1249A1
DOSE (mg/kg IV)	2.5	2.5
DETECTION METHOD	FLUORESCENCE HPLC	FLUORESCENCE HPLC
$T_{1/2\beta}$ (h)	1.6	4.71
$Cl_{\beta}$ (ml/h)	27.94	9.62
AUC [0-8] (ug/h/ml)	26.12	71.43

FIG. 5

7/29




FIG. 6

8/29




FIG. 7A




FIG. 7A-1

9/29




FIG.7B




FIG.7B-1

10/29




FIG. 8A




FIG. 8B



11/29




FIG. 9A




FIG. 9B

12/29




FIG. 10A

13/29




FIG. 10B




FIG. 11A




FIG. 11B

16/29




FIG. 12A

17/29




FIG. 12B

18/29

Trimeric No.	IP	HIV-1 Fusion	RSV Fusion
	11/2	EC-50 ng/ml	EC-50 ng/ml
HIV-1 T20 AC-	Peptide	3	>20000
HIV-1 T379 AC-	-W2 HIV-1 T20	3	
SIV T402 AC-	-W2 HIV-1 T379	3	
HIV-2 T698 AC-	-W2 SIV T402	50	
	-W2 HIV-2 T698		
HIV-1 T649 AC-	-W2 HIV-1 T649	7	
SIV T391 AC-	-W2 SIV T391	15	
HIV-2 T856 AC-	-W2 HIV-2 T856	7	
HYBRID T1052 AC-	-W2 HYBRID T1052	9	
	IV		
	11/2		
HIV-1 T625 AC-	-W2 HIV-1 T625	7	
HIV-1 T866 AC-	-W2 HIV-1 T866	5	
HIV-1 T867 AC-	-W2 HIV-1 T867	6	

FIG.13A



19/29

HIV-1/SIV/HIV-2 HYBRIDS		Hybrid (T1052-like) Core Sequence		IV 11/2	
HYBRID T1387	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1387 >10000
HYBRID T1388	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1388 >10000
HYBRID T1226	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1226 4
HYBRID T1227	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1227 7
HYBRID T1248	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1248 6
HYBRID T1267	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1267
HYBRID T1269	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1269 3
HYBRID T1311	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1311 53
HYBRID T1314	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1314 30
HYBRID T1312	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1312 12
HYBRID T1313	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1313 5
HYBRID T1275	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1275 6
HYBRID T1276	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1276 7
HYBRID T1277	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1277 3
HYBRID T1278	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1278 6
HYBRID T1279	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1279 3
HYBRID T1280	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1280 7
HYBRID T1247	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1247 1
HYBRID T1249	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1249 2
HYBRID T1353	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1353 2
HYBRID T1330	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1330 28
HYBRID T1331	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1331 30
HYBRID T1332	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1332 18
HYBRID T1333	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1333 33
HYBRID T1334	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1334 35
HYBRID T1347	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1347 8
HYBRID T1350	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1350 6
HYBRID T1348	Ac-	WQEWREI	TALLEQAQIQQEKNEYELOKLDK	-N2	HYBRID T1348 7

FIG.13B

20/29

HYBRID T1351	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLAIE	WAGLWAW	-W2	HYBRID T1351	8	20897
HYBRID T1349	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLAIE	WASLWAW	-W2	HYBRID T1349	86	15326
HYBRID T1352	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLAIE	WAGLWAW	-W2	HYBRID T1352	193	14358
HYBRID T1339	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLDK	WEWFF	-W2 45m	HYBRID T1339	13	367
HYBRID T1293	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2 2.6h	HYBRID T1293	11	3085
HYBRID T1337	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2	HYBRID T1337	4	21618
HYBRID T1338	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2	HYBRID T1338	234	579
HYBRID T1294	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLIE	WASLWAW	-W2	HYBRID T1294	32	7774
HYBRID T1309	Ac-	WQWEQKI	TALLEQAQIQQEKNE	YELQKLIE	WASLWAW	-W2	HYBRID T1309	153	>50000
HYBRID T1281	Ac-	WQWE	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2	HYBRID T1281	3	34597
HYBRID T1282	Ac-	WQWE	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2	HYBRID T1282	4	3090
HYBRID T1283	Ac-	WQWE	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2	HYBRID T1283	33	2393
HYBRID T1284	Ac-	WQWE	TALLEQAQIQQEKNE	YELQKLIE	WEWFF	-W2	HYBRID T1284	31	21022
HYBRID T1295	Ac-	WQWE	TALLEQAQIQQEKNE	YELQKLIE	WASLWAW	-W2	HYBRID T1295	60	>50000
Biological Activity									
IV		RSV		Fusion		RSV		Fusion	
11/2		EC-50		ng/ml		EC-50		ng/ml	
RSV T67	Ac-	DEFDASISQVNEKINQSLAFIRKSDELL		-W2 <5m		RSV T67	500		
RSV T786	Ac-	VYPSDEYIDASISQVNEINQALAYIRKKADELLENV		-W2 <5m		RSV T786	1200	3085	
T67 Active Core Sequence									
HIV-1/HIV-2/RSV HYBRIDS		Y T S L I H S L G G		DEFDESISQVNEKIEESLAFIRKSDELL		GGWASLWNWF		-W2	
HYBRID T1138	Ac-	Y T S L I H S L G G	DEFDESISQVNEKIEESLAFIRKSDELL	GGWASLWNWF		-W2		HYBRID T1138	1000
HYBRID T1155	Ac-	Y T S L I H S L G G	DEFDESISQVNEKIEESLAFIRKSDELL	GGWASLWNWF		-W2		HYBRID T1155	200
HYBRID T1137	Ac-	Y T S L G G	DEFDESISQVNEKIEESLAFIRKSDELL	GGWASLWNWF		-W2		HYBRID T1137	750
HYBRID T1156	Ac-	Y T S L G G	DEFDESISQVNEKIEESLAFIRKSDELL	GGWASLWNWF		-W2		HYBRID T1156	3000
HYBRID T1157	Ac-		DEFDESISQVNEKIEESLAFIRKSDELL	GGWASLWNWF		-W2		HYBRID T1157	2900
HYBRID T1158	Ac-		DEFDESISQVNEKIEESLAFIRKSDELL	GGWASLWNWF		-W2		HYBRID T1158	2900
HYBRID T1170	Ac-	W N W F	DEFDESISQVNEKIEESLAFIRKSDELL	W N W F		-W2		HYBRID T1170	2900

FIG.13C

21/29

HIV-1/HIV-2/RSV HYBRIDS		T786 Active Core Sequence							
T1474	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	T1474	1800	
T1475	Ac-	DEYDASISQVNEEINQALAYIREADEL	WQEW	DEYDASISQVNEEINQALAYIREADEL	WEWF	-NH2	T1475	1800	
HYBRID T1285	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	HYBRID T1285	1800	
HYBRID T1288	Ac-	DEYDASISQVNEEINQALAYIREADEL	WQEW	DEYDASISQVNEEINQALAYIREADEL	WEWF	-NH2	HYBRID T1288	1800	
HYBRID T1286	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	HYBRID T1286	1800	
HYBRID T1289	Ac-	DEYDASISQVNEEINQALAYIREADEL	WQEW	DEYDASISQVNEEINQALAYIREADEL	WEWF	-NH2	HYBRID T1289	1800	
HYBRID T1287	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	HYBRID T1287	1800	
HYBRID T1290	Ac-	DEYDASISQVNEEINQALAYIREADEL	WQEW	DEYDASISQVNEEINQALAYIREADEL	WEWF	-NH2	HYBRID T1290	3200	
HYBRID T1291	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	HYBRID T1291	2000	
HYBRID T1292	Ac-	DEYDASISQVNEEINQALAYIREADEL	WQEW	DEYDASISQVNEEINQALAYIREADEL	WEWF	-NH2	HYBRID T1292	3900	
HYBRID T1301	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	HYBRID T1301	1200	
HYBRID T1302	Ac-	DEYDASISQVNEEINQALAYIREADEL	WQEW	DEYDASISQVNEEINQALAYIREADEL	WEWF	-NH2	HYBRID T1302	2000	
HYBRID T1303	Ac-	DEYDASISQVNEKINQALAYIREADEL	WQEW	DEYDASISQVNEKINQALAYIREADEL	WEWF	-NH2	HYBRID T1303	1200	
LH-RH T1323	Ac-	QHSYGLRPG				-NH2	LH-RH T1323	N/A	
HIV-1/HIV-2/LH-RH HYBRIDS		LH-RH Core Sequence							
HYBRID T1326	Ac- W N W F	QHSYGLRPG	W N W F	QHSYGLRPG	W N W F	-NH2	HYBRID T1326	N/A	
HYBRID T1327	Ac- F N F F	QHSYGLRPG	F N F F	QHSYGLRPG	F N F F	-NH2	HYBRID T1327	N/A	
HYBRID T1328	Ac- G A G A	QHSYGLRPG	G A G A	QHSYGLRPG	G A G A	-NH2	HYBRID T1328	N/A	
HYBRID T1324	Ac-	QHSYGLRPG	W A S L	QHSYGLRPG	W A S L	-NH2	HYBRID T1324	N/A	
HYBRID T1325	Ac-	QHSYGLRPG	W E W E	QHSYGLRPG	W E W E	-NH2	HYBRID T1325	N/A	
HYBRID T1354	Ac-	QHSYGLRPG	W Q E W	QHSYGLRPG	W Q E W	-NH2	HYBRID T1354	N/A	
HYBRID T1355	Ac-	QHSYGLRPG	W Q A W	QHSYGLRPG	W Q A W	-NH2	HYBRID T1355	N/A	

FIG.13D




FIG.14A





FIG 14B

23/29



24/29




FIG.16A

25/29




FIG.16B

26/29




FIG.16C



27/29




FIG.17A

28/29




FIG.17B

29/29




FIG.17C

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11219

**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(6) :Please See Extra Sheet.

US CL :Please See Extra Sheet.

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/300, 313, 324, 326, 328, 350, 397, 398, 399; 514/2, 12, 13, 15

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

APS, GENESEQ, SWISSPROT, PIR, STN  
search terms: hybrid, chimeric, sequences of claims 9 and 16

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 5,723,129 A (POTTER ET AL) 03 March 1998 (03/03/98), abstract, column 4, lines 36-43, SEQ ID NO:8, especially residues 953-962.	1, 4, 7-10, 16, 18-20
X,P	US 5,763,160 A (C. WANG) 09 June 1998 (09/06/98), column 9, line 60 - column 10, line 39, column 15, line 25 - column 16, line 41, column 18, line 65 - column 19, line 10, column 20, lines 53-64.	1, 6-8, 18-20
X,P	US 5,843,913 A (LI ET AL) 01 December 1998 (01/12/98), Figure 2, SEQ ID NO:2. especially residues 506-533.	16
X	EP 0 272 858 A2 (REPLIGEN CORPORATION) 29 June 1988 (29/06/88), page 9, line 54 - page 10, line 23, page 17, line 1, page 18, lines 11-15, Table 3.	1, 2, 4-12, 16, 18-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

05 AUGUST 1999

Date of mailing of the international search report

21 OCT 1999

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

JEFFREY E. RUSSEL

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11219

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 306 912 A2 (ALBANY MEDICAL COLLEGE) 15 March 1989 (15/03/89).	1-20
X	EP 0 578 293 A1 (AKZO N.V.) 12 January 1994 (12/01/94), page 3, lines 35-58, page 4, lines 45-49.	1, 2, 4-12, 16, 18-20
X	WO 91/07664 A1 (CAMBRIDGE BIOSCIENCE CORPORATION) 30 May 1991 (30/05/91), page 4, lines 17-26, page 10, lines 9-17, Examples 3 and 4, Figures 4, 8, 12, 15, and 21.	1, 2, 4, 6-8, 18-20
A	WO 91/09872 A3 (UNIVAX BIOLOGICS, INC.) 11 July 1991 (11/07/91).	1-20
X	WO 93/14207 A1 (CONNAUGHT LABORATORIES LIMITED) 22 July 1993 (22/07/93), abstract, Figures 1 and 5.	1, 4, 7-10, 16, 18-20

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US99/11219

A. CLASSIFICATION OF SUBJECT MATTER:  
IPC (6):

A61K 38/02, 38/08, 38/10, 38/16, 38/18, 38/19, 38/22; C07K 7/06, 7/08, 14/00

A. CLASSIFICATION OF SUBJECT MATTER:  
US CL :

530/300, 313, 324, 326, 328, 350, 397, 398, 399; 514/2, 12, 13, 15